JP4195077B1 - 複数のVHおよびVκ領域を含むヒトIg遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 - Google Patents
複数のVHおよびVκ領域を含むヒトIg遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 Download PDFInfo
- Publication number
- JP4195077B1 JP4195077B1 JP2008132621A JP2008132621A JP4195077B1 JP 4195077 B1 JP4195077 B1 JP 4195077B1 JP 2008132621 A JP2008132621 A JP 2008132621A JP 2008132621 A JP2008132621 A JP 2008132621A JP 4195077 B1 JP4195077 B1 JP 4195077B1
- Authority
- JP
- Japan
- Prior art keywords
- human
- heavy chain
- mouse
- gene
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000009261 transgenic effect Effects 0.000 title claims abstract description 27
- 241000124008 Mammalia Species 0.000 title description 15
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 151
- 239000000427 antigen Substances 0.000 claims description 66
- 108091007433 antigens Proteins 0.000 claims description 66
- 102000036639 antigens Human genes 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 42
- 239000012634 fragment Substances 0.000 claims description 33
- 230000008707 rearrangement Effects 0.000 claims description 23
- 238000004519 manufacturing process Methods 0.000 claims description 22
- 238000012217 deletion Methods 0.000 claims description 15
- 230000037430 deletion Effects 0.000 claims description 15
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 14
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 14
- 230000003053 immunization Effects 0.000 claims description 11
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 3
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 3
- 210000003917 human chromosome Anatomy 0.000 claims 9
- 210000001671 embryonic stem cell Anatomy 0.000 claims 4
- 102100029567 Immunoglobulin kappa light chain Human genes 0.000 claims 2
- 101710189008 Immunoglobulin kappa light chain Proteins 0.000 claims 2
- 108700024394 Exon Proteins 0.000 claims 1
- 210000002308 embryonic cell Anatomy 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract description 65
- 108060003951 Immunoglobulin Proteins 0.000 abstract description 23
- 102000018358 immunoglobulin Human genes 0.000 abstract description 23
- 230000011712 cell development Effects 0.000 abstract description 20
- 210000003519 mature b lymphocyte Anatomy 0.000 abstract description 18
- 241001465754 Metazoa Species 0.000 abstract description 14
- 238000012452 Xenomouse strains Methods 0.000 description 111
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 107
- 241000699666 Mus <mouse, genus> Species 0.000 description 106
- 241000699670 Mus sp. Species 0.000 description 97
- 210000004027 cell Anatomy 0.000 description 74
- 230000027455 binding Effects 0.000 description 39
- 102000004890 Interleukin-8 Human genes 0.000 description 30
- 108090001007 Interleukin-8 Proteins 0.000 description 28
- 210000004602 germ cell Anatomy 0.000 description 28
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 25
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 25
- 102000001301 EGF receptor Human genes 0.000 description 23
- 238000007792 addition Methods 0.000 description 23
- 108060006698 EGF receptor Proteins 0.000 description 22
- 239000002773 nucleotide Substances 0.000 description 19
- 125000003729 nucleotide group Chemical group 0.000 description 19
- 230000006798 recombination Effects 0.000 description 17
- 238000005215 recombination Methods 0.000 description 17
- 238000002105 Southern blotting Methods 0.000 description 16
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 16
- 210000004408 hybridoma Anatomy 0.000 description 16
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 15
- 108020004414 DNA Proteins 0.000 description 15
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 15
- 108700019146 Transgenes Proteins 0.000 description 15
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 230000004048 modification Effects 0.000 description 15
- 238000012986 modification Methods 0.000 description 15
- 238000011161 development Methods 0.000 description 14
- 239000003623 enhancer Substances 0.000 description 14
- 230000016784 immunoglobulin production Effects 0.000 description 14
- 230000001105 regulatory effect Effects 0.000 description 14
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 13
- 210000000349 chromosome Anatomy 0.000 description 13
- 238000011830 transgenic mouse model Methods 0.000 description 13
- 239000013598 vector Substances 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- 230000018109 developmental process Effects 0.000 description 11
- 210000000440 neutrophil Anatomy 0.000 description 11
- 238000002649 immunization Methods 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 241000282412 Homo Species 0.000 description 9
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 9
- 101150117115 V gene Proteins 0.000 description 9
- 230000005875 antibody response Effects 0.000 description 9
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
- 230000028993 immune response Effects 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 9
- 206010069754 Acquired gene mutation Diseases 0.000 description 8
- 241000283707 Capra Species 0.000 description 8
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 8
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 230000004927 fusion Effects 0.000 description 8
- 230000013011 mating Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 230000037439 somatic mutation Effects 0.000 description 8
- 210000001185 bone marrow Anatomy 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 6
- 108700026244 Open Reading Frames Proteins 0.000 description 6
- 101150050575 URA3 gene Proteins 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000006801 homologous recombination Effects 0.000 description 6
- 238000002744 homologous recombination Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 210000001165 lymph node Anatomy 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 5
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 5
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 230000000392 somatic effect Effects 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- 101150009006 HIS3 gene Proteins 0.000 description 4
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 4
- 230000009824 affinity maturation Effects 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 230000003915 cell function Effects 0.000 description 4
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 4
- 238000011555 rabbit model Methods 0.000 description 4
- 238000003127 radioimmunoassay Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 102100030981 Beta-alanine-activating enzyme Human genes 0.000 description 3
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 description 3
- 101000773364 Homo sapiens Beta-alanine-activating enzyme Proteins 0.000 description 3
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- 101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 210000002459 blastocyst Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 108010038415 interleukin-8 receptors Proteins 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 238000000520 microinjection Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000010807 negative regulation of binding Effects 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 238000001525 receptor binding assay Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000028070 sporulation Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 101150097493 D gene Proteins 0.000 description 2
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 2
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100022338 Integrin alpha-M Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 241000609499 Palicourea Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 108010004469 allophycocyanin Proteins 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000009460 calcium influx Effects 0.000 description 2
- 230000011748 cell maturation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000035605 chemotaxis Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 102000045108 human EGFR Human genes 0.000 description 2
- 230000008348 humoral response Effects 0.000 description 2
- 210000003297 immature b lymphocyte Anatomy 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101150072531 10 gene Proteins 0.000 description 1
- 238000011714 129 mouse Methods 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- 101150096273 ADE2 gene Proteins 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 1
- 108700012434 CCL3 Proteins 0.000 description 1
- 210000003967 CLP Anatomy 0.000 description 1
- 108050006947 CXC Chemokine Proteins 0.000 description 1
- 102000019388 CXC chemokine Human genes 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102000016950 Chemokine CXCL1 Human genes 0.000 description 1
- 108010014419 Chemokine CXCL1 Proteins 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 1
- 101100231743 Homo sapiens HPRT1 gene Proteins 0.000 description 1
- 101000960969 Homo sapiens Interleukin-5 Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000851176 Homo sapiens Pro-epidermal growth factor Proteins 0.000 description 1
- 108010058683 Immobilized Proteins Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000017095 Leukocyte Common Antigens Human genes 0.000 description 1
- 108010013709 Leukocyte Common Antigens Proteins 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 101100058506 Mus musculus Bloc1s5 gene Proteins 0.000 description 1
- WGZDBVOTUVNQFP-UHFFFAOYSA-N N-(1-phthalazinylamino)carbamic acid ethyl ester Chemical compound C1=CC=C2C(NNC(=O)OCC)=NN=CC2=C1 WGZDBVOTUVNQFP-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102000001183 RAG-1 Human genes 0.000 description 1
- 108060006897 RAG1 Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 108010032099 V(D)J recombination activating protein 2 Proteins 0.000 description 1
- 102100029591 V(D)J recombination-activating protein 2 Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002870 angiogenesis inducing agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 239000002975 chemoattractant Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 101150007818 dj gene Proteins 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000010363 gene targeting Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 102000010681 interleukin-8 receptors Human genes 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 101150109301 lys2 gene Proteins 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000021121 meiosis Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- GVUGOAYIVIDWIO-UFWWTJHBSA-N nepidermin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CS)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C(C)C)C(C)C)C1=CC=C(O)C=C1 GVUGOAYIVIDWIO-UFWWTJHBSA-N 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000007500 overflow downdraw method Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 230000017363 positive regulation of growth Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000009420 retrofitting Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000012799 strong cation exchange Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- -1 β and γ Proteins 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Humanized animals, e.g. knockin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/206—Pseudochromosomes, minichrosomosomes of yeast origin, e.g. YAC, 2u
Abstract
【選択図】なし
Description
本発明により提供されるものは、ヒト重鎖遺伝子座およびヒトκ軽鎖遺伝子座の両方を含むほぼ完全なヒトIg遺伝子座を有するトランスジェニック動物である。好ましくは、重鎖遺伝子座は、ヒト重鎖可変領域の約20%を超える、より好ましくは約40%を超える、より好ましくは約50%、さらにより好ましくは約60%を超える部分を含む。ヒトκ軽鎖に関して、遺伝子座は好ましくはヒトκ軽鎖可変領域の約20%を超える、より好ましくは約40%を超える、より好ましくは約50%、さらにより好ましくは約60%を超える部分を含む。このような比率は機能的な可変領域遺伝子の比率に関して言及することが好ましい。
本明細書において本発明者らは、実質的な生殖細胞系コンフィギュレーションにある、メガベースサイズのヒトIg遺伝子座を含むマウスの、いくつかの系統の製造および特徴分析に関して記載する。このため本発明は、YAC上での大きく複雑なヒトIg遺伝子座の再構成、および対応するマウスIg遺伝子座を機能的に置換するためのメガベースサイズのYACをマウスに首尾よく導入する方法を、初めて提供するものである。
以下のマウス系統を、本明細書において記載および/または使用する。
二重不活性化(DI)系統: DI系統のマウスは、機能的な内因性マウスIgを産生しないマウスである。1つの好ましい態様において、DIマウスは不活性化されたマウスJH領域および不活性化されたマウスCκ領域を有する。この系統の構築は、別で詳細に説明されている。例えば、DI系統の作製のために用いられる技法は、1990年1月12日に提出された米国特許出願第07/466,008号、1990年11月8日に提出された第07/610,515号、1992年7月24日に提出された第07/919,297号、1993年3月15日に提出された第08/031,801号、1993年8月27日に提出された第08/112,848号、1994年4月28日に提出された第08/234,145号、1996年10月2日に提出された第08/724,752号に詳細に記載されている。1996年6月12日に認可が発行されたEP 0 463 151 B1、1994年2月3日に発行された国際特許出願国際公開公報第94/02602号、1996年10月31日に発行された国際特許出願国際公開公報第96/34096号、および1996年4月29日に提出されたPCT/US96/05928も参照されたい。上記の特許および特許出願のそれぞれの開示は、その全体が参照として本明細書に組み入れられる。DIマウスではB細胞発生が極めて未熟であることが観察および報告されている。本マウスは成熟B細胞を産生せず、プロB細胞のみを産生する。
抗体の特異性(すなわち、広範な抗原に対する、実際にはそれらの上にある広範な独立したエピトープに対する抗体を生成する能力)は、重鎖(VH)およびκ軽鎖(Vκ)ゲノム上の可変領域遺伝子に依存している。ヒト重鎖ゲノムは、免疫グロブリン分子のヒト重鎖の可変領域をコードする約95の機能的遺伝子を含む。さらに、ヒト軽鎖ゲノムはその近位端に、免疫グロブリン分子のヒトκ軽鎖の可変領域をコードする約40の遺伝子を含む。本発明者らは、可変軽鎖および重鎖をコードする複数の遺伝子を含めることによって抗体の特異性を高めうることを示した。
表I
量的多様性に加えて、V遺伝子の量的選択(すなわち、多くの多様な数のV遺伝子)および/またはV遺伝子の質的選択(すなわち、特定のV遺伝子の選択)も、本発明者らが本明細書で「質的多様性」と呼ぶ一定の役割を果たすように思われる。本明細書で用いる質的多様性とは、結合多様性および/または体細胞変異事象が導入されるV-D-J再配列における多様性を意味する。重鎖再配列の間には、特定の酵素(RAG-1、RAG-2、および他のものも考えられる)が、抗体遺伝子のコード領域であるDNAの切断に関与する。ターミナルデオキシヌクレオチジルトランスフェラーゼ(Tdt)活性はアップレギュレートされ、これはV-DおよびD-J遺伝子セグメントの間のヌクレオチドのN末端付加の原因となる。類似の酵素および他のもの(SCIDおよび他のDNA修復酵素)は、これらのコード区域の結合部に生じる欠失の原因となる。結合多様性に関しては、N付加事象および相補性決定領域3(CDR3)の双方がこの項目に含められる。理解されるであろう通り、CDR3はD領域にまたがって位置しており、V-DおよびD-J結合事象を含む。このため、D-J再配列およびV-D再配列の両方の過程におけるN付加および欠失がCDR3の多様性の原因となっている。
本発明者らは、可変領域の含有量の増加と抗体特異性との間に、直接的な因果関係があることを決定的に示してはいないが、そうであると思われ、しかもこのような多様性が提供されることにより、マウスが広範な抗原に対する免疫応答を生じる能力が実現および増強されることが期待される。さらに、このようなマウスは、個々の抗原または免疫原上の広範なエピトープに対する免疫応答を生じる性質をさらに備えるようになると考えられる。本発明者らのデータからは、本発明に従って産生される抗体は親和性も増強されると思われる。このようなデータには、本発明によるマウスおよびXenoMouse I系統との比較のほか、ジェンファームインターナショナル(GenPharm International)社およびMRCが発表した結果の考察が含まれる。XenoMouse I系統については、上記の通り、このようなマウスではB細胞産生の効率が低く、種々の抗原に対する応答性が制限される。このような結果は、一部にはV遺伝子レパートリーの制限に起因すると思われる。同じく、ジェンファームインターナショナル社およびMRCによって発表された結果は、多様な抗原に対する応答性が制限されていることを示している。
B細胞の発生はクラウス(Klaus)の、「Bリンパ球(B Lymphocytes)」(IRL Press(1990))および、「免疫グロブリン遺伝子(Immunoglobulin Genes)」(Academic Press Ltd.(1989)の1〜3章において概説されており、それらの開示は参照として本明細書に組み入れられる。一般に哺乳動物では、Bリンパ球およびTリンパ球を含む血液細胞の発生は共通の多能性幹細胞に始まる。続いてリンパ球が共通のリンパ球前駆細胞から生じる。初期の妊娠期間を経た後にB細胞の発生部位は肝臓から骨髄に移動し、哺乳動物の一生を通じてその部位に存続する。
表II
本明細書において詳細に考察されるように、予想通り、XenoMouse IIマウスは、ヒト導入遺伝子にコードされるμアイソタイプから導入遺伝子にコードされるγ2アイソタイプへの効率的および効果的なアイソタイプスイッチを生じた。本発明者らは、ヒトγ4定常領域を包含およびコードするXenoMouse II系統も開発した。上記の通り、本発明に係るマウスは、ほかのアイソタイプを生成するための他のヒト定常領域をさらに備えることができる。このようなアイソタイプには、γ1、γ2、γ3、γ4、α、ε、δおよび他の定常領域をコードする遺伝子が含まれうる。代替的な定常領域は、同一の導入遺伝子上、すなわちヒトμ定常領域から下流に含めることもでき、またはこのような他の定常領域を別の染色体上に含めることもできる。このような他の定常領域がヒトμ定常領域をコードする導入遺伝子を含む染色体と同じ染色体上に含まれる場合には、他の1つのアイソタイプまたは複数のアイソタイプへのシス転換が達成されうることは理解されるであろう。これに対して、このような他の定常領域がヒトμ定常領域をコードする導入遺伝子を含む染色体とは異なる染色体上に含まれる場合には、他の1つのアイソタイプまたは複数のアイソタイプへのトランス転換が達成されうる。このような配置(arrangement)は、広範な抗原に対する抗体を生成するためのマウスの設計および作製において多大な柔軟性を可能とする。
以下の材料および方法は、本発明に係るマウスの製造および特徴に関連して用いられる。このような材料および方法は例示を意味しており、本発明の範囲を制限するものではない。
本発明により、本発明者らがヒト重鎖およびヒトκ軽鎖の可変領域を再構成するために用いた戦略は、第1に大きな(メガベースサイズの)ヒトIg遺伝子座にまたがるYACに関してヒトYACライブラリーをスクリーニングし、第2にこのような領域にまたがるYACを、主として生殖細胞系コンフィギュレーションにある望ましい遺伝子座を含む単一のYAC中に組換え導入することであった。
ヒトκ軽鎖遺伝子座の再構成には同様の段階的組換え戦略を用いた。ヒトκ遺伝子座にまたがる3種のYACを同定した。YACは1K、2Kおよび3Kと命名した。長さ約180kbのYAC 1Kは、以前に本発明者らの第1世代のXenoMouse(登録商標)に導入された。このようなYACは、Bクラスター上にκ欠失要素(Kde)、κ3'およびイントロン性エンハンサー、Cκ、Jκならびに3種のVκ遺伝子を含む(Greenら、1994;Mendezら、1995)。YAC 2K(約480kb)および3K(約380kb)はともに、染色体2p上のκ軽鎖近位可変領域の大部分を包含する。約100kbの欠失はL13〜L5領域にまたがる(図1B;Huberら、1993)。κ遠位領域は近位領域の繰り返しであり、近位Vκ遺伝子はヒトで最も一般的に用いられるものであるため(Weicholdら、1993;Coxら、1994)、本発明者らの再構成戦略の焦点は近位領域にあった(図1B)。3種のYACの相同組換えにより、800kbの組換えYACであるyK2が回収された。この組換えYACのサイズおよび完全性を、PFGEおよびサザンブロット分析によって確認した。こうした分析から、それがLp領域に記載した通りの欠失があることを除き、生殖細胞系コンフィギュレーションにある32個のVκ遺伝子とともにヒトκ軽鎖遺伝子座の近位部をカバーすることが示された(図1B)。yK2の動原体腕および無動原体腕に、記載した通り(材料および方法)にそれぞれHPRTおよびネオマイシン選択可能マーカーを含むように改変を加えた。これが本発明者らのXenoMouse II系統の作製に用いたκ軽鎖構築物である。
本発明者らの戦略に従い、本発明者らはYAC yH2およびyK2をマウス胚性幹(ES)細胞に導入した。YAC DNAを含むES細胞がいったん単離されれば、このようなES細胞は適切な交配を通じてマウスの作出に用いられる。
YAC DNAを含むES細胞からマウスを作出するために、胚盤胞へのマイクロインジェクションを行い、続いて交配を行った。すなわち、yH2およびyK2を保持するES細胞クローンを増殖させ、マウスC57BL/6J胚盤胞へのマイクロインジェクションを行い(Greenら、1994)、得られたキメラ雄を生殖細胞系伝達に関して評価した。伝達されたYACを有する子孫をPCR分析によって同定し、サザンブロット分析によってYACの完全性を確認した。分析したすべてのトランスジェニックマウスにおいて、YACは無傷型であることが示された(図2B、3B)。マイクロインジェクションを受けた7つのyH2-ESクローンのすべて、および8つのyK2-ESクローンのうち2つは、マウス生殖細胞系を通じて伝達された。
XenoMouse II系統の特徴をさらに調べるために、本発明者らはそれらのB細胞発生およびヒト抗体産生を検討した。yH2およびyK2 YACによるXenoMouse II系統におけるB細胞発生および抗体産生の再構成を、フローサイトメトリーおよびELISAによって評価した。成熟B細胞を完全に欠くDIマウスとは対照的に、XenoMouse IIは本質的に正常なB細胞発生を示し、血中の成熟B細胞を合計すると野生型マウスで認められる値の50%を上回った(図4A)。すべてのB細胞はヒトIgMおよび高レベルのB220を発現し(ヒトIgM+/B220hi)、この集団の60%はヒトIgDも発現することが示された。XenoMouseの脾臓およびリンパ節の分析でも同様の結果が得られた(提示せず)。これらの結果は野生型マウスにおける成熟B細胞の特徴とよく相関しており、XenoMouseにおけるB細胞成熟が適切であることを示す。
L6系統のマウスは、XenoMouse II系統の作出に関する上記の過程と同じように作出した。しかし、L6 ES細胞系の作製に際して欠失事象があるために、ES細胞系および続いて得られるL6マウスはCδの遠位側にある配列の部分を伴わずに生じ、このため、Cγ定常領域およびその調節配列をもたない。交配の完了後に、L6マウスは欠失したCγ定常領域を除き、yK2構築物の全体およびyH2構築物の全体を含むと考えられる。
非免疫化XenoMouseIIの血清中でヒトCμ、Cγ2およびκ軽鎖の発現が検出され、最大値はそれぞれ700、600および800μg/mlであった。これらの値がどの程度野生型に匹敵するかを明らかにするために、本発明者らは同様の無病原体条件下に保ったC57BL/6J×129マウスにおけるマウスCμ、Cγ2およびκ軽鎖の最大値を測定した。野生型マウスにおけるCμ、Cγ2およびκ軽鎖に関する値はそれぞれ400、2000および2000μg/mlであった。免疫化を施したところ、ヒトγ鎖の値は約2.5mg/mlに上昇した。マウスλの濃度は70μg/mlに過ぎず、このことからヒトκ鎖が優先的に用いられることがさらに裏づけられた。
XenoMouse II系統における抗体レパートリーの再構成に関してさらに理解を得るために、本発明者らはマウスにいくつかの免疫原による誘発刺激を与え、このような抗体を分泌するハイブリドーマ細胞系を調製した。理解されるであろう通り、マウスでヒト抗体反応を再現させるにはyH2およびyK2 YAC上に含まれる種々のヒト可変遺伝子が多様に用いられる必要がある。XenoMouse II系統によって産生されるヒト抗体の多様性を、XenoMouseのリンパ節由来のヒト重鎖(μおよびγ)ならびにκ軽鎖転写物のクローニングおよび配列決定によって調べた。現在までの本発明者らのデータに基づくと、配列解析ではXenoMouse IIがyH2上に存在する37個の機能的VH遺伝子のうち少なくとも11個、8個の異なるDHセグメントおよび3個のJH遺伝子(JH3、JH4、JH6)を用いることが示されている(表III;本発明者らによるハイブリドーマ由来の抗体の配列決定に関してJH5も検出された)。V-D-J配列はヒトμまたはγ2定常領域と連結していた(提示せず)。
表III
表IV
本発明者らは次に、XenoMouse IIにおける広範なヒトレパートリーを、多数の抗原、特に重大な臨床的関心がもたれるヒト抗原に対するヒト抗体を産生させるために利用しうるか否かを問題にした。
表V
上記のIL-8およびEGFR-ヒトMabからの重鎖およびκ軽鎖転写物の配列を決定した。図6および図[[ ]]。4種のIL-8特異的抗体は、少なくとも3つの異なるVH遺伝子(VH4−34/VH4−21、VH3−30およびVH5−51)、4つの異なるDHセグメント(A1/A4、K1、ir3rcおよび21-10rc )および2つのJH(JH3およびJH4)遺伝子セグメントからなっていた。3つの異なるVκ遺伝子(012、018およびB3)がJκ3およびJκ4遺伝子と結合していた。このように多様な使用がみられることは、XenoMouse IIが多様な可変領域を備えた一連の抗IL-8中和抗体を産生しうることを示す。
本出願は、複雑なメガベースサイズのマウス遺伝子座を、YAC上に再構成されたサイズおよび内容の点で等価なヒトDNA断片によって、初めて機能的に置換したことを記載したものである。この手法により、マウス体液性免疫系はメガベースサイズのヒトIg遺伝子座によって「ヒト化」され、内因性抗体産生に欠陥のあるマウスにおいてヒト抗体反応が実質的に再現されるようになる。
特許、特許出願、論文、教科書などを含む本明細書中に引用したすべての参考文献、およびそれらの中で引用された参考文献は、それらが既知でない範囲において、その全体が参照として本明細書に組み入れられる。さらに、以下の参考文献も、このような参考文献において引用された参考文献を含め、その全体が参照として本明細書に組み入れられる。
Claims (9)
- 免疫グロブリン重鎖遺伝子座のD領域遺伝子からJ領域遺伝子およびCμ定常領域遺伝子を通して続くヒト14番染色体断片をゲノムに含むトランスジェニック非ヒト哺乳動物であって、
前記断片は少なくとも1つのヒト免疫グロブリン重鎖V領域遺伝子に操作可能に連結されており、
前記断片はさらに別のヒト免疫グロブリン重鎖定常領域遺伝子に操作可能に連結されており、前記別の定常領域遺伝子はヒトγ2スイッチ領域およびヒトγ4定常領域をコードするエキソンを含み、そして
操作可能に連結された前記ヒト14番染色体断片、重鎖V領域遺伝子、およびヒト定常領域遺伝子は再配列に伴いヒト免疫グロブリン重鎖をコードする、トランスジェニック非ヒト哺乳動物。 - 前記トランスジェニック非ヒト哺乳動物がさらに免疫グロブリンκ軽鎖遺伝子座のヒトVκ、ヒトJκおよびヒトCκ遺伝子セグメントを含むヒト2番染色体断片を含み、前記ヒト2番染色体断片は再配列に伴いヒトκ軽鎖をコードする、請求項1記載のトランスジェニック非ヒト哺乳動物。
- 前記ヒト2番染色体断片が3つの最も近位のVκ遺伝子セグメントからJκおよびCκ遺伝子セグメントを通して続きヒトκ欠失要素にまで及ぶ、請求項2記載のトランスジェニック非ヒト哺乳動物。
- 請求項1〜3のいずれか一項記載のトランスジェニック非ヒト哺乳動物であって、さらに以下を含むトランスジェニック非ヒト哺乳動物:
a)少なくとも1つの不活性化された内因性免疫グロブリン重鎖遺伝子座;または
b)少なくとも1つの不活性化された内因性免疫グロブリン軽鎖遺伝子座;または
c)aとbの両方。 - 所望の抗原に対して特異的な完全ヒト抗体を生産するための方法であって、以下を含む方法:
a)請求項2〜4のいずれか一項記載のトランスジェニック非ヒト哺乳動物を前記所望の抗原で免疫する工程;および
b)抗体を回収する工程。 - 胚性幹細胞からトランスジェニック非ヒト哺乳動物を生成するための方法であって、以下を含む方法:
a)免疫グロブリン重鎖遺伝子座のD領域遺伝子からJ領域遺伝子およびCμ定常領域遺伝子を通して続くヒト14番染色体断片を含む胚性幹細胞を生成する工程であって、
前記断片は少なくとも1つのヒト免疫グロブリン重鎖V領域遺伝子に操作可能に連結されており、
前記断片はさらに別のヒト免疫グロブリン重鎖定常領域遺伝子に操作可能に連結されており、前記別の定常領域遺伝子はヒトγ2スイッチ領域およびヒトγ4定常領域をコードするエキソンを含み、そして
操作可能に連結された前記ヒト14番染色体断片、重鎖V領域遺伝子、およびヒト定常領域遺伝子は再配列に伴いヒト免疫グロブリン重鎖をコードする、工程;および
b)工程aの胚性幹細胞からトランスジェニック非ヒト哺乳動物を生成する工程。 - 前記胚性細胞がさらに免疫グロブリンκ軽鎖のVκ、JκおよびCκ遺伝子セグメントを含むヒト2番染色体の断片を含む、請求項6記載の方法。
- 前記ヒト7番染色体断片が3つの最も近位のVκ遺伝子セグメントからJκおよびCκ遺伝子セグメントを通して続きヒトκ欠失要素にまで及ぶ、請求項7記載の方法。
- 請求項6〜8のいずれか一項記載の方法であって、前記胚性幹細胞がさらに以下を含む方法:
a)少なくとも1つの不活性化された内因性免疫グロブリン重鎖遺伝子座;または
b)少なくとも1つの不活性化された内因性免疫グロブリン軽鎖遺伝子座;または
c)aとbの両方。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75962096A | 1996-12-03 | 1996-12-03 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52590998A Division JP4215172B2 (ja) | 1996-12-03 | 1997-12-03 | 複数のV▲下H▼およびV▲下κ▼領域を含むヒトIg遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP4195077B1 true JP4195077B1 (ja) | 2008-12-10 |
JP2008301818A JP2008301818A (ja) | 2008-12-18 |
Family
ID=25056346
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52590998A Expired - Lifetime JP4215172B2 (ja) | 1996-12-03 | 1997-12-03 | 複数のV▲下H▼およびV▲下κ▼領域を含むヒトIg遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
JP2005021414A Expired - Lifetime JP4808412B2 (ja) | 1996-12-03 | 2005-01-28 | 複数のVHおよびVκ領域を含むヒトIg遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
JP2008124406A Withdrawn JP2008194058A (ja) | 1996-12-03 | 2008-05-12 | 複数のVHおよびVκ領域を含むヒトIg遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
JP2008132621A Expired - Lifetime JP4195077B1 (ja) | 1996-12-03 | 2008-05-21 | 複数のVHおよびVκ領域を含むヒトIg遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
JP2011146571A Withdrawn JP2011212019A (ja) | 1996-12-03 | 2011-06-30 | 複数のVHおよびVκ領域を含むヒトIg遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52590998A Expired - Lifetime JP4215172B2 (ja) | 1996-12-03 | 1997-12-03 | 複数のV▲下H▼およびV▲下κ▼領域を含むヒトIg遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
JP2005021414A Expired - Lifetime JP4808412B2 (ja) | 1996-12-03 | 2005-01-28 | 複数のVHおよびVκ領域を含むヒトIg遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
JP2008124406A Withdrawn JP2008194058A (ja) | 1996-12-03 | 2008-05-12 | 複数のVHおよびVκ領域を含むヒトIg遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011146571A Withdrawn JP2011212019A (ja) | 1996-12-03 | 2011-06-30 | 複数のVHおよびVκ領域を含むヒトIg遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 |
Country Status (13)
Country | Link |
---|---|
US (4) | US7064244B2 (ja) |
EP (5) | EP2305027B1 (ja) |
JP (5) | JP4215172B2 (ja) |
KR (3) | KR100643058B1 (ja) |
AT (2) | ATE387495T1 (ja) |
AU (1) | AU5702298A (ja) |
CA (3) | CA2616914C (ja) |
DE (1) | DE69738539T2 (ja) |
DK (2) | DK1500329T3 (ja) |
ES (2) | ES2384942T3 (ja) |
HK (2) | HK1074348A1 (ja) |
PT (2) | PT1500329E (ja) |
WO (1) | WO1998024893A2 (ja) |
Families Citing this family (1444)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US20050287630A1 (en) * | 1995-04-27 | 2005-12-29 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US20050241006A1 (en) * | 1995-04-27 | 2005-10-27 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
US7964190B2 (en) | 1996-03-22 | 2011-06-21 | Human Genome Sciences, Inc. | Methods and compositions for decreasing T-cell activity |
US6635743B1 (en) | 1996-03-22 | 2003-10-21 | Human Genome Sciences, Inc. | Apoptosis inducing molecule II and methods of use |
US7129061B1 (en) * | 1996-08-07 | 2006-10-31 | Biogen Idec Ma Inc. | Tumor necrosis factor related ligand |
EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
US6541212B2 (en) * | 1997-03-10 | 2003-04-01 | The Regents Of The University Of California | Methods for detecting prostate stem cell antigen protein |
US20020173629A1 (en) * | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
AU777918B2 (en) * | 1997-05-05 | 2004-11-04 | Amgen Fremont Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
JP2002536958A (ja) | 1997-11-21 | 2002-11-05 | ジェンセット | Chlamydiapneumoniaeゲノム配列およびポリペプチド、それらのフラグメント、ならびに特に感染症の診断、予防および治療のためのそれらの使用 |
KR100735653B1 (ko) | 1997-11-28 | 2007-07-06 | 세로노 제네틱스 인스티튜트 에스.에이. | 클라미디아 트라코마티스 게놈 서열과 폴리펩티드, 이의단편 및 이의 용도, 특히, 감염의 진단, 예방 및 치료 용도 |
DK1086223T3 (da) | 1998-06-01 | 2009-11-30 | Agensys Inc | Nye serpentintransmembranantigener udtrykt i humane cancerformer og anvendelser deraf |
GB9823930D0 (en) * | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
KR100849443B1 (ko) | 1998-12-23 | 2008-07-31 | 화이자 인크. | Ctla-4에 대한 인간 단일클론 항체 |
AU3501700A (en) | 1999-02-26 | 2000-09-14 | Human Genome Sciences, Inc. | Human endokine alpha and methods of use |
KR100743640B1 (ko) | 1999-03-09 | 2007-07-27 | 지모제넥틱스, 인코포레이티드 | 신규한 사이토킨 zalpha 11 리간드 |
US6914128B1 (en) * | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
US7883704B2 (en) * | 1999-03-25 | 2011-02-08 | Abbott Gmbh & Co. Kg | Methods for inhibiting the activity of the P40 subunit of human IL-12 |
AU780061B2 (en) | 1999-04-12 | 2005-02-24 | Agensys, Inc. | Transmembrane protein expressed in prostate and other cancers |
EP1792989A1 (en) | 1999-04-12 | 2007-06-06 | Agensys, Inc. | 13 Transmembrane protein expressed in prostate cancer |
WO2004009618A2 (en) | 2002-07-18 | 2004-01-29 | Crucell Holland B.V. | Recombinant production of mixtures of antibodies |
DK1488806T3 (en) | 1999-06-01 | 2016-02-08 | Biogen Ma Inc | Blocking monoclonal antibody to VLA-1 and its use in the treatment of vascular disorders |
US6833268B1 (en) * | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
DK1992695T3 (da) | 1999-08-12 | 2011-02-14 | Agensys Inc | Lectin-transmembran-antigen af type C udtrykt i human prostatacancer og avendelser deraf |
CN1371416B (zh) | 1999-08-24 | 2012-10-10 | 梅达里克斯公司 | 人ctla-4抗体及其应用 |
AU7491800A (en) * | 1999-09-15 | 2001-04-17 | Therapeutic Human Polyclonals, Inc. | Immunotherapy with substantially human polyclonal antibody preparations purifiedfrom genetically engineered birds |
DK2003202T3 (da) | 1999-10-05 | 2012-01-16 | Agensys Inc | G-protein-koblet receptor opreguleret i prostatacancer og anvendelser deraf |
US6893818B1 (en) | 1999-10-28 | 2005-05-17 | Agensys, Inc. | Gene upregulated in cancers of the prostate |
EP2194130A1 (en) | 1999-12-23 | 2010-06-09 | ZymoGenetics, L.L.C. | Cytokine ZCYTO18 |
CA2800450A1 (en) | 2000-02-10 | 2001-08-16 | Abbott Laboratories | Antibodies that bind human interleukin-18 and methods of making and using |
AU2001253339A1 (en) * | 2000-04-10 | 2001-10-23 | American Biogenetic Sciences Inc. | Human immunoglobulin-producing gnotobiotics |
AU2001266557A1 (en) | 2000-04-12 | 2001-10-23 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
US20030031675A1 (en) | 2000-06-06 | 2003-02-13 | Mikesell Glen E. | B7-related nucleic acids and polypeptides useful for immunomodulation |
EP2431054A3 (en) | 2000-06-15 | 2013-03-06 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
ES2609016T3 (es) | 2000-06-16 | 2017-04-18 | Human Genome Sciences, Inc. | Anticuerpos que se unen inmunoespecíficamente a BLyS |
WO2002000721A2 (en) | 2000-06-26 | 2002-01-03 | Zymogenetics, Inc. | Cytokine receptor zcytor17 |
HUP0301002A3 (en) | 2000-06-29 | 2005-12-28 | Abbott Lab | Dual specificity antibodies and methods of making and using |
ATE404670T1 (de) | 2000-06-30 | 2008-08-15 | Zymogenetics Inc | Allelische variante des interferon-ähnlichen proteins zcyto21 |
JP2004511219A (ja) | 2000-07-12 | 2004-04-15 | アジェンシス,インコーポレイテッド | 膀胱癌、卵巣癌、肺癌、および腎臓癌の診断および治療に有用な腫瘍抗原 |
AU2001284703B2 (en) * | 2000-08-03 | 2007-03-22 | Therapeutic Human Polyclonals Inc. | Production of humanized antibodies in transgenic animals |
US7288390B2 (en) | 2000-08-07 | 2007-10-30 | Centocor, Inc. | Anti-dual integrin antibodies, compositions, methods and uses |
US6902734B2 (en) | 2000-08-07 | 2005-06-07 | Centocor, Inc. | Anti-IL-12 antibodies and compositions thereof |
UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
ATE403716T1 (de) | 2000-08-28 | 2008-08-15 | Agensys Inc | Nukleinsäure und korrespondierendes protein 85p1b3, nützlich zur behandlung und detektion von krebserkrankungen |
AU2002246746B2 (en) | 2000-10-18 | 2007-05-31 | Kirin-Amgen, Inc. | Methods for treating rheumatoid arthritis using il-17 antagonists |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
JP3797974B2 (ja) | 2000-11-17 | 2006-07-19 | ヘマテック,エルエルシー | クローン化トランスジェニック有蹄動物における異種(ヒト)免疫グロブリンの発現 |
EP2338512A1 (en) | 2000-11-28 | 2011-06-29 | MedImmune, LLC | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
WO2002046477A2 (en) | 2000-12-07 | 2002-06-13 | Chiron Corporation | Endogenous retroviruses up-regulated in prostate cancer |
EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
US20030093818A1 (en) * | 2000-12-19 | 2003-05-15 | Belmont Heather J. | Transgenic animals comprising a humanized immune system |
DK1399483T3 (da) | 2001-01-05 | 2010-08-02 | Pfizer | Antistoffer til insulinlignende vækstfaktorrecptor I |
CN1564826A (zh) | 2001-02-09 | 2005-01-12 | 人类基因组科学公司 | 人类g蛋白趋化因子受体(ccr5)hdgnr10 |
US6924358B2 (en) | 2001-03-05 | 2005-08-02 | Agensys, Inc. | 121P1F1: a tissue specific protein highly expressed in various cancers |
US7271240B2 (en) | 2001-03-14 | 2007-09-18 | Agensys, Inc. | 125P5C8: a tissue specific protein highly expressed in various cancers |
US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
EP1379125A4 (en) | 2001-03-22 | 2004-12-08 | Abbott Gmbh & Co Kg | TRANSGENIC ANIMALS THAT EXPRESS SPECIFIC ANTIBODIES FOR INTERESTING GENES AND THEIR USE |
WO2002081641A2 (en) | 2001-04-06 | 2002-10-17 | Georgetown University | Gene scc-112 and diagnostic and therapeutic uses thereof |
US20030191073A1 (en) | 2001-11-07 | 2003-10-09 | Challita-Eid Pia M. | Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer |
US7736654B2 (en) | 2001-04-10 | 2010-06-15 | Agensys, Inc. | Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers |
DK1385864T3 (da) | 2001-04-13 | 2010-08-16 | Human Genome Sciences Inc | Anti-VEGF-2-antistoffer |
CZ303450B6 (cs) | 2001-04-13 | 2012-09-19 | Biogen Idec Ma Inc. | Protilátky k VLA-1, kompozice je obsahující a nukleové kyseliny, které je kódují, zpusob stanovení hladiny VLA-1 a použití pri lécení imunologického onemocnení |
WO2002092017A2 (en) | 2001-05-16 | 2002-11-21 | Albert Einstein College Of Medicine Of Yeshiva University | Human antipneumococcal antibodies from non-human animals |
KR100942393B1 (ko) | 2001-05-25 | 2010-02-17 | 휴먼 게놈 사이언시즈, 인코포레이티드 | Trail 수용체에 면역특이적으로 결합하는 항체 |
DE122010000047I1 (de) | 2001-06-26 | 2011-05-05 | Amgen Fremont Inc | Antikörper gegen opgl |
JP2005505271A (ja) | 2001-09-06 | 2005-02-24 | アジェンシス, インコーポレイテッド | 癌の処置および検出において有用なsteap−1と名称が与えられる核酸および対応するタンパク質 |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
AU2002348263B2 (en) | 2001-11-30 | 2008-10-16 | Amgen Fremont Inc. | Transgenic animals bearing human IgLamda light chain genes |
WO2003060071A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
AU2002361887A1 (en) | 2001-12-28 | 2003-07-24 | Abgenix, Inc. | Use of antibodies against the muc18 antigen |
JP2005516965A (ja) | 2001-12-28 | 2005-06-09 | アブジェニックス・インコーポレーテッド | 抗muc18抗体を使用する方法 |
US7135174B2 (en) * | 2002-01-07 | 2006-11-14 | Amgen Fremont, Inc. | Antibodies directed to PDGFD and uses thereof |
CA2471702C (en) * | 2002-01-09 | 2013-03-19 | Medarex, Inc. | Human monoclonal antibodies against cd30 |
PL211833B1 (pl) | 2002-01-18 | 2012-06-29 | Zymogenetics Inc | Wyizolowany polipeptyd, białko fuzyjne, wyizolowana cząsteczka polinukleotydu, wektor ekspresji, hodowana komórka, sposób wytwarzania polipeptydu, sposób wytwarzania przeciwciała, przeciwciało, przeciwciało lub fragment przeciwciała, zastosowanie przeciwciała, sposób wykrywania obecności polipeptydu, sposób inhibicji proliferacji lub różnicowania komórek krwiotwórczych, zastosowanie polipeptydu, sposób rozprzestrzeniania komórek krwiotwórczych, sposób wykrywania obecności RNA, sposób zabijania komórek nowotworowych in vitro lub in vivo, zastosowanie polipeptydu, zastosowanie antagonisty polipeptydu i sposób wykrywania zapalenia u pacjenta |
EP2840089A1 (en) | 2002-01-18 | 2015-02-25 | ZymoGenetics, Inc. | Cytokine receptor zcytor17 multimers |
AU2003202297C1 (en) | 2002-01-25 | 2006-05-18 | G2 Therapies Ltd | Anti-C5aR antibodies and uses thereof |
US20040023267A1 (en) | 2002-03-21 | 2004-02-05 | Morris David W. | Novel compositions and methods in cancer |
PT1527100E (pt) | 2002-03-29 | 2009-08-25 | Schering Corp | Anticorpos monoclonais humanos para interleucina-5 e métodos e composições compreendendo os mesmos |
MXPA04009681A (es) * | 2002-04-05 | 2005-01-11 | Amgen Inc | Anticuerpos humanos neutralizantes anti-ligando de osteoprotegerina como inhibidores selectivos de la ruta del ligando de osteoprotegerina. |
US7357928B2 (en) | 2002-04-08 | 2008-04-15 | University Of Louisville Research Foundation, Inc. | Method for the diagnosis and prognosis of malignant diseases |
US7541150B2 (en) | 2002-04-08 | 2009-06-02 | University Of Louisville Research Foundation, Inc | Method for the diagnosis and prognosis of malignant diseases |
US7244565B2 (en) | 2002-04-10 | 2007-07-17 | Georgetown University | Gene shinc-3 and diagnostic and therapeutic uses thereof |
CA2481747A1 (en) | 2002-04-12 | 2003-10-23 | Medimmune, Inc. | Recombinant anti-interleukin-9 antibodies |
CN1652820A (zh) | 2002-04-12 | 2005-08-10 | 梅达雷克斯公司 | 使用ctla-4抗体的治疗方法 |
US8330026B2 (en) | 2002-04-18 | 2012-12-11 | Yeda Research and Development Co., Ltd., Weizmann Institute of Science | Derivatives of the NF-κB inducing enzyme, their preparation and use |
DE60335536D1 (de) | 2002-04-19 | 2011-02-10 | Bristol Myers Squibb Co | Verfahren zum nachweis oder zur modulierung der wechselwirkung eines cytokinrezeptors mit seinem ligand |
CA2484655A1 (en) | 2002-05-17 | 2003-11-27 | Hematech, Llc | Transgenic ungulates capable of human antibody production |
JP2006508899A (ja) * | 2002-05-20 | 2006-03-16 | アブジエニツクス・インコーポレイテツド | EGFrに対する抗体を使用する腎癌の治療方法 |
AU2003274463B2 (en) | 2002-06-10 | 2009-10-29 | University Of Rochester | Gene differentially expressed in breast and bladder cancer and encoded polypeptides |
AU2003276679A1 (en) | 2002-06-13 | 2003-12-31 | Chiron Corporation | Vectors for expression of hml-2 polypeptides |
US7425618B2 (en) | 2002-06-14 | 2008-09-16 | Medimmune, Inc. | Stabilized anti-respiratory syncytial virus (RSV) antibody formulations |
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
EP1534335B9 (en) | 2002-08-14 | 2016-01-13 | Macrogenics, Inc. | Fcgammariib-specific antibodies and methods of use thereof |
US20040081653A1 (en) | 2002-08-16 | 2004-04-29 | Raitano Arthur B. | Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer |
CN100471871C (zh) | 2002-09-06 | 2009-03-25 | 安姆根有限公司 | 治疗性人抗-il-1r1单克隆抗体 |
US7335743B2 (en) | 2002-10-16 | 2008-02-26 | Amgen Inc. | Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors |
AU2003290689A1 (en) | 2002-11-08 | 2004-06-03 | Kyowa Hakko Kirin Co., Ltd. | Transgenic ungulates having reduced prion protein activity and uses thereof |
EP2287192B1 (en) | 2002-11-15 | 2015-08-26 | Novartis Vaccines and Diagnostics, Inc. | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
US7285269B2 (en) | 2002-12-02 | 2007-10-23 | Amgen Fremont, Inc. | Antibodies directed to tumor necrosis factor |
CA2510315C (en) | 2002-12-20 | 2014-01-28 | Protein Design Labs, Inc. | Antibodies against gpr64 and uses thereof |
US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
EP2343315A3 (en) | 2003-02-10 | 2011-11-23 | Agensys, Inc. | Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers |
WO2004074321A2 (en) | 2003-02-14 | 2004-09-02 | Sagres Discovery, Inc. | Therapeutic gpcr targets in cancer |
US20040248798A1 (en) | 2003-02-14 | 2004-12-09 | Peter Sutovsky | Contraceptive methods and compositions related to proteasomal interference |
CA2516455C (en) | 2003-02-20 | 2012-05-01 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
SI2248899T1 (sl) | 2003-03-19 | 2015-07-31 | Biogen Ma Inc. | Vezavni protein receptorja Nogo |
WO2004084823A2 (en) | 2003-03-19 | 2004-10-07 | Abgenix, Inc. | Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof |
KR20120035234A (ko) | 2003-04-11 | 2012-04-13 | 메디뮨 엘엘씨 | 재조합 il?9 항체 및 그의 용도 |
CA2526398C (en) * | 2003-05-21 | 2014-07-15 | Medarex, Inc. | Human monoclonal antibodies against bacillus anthracis protective antigen |
US7622564B2 (en) | 2003-05-30 | 2009-11-24 | Agensys, Inc. | Prostate stem cell antigen (PSCA) variants and subsequences thereof |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
US9708410B2 (en) | 2003-05-30 | 2017-07-18 | Janssen Biotech, Inc. | Anti-tissue factor antibodies and compositions |
CA2527694C (en) | 2003-05-30 | 2015-07-14 | Hendricus Renerus Jacobus Mattheus Hoogenboom | Fab library for the preparation of anti vegf and anti rabies virus fabs |
KR20120098932A (ko) | 2003-06-27 | 2012-09-05 | 암젠 프레몬트 인코포레이티드 | 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도 |
AU2004259727A1 (en) | 2003-07-15 | 2005-02-03 | Barros Research Institute | Compositions and methods for immunotherapy of cancer and infectious diseases. |
PT1648998E (pt) | 2003-07-18 | 2014-11-04 | Amgen Inc | Agentes de ligação específica ao factor de crescimento do hepatócito |
EP1659918B1 (en) | 2003-08-08 | 2009-01-14 | Amgen Fremont Inc. | Antibodies directed to parathyroid hormone (pth) and uses thereof |
JP2007511738A (ja) | 2003-08-08 | 2007-05-10 | ジーンニュース インコーポレーテッド | 変形性関節症のバイオマーカー及びその使用 |
WO2005019463A1 (en) * | 2003-08-11 | 2005-03-03 | Therapeutic Human Polyclonals, Inc. | Improved transgenesis with humanized immunoglobulin loci |
CA2535171A1 (en) * | 2003-08-12 | 2005-03-03 | Dyax Corp. | Tie1-binding ligands |
AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
IL158287A0 (en) | 2003-10-07 | 2004-05-12 | Yeda Res & Dev | Antibodies to nik, their preparation and use |
US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
PT2805728T (pt) | 2003-12-23 | 2020-04-08 | Genentech Inc | Novos anticorpos anti-il13 e o uso dos mesmos |
AU2004304665B2 (en) * | 2003-12-24 | 2009-03-12 | Novo Nordisk A/S | Transgenic non-human mammal comprising a polynucleotide encoding human or humanized C5aR |
EP2311873B1 (en) | 2004-01-07 | 2018-08-29 | Novartis Vaccines and Diagnostics, Inc. | M-csf-specific monoclonal antibody and uses thereof |
PE20051053A1 (es) | 2004-01-09 | 2005-12-12 | Pfizer | ANTICUERPOS CONTRA MAdCAM |
ES2567634T3 (es) | 2004-02-09 | 2016-04-25 | Human Genome Sciences, Inc. | Proteínas de fusión de albúmina |
US7625549B2 (en) | 2004-03-19 | 2009-12-01 | Amgen Fremont Inc. | Determining the risk of human anti-human antibodies in transgenic mice |
WO2005092926A2 (en) | 2004-03-19 | 2005-10-06 | Amgen Inc. | Reducing the risk of human and anti-human antibodies through v gene manipulation |
JP4879884B2 (ja) | 2004-04-12 | 2012-02-22 | メディミューン,エルエルシー | 抗−il−9抗体製剤及びその使用法 |
NZ550106A (en) | 2004-04-22 | 2009-06-26 | Kyowa Hakko Kirin Co Ltd | Transgenic animals and uses thereof |
PL1753871T3 (pl) | 2004-05-28 | 2016-01-29 | Agensys Inc | Przeciwciała i powiązane cząsteczki, które wiążą się z antygenem komórek macierzystych prostaty (PSCA) |
US8124101B2 (en) | 2004-06-01 | 2012-02-28 | Mount Sinai School Of Medicine | Genetically engineered swine influenza virus and uses thereof |
BRPI0511755A (pt) | 2004-06-01 | 2008-01-02 | Domantis Ltd | composições, fusões e conjugados de drogas e métodos de produção, tratamento e utilização |
EP2474317A1 (en) | 2004-06-24 | 2012-07-11 | Biogen Idec MA Inc. | Treatment of conditions involving demyelination |
CA2601417C (en) | 2004-07-01 | 2018-10-30 | Novo Nordisk A/S | Human anti-kir antibodies |
EP2199801B1 (en) | 2004-07-14 | 2013-05-29 | The Regents of The University of California | Biomarkers for early detection of ovarian cancer |
ME00226B (me) | 2004-07-15 | 2011-02-10 | Medarex Llc | Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade |
CN101014365B (zh) | 2004-07-16 | 2011-04-13 | 辉瑞产品公司 | 使用抗-igf-1r抗体联合治疗非血液的恶性肿瘤 |
US20060024677A1 (en) | 2004-07-20 | 2006-02-02 | Morris David W | Novel therapeutic targets in cancer |
KR101457753B1 (ko) | 2004-07-22 | 2014-11-03 | 에라스무스 유니버시티 메디컬 센터 로테르담 | 결합 분자 |
EP2329714A1 (en) | 2004-08-03 | 2011-06-08 | Biogen Idec MA Inc. | Influence of TAJ in the neuronal functions |
AU2005267722B2 (en) | 2004-08-04 | 2009-10-08 | Amgen Inc. | Antibodies to Dkk-1 |
EP1791568B1 (en) | 2004-08-16 | 2012-08-15 | Quark Pharmaceuticals, Inc. | Therapeutic uses of inhibitors of rtp801 |
CA2478458A1 (en) * | 2004-08-20 | 2006-02-20 | Michael Panzara | Treatment of pediatric multiple sclerosis |
AU2004224925C1 (en) | 2004-08-30 | 2011-07-21 | Biotest Ag | Immunoconjugates targeting syndecan-1 expressing cells and use thereof |
US20060051347A1 (en) | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
WO2006034292A2 (en) | 2004-09-21 | 2006-03-30 | Medimmune, Inc. | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
AU2005292227A1 (en) | 2004-10-01 | 2006-04-13 | Medarex, Inc. | Methods of treating CD30 positive lymphomas |
US20080026457A1 (en) | 2004-10-22 | 2008-01-31 | Kevin Wells | Ungulates with genetically modified immune systems |
US20060130157A1 (en) | 2004-10-22 | 2006-06-15 | Kevin Wells | Ungulates with genetically modified immune systems |
US20060121042A1 (en) | 2004-10-27 | 2006-06-08 | Medimmune, Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
ATE492563T1 (de) | 2004-11-17 | 2011-01-15 | Amgen Inc | Vollständige humane monoklonale antikörper gegen il-13 |
US20090202527A1 (en) | 2004-11-19 | 2009-08-13 | Biogen Idec Ma Inc. | Treatment for multiple sclerosis |
GB0426146D0 (en) | 2004-11-29 | 2004-12-29 | Bioxell Spa | Therapeutic peptides and method |
EP1841796A2 (en) | 2004-12-02 | 2007-10-10 | Domantis Limited | Bispecific domain antibodies targeting serum albumin and glp-1 or pyy |
NZ581497A (en) * | 2004-12-03 | 2012-07-27 | Biogen Idec Inc | Delaying or preventing onset of multiple sclerosis by vla-4 ginding antibody |
CA2585104A1 (en) | 2004-12-06 | 2006-06-15 | Kirin Beer Kabushiki Kaisha | Human monoclonal antibodies to influenza m2 protein and methods of making and using same |
WO2006068975A2 (en) | 2004-12-20 | 2006-06-29 | Abgenix, Inc. | Binding proteins specific for human matriptase |
ES2371083T3 (es) | 2004-12-21 | 2011-12-27 | Medimmune Limited | Anticuerpos dirigidos contra la angiopoyetina-2 y usos de los mismos. |
KR20200058588A (ko) | 2005-01-21 | 2020-05-27 | 제넨테크, 인크. | Her 항체의 고정 용량 투여법 |
WO2006081139A2 (en) | 2005-01-26 | 2006-08-03 | Abgenix, Inc. | Antibodies against interleukin-1 beta |
US7402730B1 (en) | 2005-02-03 | 2008-07-22 | Lexicon Pharmaceuticals, Inc. | Knockout animals manifesting hyperlipidemia |
JP5265923B2 (ja) | 2005-02-07 | 2013-08-14 | ジーンニュース インコーポレーテッド | 軽度の変形性関節症のバイオマーカーおよびその使用 |
EP1853718B1 (en) | 2005-02-15 | 2015-08-05 | Duke University | Anti-cd19 antibodies and uses in oncology |
DK2529619T3 (en) | 2005-02-17 | 2016-01-11 | Biogen Ma Inc | Treatment of neurological disorders |
JP2008530244A (ja) | 2005-02-18 | 2008-08-07 | メダレックス, インク. | フコシル残基を欠くcd30に対するモノクローナル抗体 |
ZA200707078B (en) | 2005-02-23 | 2008-11-26 | Genentech Inc | Extending time to disease progression or survival in cancer patients |
JP2008531719A (ja) | 2005-03-02 | 2008-08-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Th2介在性状態の治療のためのKIM−1抗体 |
EP1858545A2 (en) | 2005-03-04 | 2007-11-28 | Curedm Inc. | Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions |
JP5670004B2 (ja) | 2005-03-08 | 2015-02-18 | ファイザー・プロダクツ・インク | 抗ctla−4抗体組成物 |
WO2007059082A1 (en) | 2005-11-10 | 2007-05-24 | Curagen Corporation | Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen |
EP1863848A4 (en) | 2005-03-31 | 2009-09-23 | Agensys Inc | CORRESPONDING ANTIBODIES AND MOLECULES THAT ATTACH PROTEINS 161P2F10B |
JP5313660B2 (ja) | 2005-03-31 | 2013-10-09 | ザ ジェネラル ホスピタル コーポレイション | Hgf/hgfr活性の観察と調節 |
LT3264094T (lt) | 2005-04-04 | 2021-04-12 | Biogen Ma Inc. | Imuninio atsako į terapijos agentą įvertinimo būdai |
EP1865981A2 (en) | 2005-04-07 | 2007-12-19 | Chiron Corporation | Cacna1e in cancer diagnosis, detection and treatment |
US20090220495A1 (en) | 2005-04-07 | 2009-09-03 | Abdallah Fanidi | Cancer Related Genes (PRLR) |
US9296816B2 (en) | 2005-04-15 | 2016-03-29 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
EP1874820A4 (en) * | 2005-04-20 | 2010-09-22 | Amgen Fremont Inc | HIGH AFFINE, COMPLETELY HUMAN MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-8 AND EPITOPES FOR SUCH ANTIBODIES |
EA015534B1 (ru) | 2005-04-25 | 2011-08-30 | Пфайзер Инк. | Антитела к миостатину и способы их применения |
WO2006114704A2 (en) | 2005-04-26 | 2006-11-02 | Pfizer Inc. | P-cadherin antibodies |
PE20061324A1 (es) | 2005-04-29 | 2007-01-15 | Centocor Inc | Anticuerpos anti-il-6, composiciones, metodos y usos |
CA2607281C (en) | 2005-05-05 | 2023-10-03 | Duke University | Anti-cd19 antibody therapy for autoimmune disease |
AU2006244014B2 (en) | 2005-05-10 | 2011-03-17 | Biogen Ma Inc. | Treating and evaluating inflammatory disorders |
CA2726759C (en) | 2005-05-25 | 2016-02-16 | Curedm Group Holdings, Llc | Human proislet peptide, derivatives and analogs thereof, and methods of using same |
EP2460831B1 (en) | 2005-05-27 | 2016-10-19 | Biogen MA Inc. | Tweak binding antibodies |
WO2006138219A2 (en) | 2005-06-13 | 2006-12-28 | Biogen Idec Ma Inc. | Methods of diagnosis / prognosis of inflammatory conditions |
KR20080025174A (ko) | 2005-06-23 | 2008-03-19 | 메디뮨 인코포레이티드 | 응집 및 단편화 프로파일이 최적화된 항체 제제 |
PL1896073T3 (pl) | 2005-06-30 | 2013-08-30 | Janssen Biotech Inc | Przeciwciała anty-IL-23, kompozycje, sposoby i zastosowania |
WO2007008547A2 (en) | 2005-07-08 | 2007-01-18 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
BRPI0614040B8 (pt) | 2005-07-18 | 2021-05-25 | Amgen Inc | anticorpo isolado que se liga especificamente a b7rp1, polipeptídeo, composição farmacêutica, vetor de expressão, célula hospedeira, linhagem celular isolada e métodos para a detecção de b7rp1 em uma amostra biológica e de produção de um anticorpo ou polipeptídeo |
US8652469B2 (en) | 2005-07-28 | 2014-02-18 | Novartis Ag | M-CSF-specific monoclonal antibody and uses thereof |
SI2573114T1 (sl) | 2005-08-10 | 2016-08-31 | Macrogenics, Inc. | Identifikacija in inženiring protiteles z variantnimi fc regijami in postopki za njih uporabo |
EP2500357A3 (en) | 2005-08-19 | 2012-10-24 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
MY169746A (en) | 2005-08-19 | 2019-05-14 | Abbvie Inc | Dual variable domain immunoglobulin and uses thereof |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
PT2447283E (pt) | 2005-09-07 | 2015-10-08 | Pfizer | Anticorpos monoclonais humanos para cinase-1 tipo recetor de activina (alk-1) |
US9062126B2 (en) | 2005-09-16 | 2015-06-23 | Raptor Pharmaceuticals Inc. | Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof |
WO2007039256A2 (de) | 2005-09-30 | 2007-04-12 | Abbott Gmbh & Co. Kg | Bindungsdomänen von proteinen der repulsive guidance molecule (rgm) proteinfamilie und funktionale fragmente davon sowie deren verwendung |
EP2319941A3 (en) | 2005-10-21 | 2011-08-17 | GeneNews Inc. | Method and apparatus for correlating levels of biomarker products with disease |
PE20070796A1 (es) * | 2005-10-24 | 2007-08-15 | Wyeth Corp | Metodo de produccion proteica utilizando compuestos anti-senescencia |
US20090246189A1 (en) | 2005-11-04 | 2009-10-01 | Biogen Idec Ma Inc. And Mclean Hospital | Methods for Promoting Neurite Outgrowth and Survival of Dopaminergic Neurons |
MY151064A (en) | 2005-11-04 | 2014-03-31 | Genentech Inc | Use of complement pathway inhibitors to treat ocular diseases |
ZA200804082B (en) | 2005-11-07 | 2010-02-24 | Scripps Research Inst | Compositions and methods for controlling tissue factor signaling specificity |
WO2007059430A2 (en) | 2005-11-10 | 2007-05-24 | Bristol-Myers Squibb Pharma Company | Moesin, caveolin 1 and yes associated protein 1 as predictive markers of response to dasatinib in breast cancers |
US7723484B2 (en) | 2005-11-12 | 2010-05-25 | Applied Molecular Evolution, Inc. | Anti-EGFR antibodies |
TW200736277A (en) | 2005-11-14 | 2007-10-01 | Amgen Inc | RANKL antibody-PTH/PTHrP chimeric molecules |
TWI461436B (zh) | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類cd134(ox40)之人類單株抗體及其製造及使用方法 |
EP2805971A1 (en) | 2005-11-28 | 2014-11-26 | ZymoGenetics, Inc. | IL-21 antagonists |
US8497072B2 (en) | 2005-11-30 | 2013-07-30 | Abbott Laboratories | Amyloid-beta globulomer antibodies |
PL1954718T3 (pl) | 2005-11-30 | 2015-04-30 | Abbvie Inc | Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał |
KR101453570B1 (ko) | 2005-12-02 | 2014-10-22 | 제넨테크, 인크. | Il-22 및 il-22r에 결합하는 항체를 포함하는,사이토카인 신호 전달과 관련된 질환 및 장애 치료용조성물 및 치료 방법 |
JP5312039B2 (ja) | 2005-12-02 | 2013-10-09 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 脱髄の関与する状態の処置 |
NZ595736A (en) | 2005-12-02 | 2013-05-31 | Sinai School Medicine | Chimeric viruses presenting non-native surface proteins and uses thereof |
CN101325971A (zh) | 2005-12-07 | 2008-12-17 | 米德列斯公司 | Ctla-4抗体剂量递增方案 |
US20070134249A1 (en) * | 2005-12-08 | 2007-06-14 | Genitope Corporation | Combination therapy and antibody panels |
CA2633956C (en) | 2005-12-13 | 2016-12-06 | Olivia Raeber | Binding proteins specific for insulin-like growth factors and uses thereof |
CA2633887C (en) | 2005-12-15 | 2015-12-22 | Genentech, Inc. | Methods and compositions for targeting polyubiquitin |
CN103341168B (zh) | 2005-12-15 | 2016-11-02 | 阿斯利康(瑞典)有限公司 | 治疗癌症的促血管生成素-2拮抗剂和VEGF-A、KDR和/或Flt1拮抗剂的组合 |
CA2635588C (en) | 2005-12-30 | 2015-11-10 | Dyax Corp. | Metalloproteinase binding proteins |
AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
EP2749571A3 (en) | 2006-01-10 | 2014-08-13 | ZymoGenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using IL-31RA and OSMRb antagonists |
WO2007084321A2 (en) | 2006-01-12 | 2007-07-26 | Alexion Pharmaceuticals, Inc. | Antibodies to ox-2/cd200 and uses thereof |
JP2009523807A (ja) | 2006-01-18 | 2009-06-25 | ザ ジェネラル ホスピタル コーポレイション | リンパ機能を高める方法 |
NL2000439C2 (nl) | 2006-01-20 | 2009-03-16 | Quark Biotech | Therapeutische toepassingen van inhibitoren van RTP801. |
BRPI0706750A2 (pt) | 2006-01-25 | 2011-04-05 | Univ Erasmus Medical Ct | geração de anticorpos de cadeia pesada em animais transgênicos |
CN103215293B (zh) | 2006-01-27 | 2015-10-28 | 比奥根Ma公司 | Nogo受体拮抗剂 |
TW200744634A (en) | 2006-02-21 | 2007-12-16 | Wyeth Corp | Methods of using antibodies against human IL-22 |
TWI417301B (zh) | 2006-02-21 | 2013-12-01 | Wyeth Corp | 對抗人類介白素-22(il-22)之抗體及其用途 |
JP2009529915A (ja) | 2006-03-20 | 2009-08-27 | ゾーマ テクノロジー リミテッド | ガストリン物質に対して特異的なヒト抗体および方法 |
EP2014297B1 (en) | 2006-03-20 | 2013-03-13 | Japan Science and Technology Agency | Control of intracellular target molecule by ip3 receptor-binding protein |
US7910798B2 (en) | 2006-03-31 | 2011-03-22 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
AU2007243946B2 (en) | 2006-04-05 | 2012-11-29 | Curis, Inc. | Method for using BOC/CDO to modulate hedgehog signaling |
US8071323B2 (en) | 2006-04-07 | 2011-12-06 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Human monoclonal antibodies that bind human insulin like growth factors and their use |
TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
JP2009541208A (ja) | 2006-04-13 | 2009-11-26 | ノバルティス・バクシーンズ・アンド・ダイアグノスティクス・インコーポレイテッド | がんを処置し、診断しもしくは検出する方法 |
ES2509878T3 (es) | 2006-05-25 | 2014-10-20 | Biogen Idec Ma Inc. | Anticuerpo anti-VLA-1 para tratar accidente cerebrovascular |
KR101328756B1 (ko) | 2006-05-30 | 2013-11-18 | 제넨테크, 인크. | 항체 및 면역접합체 및 이들의 용도 |
WO2007143090A2 (en) | 2006-06-02 | 2007-12-13 | Aveo Pharmaceuticals, Inc. | Hepatocyte growth factor (hgf) binding proteins |
KR101196184B1 (ko) | 2006-06-02 | 2012-11-01 | 아베오 파마슈티컬즈, 인크. | 간세포 성장 인자 (hgf) 결합 단백질 |
CL2007001623A1 (es) | 2006-06-06 | 2008-01-18 | Genentech Inc | Anticuerpo anti-dll4; polinucleotido que lo codifica; vector y celula huesped que comprenden dicho polinucleotido; metodo para elaborar el anticuerpo e inmunojugado; metodo de deteccion de dll4 y metodo diagnostico de un trastorno asociado a dll4; composicion que comprende al anticuerpo. |
EP2037961B1 (en) | 2006-06-14 | 2015-11-11 | MacroGenics, Inc. | Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity |
WO2008019199A2 (en) | 2006-06-26 | 2008-02-14 | Macrogenics, Inc. | FCγRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF |
CA2656221A1 (en) | 2006-06-28 | 2008-01-03 | Yeda Research And Development Co. Ltd. | Caspase-8 and inflammation, infection and wound healing |
US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
US20130004480A1 (en) | 2006-07-04 | 2013-01-03 | Paul Parren | CD20 Binding Molecules for the Treatment of Copd |
SG173371A1 (en) | 2006-07-13 | 2011-08-29 | Univ Iowa Res Found | Methods and reagents for treatment and diagnosis of vascular disorders and age-related macular degeneration |
ZA200900545B (en) | 2006-07-18 | 2010-03-31 | Sanofi Aventis | Antagonist antibody against EPHA2 for the treatment of cancer |
AU2007348941B2 (en) | 2006-08-03 | 2011-08-04 | Medimmune Limited | Antibodies directed to alphaVbeta6 and uses thereof |
CL2007002225A1 (es) | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
EP2054444B1 (en) | 2006-08-04 | 2016-11-02 | MedImmune Limited | Antibodies to erbb2 |
EP2420252A1 (en) | 2006-08-04 | 2012-02-22 | Novartis AG | EPHB3-specific antibody and uses thereof |
TW201441262A (zh) | 2006-08-18 | 2014-11-01 | Novartis Ag | 催乳激素受體(prlr)之專一性抗體及其用途 |
WO2008022390A1 (en) | 2006-08-22 | 2008-02-28 | G2 Inflammation Pty Ltd | Anti-c5ar antibodies with improved properties |
DK2484696T3 (en) | 2006-08-28 | 2017-10-02 | Kyowa Hakko Kirin Co Ltd | Antagonistic hLIGHT-specific human monoclonal antibodies |
US10118970B2 (en) | 2006-08-30 | 2018-11-06 | Genentech, Inc. | Multispecific antibodies |
US20090053210A1 (en) | 2006-09-01 | 2009-02-26 | Roland Buelow | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
CN101506235B (zh) | 2006-09-01 | 2012-07-25 | 人类多细胞株治疗学公司 | 人或人源化免疫球蛋白在非人转基因动物中增强的表达 |
ES2817756T3 (es) | 2006-09-08 | 2021-04-08 | Abbvie Bahamas Ltd | Proteínas de unión a interleuquina-13 |
CA2662236A1 (en) | 2006-09-12 | 2008-03-20 | Genentech, Inc. | Methods and compositions for the diagnosis and treatment of cancer |
US7833527B2 (en) * | 2006-10-02 | 2010-11-16 | Amgen Inc. | Methods of treating psoriasis using IL-17 Receptor A antibodies |
CA2664567C (en) | 2006-10-04 | 2016-04-26 | Dana-Farber Cancer Institute, Inc. | Tumor immunity |
CA2665423A1 (en) * | 2006-10-12 | 2008-04-17 | Wyeth | Methods and compositions with reduced opalescence |
JP2010506842A (ja) | 2006-10-16 | 2010-03-04 | メディミューン,エルエルシー | 半減期が短縮された分子、その組成物および使用 |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
US7846434B2 (en) | 2006-10-24 | 2010-12-07 | Trubion Pharmaceuticals, Inc. | Materials and methods for improved immunoglycoproteins |
RS52452B (en) | 2006-10-27 | 2013-02-28 | Genentech Inc. | Antibodies and Immunoconjugates and Their Use |
ES2541546T3 (es) * | 2006-11-03 | 2015-07-21 | Wyeth Llc | Sustancias que inhiben la glucólisis en cultivo celular |
WO2008064306A2 (en) | 2006-11-22 | 2008-05-29 | Curedm, Inc. | Methods and compositions relating to islet cell neogenesis |
US20080199475A1 (en) | 2006-11-27 | 2008-08-21 | Patrys Limited | Novel glycosylated peptide target in neoplastic cells |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
EP2687232A1 (en) | 2006-12-06 | 2014-01-22 | MedImmune, LLC | Methods of treating systemic lupus erythematosus |
MX2009006034A (es) | 2006-12-07 | 2009-10-12 | Novartis Ag | Anticuerpos antagonistas contra ephb3. |
CA2672049C (en) | 2006-12-08 | 2016-05-10 | Lexicon Pharmaceuticals, Inc. | Monoclonal antibodies against angptl3 |
US7935791B2 (en) | 2006-12-18 | 2011-05-03 | Genentech, Inc. | Antagonist anti-Notch3 antibodies and their use in the prevention and treatment of Notch3-related diseases |
WO2008077145A2 (en) | 2006-12-20 | 2008-06-26 | Xoma Technology Ltd. | Treatment of il-1-beta related diseases |
ES2635317T3 (es) | 2007-01-05 | 2017-10-03 | University Of Zurich | Anticuerpo anti-beta-amiloide y sus usos |
EP2740744B1 (en) | 2007-01-09 | 2018-03-28 | Biogen MA Inc. | Sp35 antibodies and uses thereof |
US8128926B2 (en) | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
SG177982A1 (en) | 2007-01-16 | 2012-02-28 | Abbott Lab | Methods for treating psoriasis |
CL2008000420A1 (es) | 2007-02-09 | 2008-06-27 | Genentech Inc | Anticuerpo anti-robo4; y su uso para modular la angiogenesis. |
US8685666B2 (en) | 2007-02-16 | 2014-04-01 | The Board Of Trustees Of Southern Illinois University | ARL-1 specific antibodies and uses thereof |
US8114606B2 (en) | 2007-02-16 | 2012-02-14 | The Board Of Trustees Of Southern Illinois University | ARL-1 specific antibodies |
EP2121162A4 (en) * | 2007-02-22 | 2011-03-02 | Roger M Simonson | MAGNETIC FILTER AND MAGNETIC FILTER ASSEMBLY |
AU2008218199B2 (en) | 2007-02-22 | 2013-10-31 | Genentech, Inc. | Methods for detecting inflammatory bowel disease |
EP2486928A1 (en) | 2007-02-27 | 2012-08-15 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
DK2132573T3 (da) | 2007-03-02 | 2014-07-14 | Genentech Inc | Forudsigelse af respons på en her-dimeriseringsinhibitor på basis af lav her3-ekspression |
CL2008000717A1 (es) | 2007-03-13 | 2008-09-22 | Amgen Inc | Metodo para pronosticar si un paciente sera no respondedor al tratamiento con un agente de union especifica a un polipeptido de egfr que comprende determinar la presencia o ausencia de una mutacion de k-ras en un tumor del paciente. |
SI2412828T1 (sl) | 2007-03-13 | 2013-10-30 | Amgen Inc. | Mutacije k-ras in b-raf ter terapija s protitelesom anti-egfr |
JP2010521180A (ja) | 2007-03-14 | 2010-06-24 | ノバルティス アーゲー | 癌を処置、診断または検出するためのapcdd1阻害剤 |
DK2125894T3 (en) | 2007-03-22 | 2019-03-18 | Biogen Ma Inc | BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, SPECIFICALLY BINDING CD154 AND APPLICATIONS THEREOF |
US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
WO2008118324A2 (en) | 2007-03-26 | 2008-10-02 | Macrogenics, Inc. | Composition and method of treating cancer with an anti-uroplakin ib antibody |
NZ580379A (en) | 2007-03-29 | 2012-10-26 | Abbott Lab | Crystalline anti-human il-12 antibodies |
CA2682170A1 (en) | 2007-03-30 | 2008-10-09 | Medimmune, Llc | Antibodies with decreased deamidation profiles |
CL2008000935A1 (es) | 2007-04-02 | 2008-11-07 | Amgen Fremont Inc | Anticuerpo monoclonal humano anti-ige o fragmento del mismo; acido nucleico que lo codifica; vector y celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos relacionados con ige. |
TW200902708A (en) * | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
DK3072525T3 (en) | 2007-05-14 | 2018-04-30 | Astrazeneca Ab | PROCEDURES FOR REDUCING BASOFILE CELL LEVELS |
US20110046094A1 (en) | 2007-05-21 | 2011-02-24 | Behrens Timothy W | Methods and compositions for identifying and treating lupus |
PT2152880E (pt) * | 2007-06-01 | 2011-12-15 | Omt Inc | Composições e métodos para inibição de genes de imunoglobulinas endógenas e produção de anticorpos idiótipos humanos transgénicos |
ES2583377T3 (es) | 2007-06-08 | 2016-09-20 | Genentech, Inc. | Marcadores de expresión génica de la resistencia tumoral al tratamiento con inhibidor de HER2 |
AU2008266051B2 (en) | 2007-06-14 | 2014-07-31 | Biogen Ma Inc. | Antibody formulations |
PL2158221T3 (pl) | 2007-06-21 | 2019-02-28 | Macrogenics, Inc. | Kowalencyjne diaciała i ich zastosowania |
CL2008001887A1 (es) | 2007-06-29 | 2008-10-03 | Amgen Inc | Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende. |
CA2691692C (en) | 2007-07-09 | 2021-05-18 | Genentech, Inc. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
ES2453592T3 (es) | 2007-08-02 | 2014-04-08 | Novimmune Sa | Anticuerpos anti-RANTES y métodos de uso de los mismos |
TWI595005B (zh) | 2007-08-21 | 2017-08-11 | 安健股份有限公司 | 人類c-fms抗原結合蛋白質 |
EP2615113A3 (en) | 2007-08-23 | 2013-11-13 | Amgen Inc. | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9) |
JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
US8647622B2 (en) | 2007-08-29 | 2014-02-11 | Sanofi | Humanized anti-CXCR5 antibodies, derivatives thereof and their use |
JP2010538017A (ja) | 2007-08-30 | 2010-12-09 | キュアーディーエム、インク. | 膵島形成促進性ペプチドおよびそのアナログを使用する組成物および方法 |
EP2198304B1 (en) | 2007-09-06 | 2016-01-13 | University of Washington | Molecules and methods for treatment and detection of diabetes |
US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
TW200918553A (en) | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
CN101970485B (zh) | 2007-09-26 | 2014-05-14 | U3制药有限公司 | 肝素结合表皮生长因子样生长因子抗原结合蛋白 |
ES2750254T3 (es) | 2007-09-27 | 2020-03-25 | Amgen Inc | Formulaciones farmacéuticas |
EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
RU2530561C2 (ru) | 2007-11-05 | 2014-10-10 | Медиммун, Ллк | Способы лечения склеродермии |
RS57021B1 (sr) | 2007-11-07 | 2018-05-31 | Genentech Inc | Il-22 za upotrebu u tretiranju mikrobnih poremećaja |
AU2008323701B2 (en) | 2007-11-07 | 2015-03-26 | Genentech, Inc | Methods and compositions for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies |
EP2918605A1 (en) | 2007-11-12 | 2015-09-16 | U3 Pharma GmbH | Axl antibodies |
US8796206B2 (en) | 2007-11-15 | 2014-08-05 | Amgen Inc. | Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration |
WO2009064944A2 (en) | 2007-11-16 | 2009-05-22 | Nuvelo, Inc. | Antibodies to lrp6 |
JP5490714B2 (ja) | 2007-11-28 | 2014-05-14 | メディミューン,エルエルシー | タンパク質製剤 |
TWI580694B (zh) | 2007-11-30 | 2017-05-01 | 建南德克公司 | 抗-vegf抗體 |
AU2008343085B2 (en) | 2007-12-20 | 2015-03-12 | Xoma (Us) Llc | Methods for the treatment of gout |
US8414893B2 (en) | 2007-12-21 | 2013-04-09 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
WO2009080831A1 (en) | 2007-12-26 | 2009-07-02 | Biotest Ag | Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates |
WO2009080832A1 (en) | 2007-12-26 | 2009-07-02 | Biotest Ag | Methods and agents for improving targeting of cd138 expressing tumor cells |
KR20100097753A (ko) | 2007-12-26 | 2010-09-03 | 바이오테스트 아게 | Cd138 표적성 면역접합체 및 이의 용도 |
ES2475201T3 (es) | 2007-12-26 | 2014-07-10 | Biotest Ag | Agentes dirigidos contra CD138 y usos de los mismos |
JP2011509675A (ja) | 2008-01-18 | 2011-03-31 | メディミューン,エルエルシー | 部位特異的コンジュゲーションのためのシステイン操作抗体 |
ES2500066T3 (es) | 2008-01-25 | 2014-09-30 | Amgen, Inc | Anticuerpos frente a ferroportina y métodos de uso |
SG188129A1 (en) | 2008-02-08 | 2013-03-28 | Medimmune Llc | Anti-ifnar1 antibodies with reduced fc ligand affinity |
IL189408A0 (en) | 2008-02-10 | 2009-02-11 | Yeda Res & Dev | Siva3, its preparation and pharmaceutical compositions containing it |
WO2009103113A1 (en) | 2008-02-20 | 2009-08-27 | G2 Inflammation Pty Ltd | HUMANIZED ANTI-C5aR ANTIBODIES |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
EP2098536A1 (en) | 2008-03-05 | 2009-09-09 | 4-Antibody AG | Isolation and identification of antigen- or ligand-specific binding proteins |
AU2009225797A1 (en) | 2008-03-18 | 2009-09-24 | Abbvie Inc. | Methods for treating psoriasis |
WO2009118300A1 (en) | 2008-03-25 | 2009-10-01 | Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by down-regulating frizzled-4 and/or frizzled-1 |
AU2009231733B2 (en) | 2008-03-31 | 2015-12-24 | Genentech, Inc. | Compositions and methods for treating and diagnosing asthma |
US8012714B2 (en) * | 2008-04-14 | 2011-09-06 | Innovative Targeting Solutions, Inc. | Sequence diversity generation in immunoglobulins |
JP6106854B2 (ja) | 2008-04-25 | 2017-04-05 | ダイアックス、コープDyax Corp. | FcRnに対する抗体及びその使用 |
CA2722043A1 (en) | 2008-04-25 | 2009-10-29 | Toray Industries, Inc. | Nucleic acid comprising chimeric gene derived from hepatitis c virus |
US9029508B2 (en) | 2008-04-29 | 2015-05-12 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
AU2009246946B2 (en) | 2008-05-01 | 2013-09-26 | Amgen Inc. | Anti-hepcidin antibodies and methods of use |
ES2458541T3 (es) | 2008-05-02 | 2014-05-06 | Seattle Genetics, Inc. | Métodos y composiciones para elaborar anticuerpos y derivados de anticuerpos con fucosilación del núcleo reducida |
MY159667A (en) | 2008-05-09 | 2017-01-13 | Abbvie Inc | Antibodies to receptor of advanced glycation end products (rage) and uses thereof |
EP2599793A1 (en) | 2008-05-29 | 2013-06-05 | Nuclea Biotechnologies, Inc. | Anti-phospho-akt antibodies |
BRPI0913406A2 (pt) | 2008-06-03 | 2018-01-09 | Abbott Lab | imunoglobulinas de domínio variável duplo e usos das mesmas |
KR20110016959A (ko) | 2008-06-03 | 2011-02-18 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
CA2728347A1 (en) | 2008-06-16 | 2010-01-14 | Patrys Limited | Lm-1 antibodies, functional fragments, lm-1 target antigen, and methods for making and using same |
WO2009158432A2 (en) | 2008-06-27 | 2009-12-30 | Amgen Inc. | Ang-2 inhibition to treat multiple sclerosis |
CA2728909A1 (en) | 2008-07-08 | 2010-01-14 | Abbott Laboratories | Prostaglandin e2 binding proteins and uses thereof |
MX2010014574A (es) | 2008-07-08 | 2011-04-27 | Abbott Lab | Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas. |
US8058406B2 (en) | 2008-07-09 | 2011-11-15 | Biogen Idec Ma Inc. | Composition comprising antibodies to LINGO or fragments thereof |
US8680020B2 (en) | 2008-07-15 | 2014-03-25 | Academia Sinica | Glycan arrays on PTFE-like aluminum coated glass slides and related methods |
MY153074A (en) | 2008-08-14 | 2014-12-31 | Teva Pharmaceuticals Australia Pty Ltd | Anti-il-12/11-23 antibodies |
CN102239180B (zh) | 2008-08-18 | 2014-12-31 | 辉瑞大药厂 | 抗ccr2抗体 |
CA2734905A1 (en) | 2008-09-03 | 2010-03-11 | Jenny M. Bostrom | Multispecific antibodies |
CA2735433C (en) | 2008-09-07 | 2016-02-16 | Glyconex Inc. | Anti-extended type i glycosphingolipid antibody, derivatives thereof and use |
EP2344536A1 (en) | 2008-09-19 | 2011-07-20 | MedImmune, LLC | Antibodies directed to dll4 and uses thereof |
JP2012504939A (ja) | 2008-09-23 | 2012-03-01 | ワイス・エルエルシー | 架橋結合タンパク質による活性化シグナルの産生を予測するための方法 |
AU2009298458B2 (en) | 2008-09-30 | 2015-10-08 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
US20110262446A1 (en) | 2008-10-14 | 2011-10-27 | Dyax Corp. | Use of igf-ii/igf-iie binding proteins for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis |
PE20150682A1 (es) | 2008-10-14 | 2015-05-20 | Genentech Inc | Variantes de inmunoglobulinas y sus usos |
US20120251502A1 (en) | 2008-10-24 | 2012-10-04 | The Government of the US as Represented by the Secretary of the Dept. of health | Human Ebola Virus Species and Compositions and Methods Thereof |
DK2348827T3 (en) | 2008-10-27 | 2015-07-20 | Revivicor Inc | IMMUNICIPLY COMPROMATED PETS |
MX2011004558A (es) | 2008-10-29 | 2011-06-01 | Wyeth Llc | Procedimientos para la purificacion de moleculas de union a antigeno de un unico dominio. |
BR122018013284B1 (pt) | 2008-10-29 | 2022-03-03 | Ablynx N.V | Formulações de moléculas de ligação ao antígeno de domínio único, seu método de formulação e seu uso, kit ou artigo de fabricação, bem como método para preparar uma formulação reconstituída contendo uma molécula de sdab |
WO2010052288A1 (en) | 2008-11-07 | 2010-05-14 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | Teneurin and cancer |
CN109045296A (zh) | 2008-11-10 | 2018-12-21 | 阿雷克森制药公司 | 用于治疗补体相关障碍的方法和组合物 |
US20140086919A1 (en) * | 2012-09-24 | 2014-03-27 | Herbert Y. Lin | Methods and compositons for regulating iron homeostasis by modulation of bmp-6 |
EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
EP2191842A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
EP2191843A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
JP2012510468A (ja) * | 2008-11-28 | 2012-05-10 | アボット・ラボラトリーズ | 安定な抗体組成物およびこれを安定させるための方法 |
EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
CN114835812A (zh) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
RU2011129459A (ru) * | 2008-12-18 | 2013-01-27 | Эрасмус Юниверсити Медикал Сентр Роттердам | Трансгенные животные (не человек), экспрессирующие гуманизированные антитела, и их применение |
BRPI0918122A8 (pt) | 2008-12-19 | 2017-01-24 | Macrogenics Inc | molécula de diabody, diabody, e mólecula dart |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
CA2748158A1 (en) | 2008-12-23 | 2010-07-01 | Astrazeneca Ab | Targeted binding agents directed to .alpha.5.beta.1 and uses thereof |
US20120009182A1 (en) | 2008-12-23 | 2012-01-12 | Genentech, Inc. | Immunoglobulin variants with altered binding to protein a |
JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
JP2012514458A (ja) | 2008-12-31 | 2012-06-28 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 抗リンホトキシン抗体 |
CA2749572A1 (en) | 2009-01-14 | 2010-07-22 | Iq Therapeutics Bv | Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins |
WO2010085510A1 (en) | 2009-01-20 | 2010-07-29 | Zadeh Homayoun H | Antibody mediated osseous regeneration |
WO2010087927A2 (en) | 2009-02-02 | 2010-08-05 | Medimmune, Llc | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
US8309530B2 (en) | 2009-02-04 | 2012-11-13 | Washington State University | Compositions and methods for modulating ghrelin-mediated conditions |
CA2750520C (en) * | 2009-02-04 | 2017-12-05 | Molecular Innovations | Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein |
WO2010093993A2 (en) | 2009-02-12 | 2010-08-19 | Human Genome Sciences, Inc. | Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance |
NZ611324A (en) | 2009-03-05 | 2015-02-27 | Abbvie Inc | Il-17 binding proteins |
WO2010100247A1 (en) | 2009-03-06 | 2010-09-10 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | Novel therapy for anxiety |
RU2504553C2 (ru) | 2009-03-20 | 2014-01-20 | Дженентек, Инк. | Антитела к her |
WO2010108154A2 (en) | 2009-03-20 | 2010-09-23 | Amgen Inc. | Selective and potent peptide inhibitors of kv1.3 |
US8524869B2 (en) | 2009-03-24 | 2013-09-03 | Teva Biopharmaceuticals Usa, Inc. | Humanized antibodies against LIGHT and uses thereof |
US9051359B2 (en) | 2009-03-30 | 2015-06-09 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccines and uses thereof |
MA33248B1 (fr) | 2009-04-01 | 2012-05-02 | Genentech Inc | Traitement de troubles résistant à l'insuline |
US20100297127A1 (en) | 2009-04-08 | 2010-11-25 | Ghilardi Nico P | Use of il-27 antagonists to treat lupus |
JP5748653B2 (ja) | 2009-04-10 | 2015-07-15 | 協和発酵キリン株式会社 | 抗tim−3抗体を用いた血液腫瘍治療法 |
EP2241323A1 (en) | 2009-04-14 | 2010-10-20 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Tenascin-W and brain cancers |
CA2758964A1 (en) | 2009-04-16 | 2010-10-21 | Abbott Biotherapeutics Corp. | Anti-tnf-.alpha. antibodies and their uses |
WO2010121141A1 (en) * | 2009-04-17 | 2010-10-21 | Biogen Idec Ma Inc. | Compositions and methods to treat acute myelogenous leukemia |
EP2419531B1 (en) | 2009-04-18 | 2016-09-07 | Genentech, Inc. | Methods for assessing responsiveness of b-cell lymphoma to treatment with anti-cd40 antibodies |
KR101732201B1 (ko) | 2009-04-27 | 2017-05-02 | 교와 핫꼬 기린 가부시키가이샤 | 혈액 종양 치료를 목적으로 하는 항IL-3Rα 항체 |
JP5925116B2 (ja) | 2009-04-29 | 2016-05-25 | ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド | Ergモノクローナル抗体 |
KR101811886B1 (ko) | 2009-05-05 | 2017-12-22 | 노비뮨 에스 에이 | 항―il―17f 항체 및 이의 사용 방법 |
US8673314B2 (en) | 2009-05-26 | 2014-03-18 | Mount Sinai School Of Medicine | Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof |
WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
AU2010262836B2 (en) | 2009-06-17 | 2015-05-28 | Abbvie Biotherapeutics Inc. | Anti-VEGF antibodies and their uses |
JP5918129B2 (ja) | 2009-06-22 | 2016-05-18 | メディミューン,エルエルシー | 部位特異的共役のための操作されたFc領域 |
US20120204278A1 (en) | 2009-07-08 | 2012-08-09 | Kymab Limited | Animal models and therapeutic molecules |
EP3028565B1 (en) | 2009-07-08 | 2017-09-27 | Kymab Limited | Animal models and therapeutic molecules |
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
WO2011006001A1 (en) | 2009-07-09 | 2011-01-13 | Genentech, Inc. | Animal model for the evaluation of adjuvant therapies of cancer |
WO2011003996A1 (en) | 2009-07-09 | 2011-01-13 | F. Hoffmann-La Roche Ag | In vivo tumor vasculature imaging |
CN102482715A (zh) | 2009-07-13 | 2012-05-30 | 霍夫曼-拉罗奇有限公司 | 用于癌症治疗的诊断方法和组合物 |
WO2011014457A1 (en) | 2009-07-27 | 2011-02-03 | Genentech, Inc. | Combination treatments |
WO2011014504A1 (en) | 2009-07-27 | 2011-02-03 | Mount Sinai School Of Medicine Of New York University | Recombinant influenza virus vectors and uses thereof |
WO2011014645A1 (en) | 2009-07-30 | 2011-02-03 | Mount Sinai School Of Medicine Of New York University | Influenza viruses and uses thereof |
WO2011014750A1 (en) | 2009-07-31 | 2011-02-03 | Genentech, Inc. | Inhibition of tumor metastasis using bv8- or g-csf-antagonists |
WO2011019620A1 (en) | 2009-08-10 | 2011-02-17 | Genentech, Inc. | Antibodies with enhanced adcc function |
LT2464725T (lt) | 2009-08-11 | 2020-06-10 | F. Hoffmann-La Roche Ag | Baltymų gamyba ląstelių mitybinėje terpėje, kurioje nėra glutamino |
WO2011019844A1 (en) | 2009-08-13 | 2011-02-17 | Crystal Bioscience Inc. | Transgenic animal for production of antibodies having minimal cdrs |
JP5762408B2 (ja) | 2009-08-13 | 2015-08-12 | クルセル ホランド ベー ヴェー | ヒト呼吸器合胞体ウイルス(rsv)に対する抗体および使用方法 |
SG178360A1 (en) | 2009-08-14 | 2012-03-29 | Genentech Inc | Biological markers for monitoring patient response to vegf antagonists |
WO2011019622A1 (en) | 2009-08-14 | 2011-02-17 | Genentech, Inc. | Cell culture methods to make antibodies with enhanced adcc function |
EP2292266A1 (en) | 2009-08-27 | 2011-03-09 | Novartis Forschungsstiftung, Zweigniederlassung | Treating cancer by modulating copine III |
AU2010286518C1 (en) | 2009-08-29 | 2015-08-27 | Abbvie Inc. | Therapeutic DLL4 binding proteins |
RU2012112550A (ru) | 2009-09-01 | 2013-10-10 | Эбботт Лэборетриз | Иммуноглобулины с двумя вариабельными доменами и их применение |
JP5887270B2 (ja) | 2009-09-02 | 2016-03-16 | ジェネンテック, インコーポレイテッド | 突然変異体smoothenedおよびその使用方法 |
MX353186B (es) | 2009-09-03 | 2018-01-05 | Genentech Inc | Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide. |
JO3246B1 (ar) | 2009-09-09 | 2018-03-08 | Regeneron Pharma | اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري |
CA2773662A1 (en) | 2009-09-11 | 2011-03-17 | Genentech, Inc. | Method to identify a patient with an increased likelihood of responding to an anti-cancer agent |
RU2012114854A (ru) | 2009-09-14 | 2013-10-27 | Эбботт Лэборетриз | Способы лечения псориаза |
CA2772670A1 (en) | 2009-09-17 | 2011-03-24 | F. Hoffmann-La Roche Ag | Methods and compositions for diagnostics use in cancer patients |
EP2480573A1 (en) | 2009-09-22 | 2012-08-01 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by modulating mex-3 |
US8926976B2 (en) | 2009-09-25 | 2015-01-06 | Xoma Technology Ltd. | Modulators |
US9885711B2 (en) | 2009-09-25 | 2018-02-06 | Xoma Technology Ltd. | Screening methods |
KR101108642B1 (ko) | 2009-09-29 | 2012-02-09 | 주식회사 녹십자 | 표피 성장 인자 수용체에 특이적으로 결합하는 항체 |
ES2580229T3 (es) | 2009-09-30 | 2016-08-22 | F. Hoffmann-La Roche Ag | Anticuerpos antagonistas anti-Notch3 para el tratamiento de una leucemia de linfocitos T positiva a un inhibidor de la gamma-secretasa que no responde a un anticuerpo antagonista anti-Notch1 |
AR078470A1 (es) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | Anticuerpos que se unen especificamente al receptor epha2 |
CN106929568A (zh) | 2009-10-07 | 2017-07-07 | 弗·哈夫曼-拉罗切有限公司 | 用于治疗、诊断和监控狼疮的方法 |
WO2011044368A1 (en) | 2009-10-07 | 2011-04-14 | Macrogenics, Inc. | Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use |
CA2776756A1 (en) | 2009-10-11 | 2011-04-14 | Biogen Idec Ma Inc. | Anti-vla-4 related assays |
TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
WO2011045352A2 (en) | 2009-10-15 | 2011-04-21 | Novartis Forschungsstiftung | Spleen tyrosine kinase and brain cancers |
BR112012008833A2 (pt) | 2009-10-15 | 2015-09-08 | Abbott Lab | imunoglobulinas de dominio variavel duplo e usos das mesmas |
WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
KR101832510B1 (ko) | 2009-10-26 | 2018-02-26 | 제넨테크, 인크. | 치료 항-ige 항체에 대해 특이적인 항체를 검출하기 위한 검정 및 아나필락시스에서의 이의 용도 |
WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
JO3244B1 (ar) | 2009-10-26 | 2018-03-08 | Amgen Inc | بروتينات ربط مستضادات il – 23 البشرية |
WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
TW201122101A (en) | 2009-10-28 | 2011-07-01 | Facet Biotech Corp | Anti-EGFR antibodies and their uses |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
US20120213801A1 (en) | 2009-10-30 | 2012-08-23 | Ekaterina Gresko | Phosphorylated Twist1 and cancer |
WO2011053707A1 (en) | 2009-10-31 | 2011-05-05 | Abbott Laboratories | Antibodies to receptor for advanced glycation end products (rage) and uses thereof |
US20120277144A1 (en) | 2009-11-04 | 2012-11-01 | Henricus Johannes Duckers | Novel compounds for modulating neovascularisation and methods of treatment using these compounds |
GB0919751D0 (en) | 2009-11-11 | 2009-12-30 | King S College Hospital Nhs Fo | Conjugate molecule |
WO2011060015A1 (en) | 2009-11-11 | 2011-05-19 | Genentech, Inc. | Methods and compositions for detecting target proteins |
EP3670539A1 (en) | 2009-11-13 | 2020-06-24 | Daiichi Sankyo Europe GmbH | Material and methods for treating or preventing her-3 associated diseases |
CN102770529B (zh) | 2009-11-17 | 2018-06-05 | Musc研究发展基金会 | 针对人核仁素的人单克隆抗体 |
CA2781532A1 (en) * | 2009-11-20 | 2011-05-26 | Amgen Inc. | Anti-orai1 antigen binding protein that binds the second extracellular loop of orai1 |
LT3279215T (lt) | 2009-11-24 | 2020-04-10 | Medimmune Limited | Tiksliniai surišantys agentai prieš b7-h1 |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
AU2010329955A1 (en) | 2009-12-08 | 2012-05-24 | Abbott Gmbh & Co. Kg | Monoclonal antibodies against the RGM A protein for use in the treatment of retinal nerve fiber layer degeneration |
JP5818805B2 (ja) | 2009-12-11 | 2015-11-18 | ジェネンテック, インコーポレイテッド | 抗vegf−c抗体及びその使用方法 |
WO2011084496A1 (en) | 2009-12-16 | 2011-07-14 | Abbott Biotherapeutics Corp. | Anti-her2 antibodies and their uses |
ES2765657T3 (es) | 2009-12-21 | 2020-06-10 | Hoffmann La Roche | Formulación farmacéutica de bevacizumab |
KR101973524B1 (ko) | 2009-12-21 | 2019-09-02 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화된 FcγR 마우스 |
CN103068849B (zh) | 2009-12-23 | 2016-04-06 | 霍夫曼-拉罗奇有限公司 | 抗Bv8抗体及其用途 |
LT2521568T (lt) | 2010-01-06 | 2018-12-10 | Dyax Corp. | Plazmos kalikreiną surišantys baltymai |
AU2011203879A1 (en) | 2010-01-11 | 2012-08-02 | Alexion Pharmaceuticals, Inc. | Biomarkers of immunomodulatory effects in humans treated with anti-CD200 antibodies |
PT2523688T (pt) | 2010-01-15 | 2018-01-05 | Kirin Amgen Inc | Formulação de anticorpo e regimes terapêuticos |
US8865462B2 (en) * | 2010-01-20 | 2014-10-21 | Crystal Bioscience Inc. | Sustained culture of avian gonocytes |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
ES2728942T3 (es) | 2010-02-08 | 2019-10-29 | Regeneron Pharma | Cadena ligera común de ratón |
BR112012020102A2 (pt) | 2010-02-10 | 2016-11-29 | Immunogen Inc | anticorpos cd20 e usos dos mesmos. |
US9029509B2 (en) | 2010-02-12 | 2015-05-12 | The Regents Of The University Of California | Antibodies and pharmaceutical compositions thereof which bind urokinase-type plasminogen activator receptor (uPAR) |
BR112012020839A2 (pt) | 2010-02-18 | 2017-11-21 | Sinai School Medicine | vacinas para uso na profilaxe e tratamento de doença de vírus da influenza |
EP3072904A1 (en) | 2010-03-02 | 2016-09-28 | Abbvie Inc. | Therapeutic dll4 binding proteins |
WO2011107586A1 (en) | 2010-03-05 | 2011-09-09 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research, | Smoc1, tenascin-c and brain cancers |
KR20130075732A (ko) | 2010-03-30 | 2013-07-05 | 마운트 시나이 스쿨 오브 메디슨 | 인플루엔자 바이러스 백신 및 이의 용도 |
KR101830020B1 (ko) | 2010-03-31 | 2018-02-19 | 아블렉시스, 엘엘씨 | 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작 |
WO2011130332A1 (en) | 2010-04-12 | 2011-10-20 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
EP3670534A3 (en) | 2010-04-15 | 2020-09-09 | Amgen Inc. | Human fgf receptor and beta-klotho binding proteins |
DK3466977T3 (en) | 2010-04-16 | 2022-04-11 | Biogen Ma Inc | Anti-vla-4-antistoffer |
WO2011131611A1 (en) | 2010-04-19 | 2011-10-27 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Modulating xrn1 |
WO2011133931A1 (en) | 2010-04-22 | 2011-10-27 | Genentech, Inc. | Use of il-27 antagonists for treating inflammatory bowel disease |
WO2011137395A1 (en) | 2010-04-30 | 2011-11-03 | Rother Russell P | Anti-c5a antibodies and methods for using the antibodies |
IL208820A0 (en) | 2010-10-19 | 2011-01-31 | Rachel Teitelbaum | Biologic female contraceptives |
CA2835489C (en) | 2010-05-10 | 2018-03-06 | Chi-Huey Wong | Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses |
EP2569335B1 (en) | 2010-05-14 | 2018-08-22 | Orega Biotech | Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists |
PE20130205A1 (es) | 2010-05-14 | 2013-03-24 | Abbvie Inc | Proteinas de union a il-1 |
WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
WO2011153224A2 (en) | 2010-06-02 | 2011-12-08 | Genentech, Inc. | Diagnostic methods and compositions for treatment of cancer |
JP6048973B2 (ja) | 2010-06-03 | 2016-12-27 | ジェネンテック, インコーポレイテッド | 抗体及びイムノコンジュゲートのイムノpetイメージング及びこれらの使用方法 |
WO2011154485A1 (en) | 2010-06-10 | 2011-12-15 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Research | Treating cancer by modulating mammalian sterile 20-like kinase 3 |
KR101834026B1 (ko) | 2010-06-19 | 2018-03-02 | 메모리얼 슬로안-케터링 캔서 센터 | 항-gd2 항체 |
CN103249432A (zh) | 2010-06-22 | 2013-08-14 | 科罗拉多大学董事会,法人团体 | 补体成分3的C3d片段的抗体 |
BR122020013427B1 (pt) * | 2010-06-22 | 2021-08-03 | Regeneron Pharmaceuticals, Inc | Método para fazer um camundongo, uma célula ou tecido derivado de um camundongo e um hibridoma |
CN103068400A (zh) | 2010-06-25 | 2013-04-24 | 阿斯顿大学 | 具有脂类动员性质的糖蛋白及其治疗用途 |
WO2012012141A1 (en) | 2010-06-30 | 2012-01-26 | Amgen Inc. | Scnn1a/tnfrsf1a fusion proteins in cancer |
WO2012006500A2 (en) | 2010-07-08 | 2012-01-12 | Abbott Laboratories | Monoclonal antibodies against hepatitis c virus core protein |
UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
CN106188284B (zh) | 2010-07-09 | 2020-05-08 | 扬森疫苗与预防公司 | 抗人呼吸道合胞病毒(rsv)抗体以及使用方法 |
WO2012009705A1 (en) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Ang-2 binding complexes and uses thereof |
JP2013536175A (ja) | 2010-07-16 | 2013-09-19 | アブリンクス エン.ヴェー. | 修飾された単一ドメイン抗原結合分子及びその使用 |
WO2012010550A1 (en) | 2010-07-19 | 2012-01-26 | F. Hoffmann-La Roche Ag | Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy |
MX2013000667A (es) | 2010-07-19 | 2013-02-27 | Hoffmann La Roche | Metodo para identificar pacientes con probabilidad incrementada de responder a una terapia anticancer. |
GB201012420D0 (en) | 2010-07-23 | 2010-09-08 | Univ Erasmus Medical Ct | Foetal heamoglobin inhibitor |
GB201012410D0 (en) | 2010-07-23 | 2010-09-08 | Medical Res Council | Intracellular immunity |
CN103025884B (zh) | 2010-07-26 | 2015-11-25 | 特里安尼公司 | 转基因动物和使用方法 |
US10793829B2 (en) | 2010-07-26 | 2020-10-06 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
US10662256B2 (en) | 2010-07-26 | 2020-05-26 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
PL3470421T3 (pl) | 2010-07-29 | 2023-10-23 | Buzzard Pharmaceuticals AB | Chimeryczne antagonisty receptora il-1 typu i |
EP2601298B1 (en) | 2010-08-02 | 2016-11-30 | Regeneron Pharmaceuticals, Inc. | Mice that make binding proteins comprising vl domains |
ES2667100T3 (es) | 2010-08-02 | 2018-05-09 | Macrogenics, Inc. | Diacuerpos covalentes y sus usos |
JP2013537415A (ja) | 2010-08-03 | 2013-10-03 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
EP2601220A2 (en) | 2010-08-06 | 2013-06-12 | U3 Pharma GmbH | Use of her3 binding agents in prostate treatment |
AU2011289426A1 (en) | 2010-08-10 | 2013-02-28 | Amgen Inc. | Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies |
EP2420250A1 (en) | 2010-08-13 | 2012-02-22 | Universitätsklinikum Münster | Anti-Syndecan-4 antibodies |
WO2012024187A1 (en) | 2010-08-14 | 2012-02-23 | Abbott Laboratories | Amyloid-beta binding proteins |
PT3333188T (pt) | 2010-08-19 | 2022-03-28 | Zoetis Belgium S A | Anticorpos de anti-ngf e a sua utilização |
JP2013539364A (ja) | 2010-08-26 | 2013-10-24 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
WO2012032143A1 (en) | 2010-09-10 | 2012-03-15 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | Phosphorylated twist1 and metastasis |
EP2725034B1 (en) | 2010-09-22 | 2019-04-03 | Amgen Inc. | Carrier immunoglobulins with no specificity for human tissues and uses thereof |
EP2625197B1 (en) | 2010-10-05 | 2016-06-29 | Genentech, Inc. | Mutant smoothened and methods of using the same |
WO2012054748A2 (en) | 2010-10-22 | 2012-04-26 | Seattle Genetics, Inc. | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway |
EP2632951B1 (en) | 2010-10-27 | 2017-08-02 | Amgen Inc. | Dkk1 antibodies and methods of use |
WO2012065937A1 (en) | 2010-11-15 | 2012-05-24 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | Anti-fungal agents |
SG189982A1 (en) | 2010-11-24 | 2013-06-28 | Lexicon Pharmaceuticals Inc | Antibodies to notum pectinacetylesterase |
UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
US8853365B2 (en) | 2010-12-21 | 2014-10-07 | Abbvie Inc. | Dual variable domain immunnoglobulins and uses thereof |
TW201307388A (zh) | 2010-12-21 | 2013-02-16 | Abbott Lab | Il-1結合蛋白 |
ES2720136T3 (es) | 2010-12-22 | 2019-07-18 | Teva Pharmaceuticals Australia Pty Ltd | Anticuerpo modificado con semivida mejorada |
WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
US20120171195A1 (en) | 2011-01-03 | 2012-07-05 | Ravindranath Mepur H | Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use |
US20120185956A1 (en) | 2011-01-18 | 2012-07-19 | Gingras Jacinthe | Global nav1.7 knockout mice and uses |
EP2665751A1 (en) | 2011-01-19 | 2013-11-27 | Bayer Intellectual Property GmbH | Binding proteins to inhibitors of coagulation factors |
WO2012102679A1 (en) | 2011-01-24 | 2012-08-02 | National University Of Singapore | Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins |
WO2012103240A2 (en) | 2011-01-25 | 2012-08-02 | Eleven Biotherapeutics, Inc. | Receptor binding agents |
US20120189633A1 (en) | 2011-01-26 | 2012-07-26 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
AR085141A1 (es) | 2011-02-03 | 2013-09-11 | Alexion Pharma Inc | Un metodo para prolongar la supervivencia de un aloinjerto renal, uso de un anticuerpo anti-cd200 para prolongar la supervivencia de aloinjertos |
PL2738258T5 (pl) | 2011-02-25 | 2023-05-15 | Regeneron Pharmaceuticals, Inc. | Myszy adam6 |
KR20140022815A (ko) | 2011-02-28 | 2014-02-25 | 제넨테크, 인크. | B-세포 길항제에 대한 반응을 예측하기 위한 생물학적 마커 및 방법 |
EP2681242B1 (en) | 2011-03-01 | 2018-01-24 | Amgen Inc. | Sclerostin and dkk-1 bispecific binding agents |
EP2686014A1 (en) | 2011-03-16 | 2014-01-22 | Sanofi | Uses of a dual v region antibody-like protein |
US20140010756A1 (en) | 2011-03-18 | 2014-01-09 | Kagoshima University | Composition for treatment and diagnosis of pancreatic cancer |
CN103547592A (zh) | 2011-03-30 | 2014-01-29 | 埃博灵克斯股份有限公司 | 使用针对TNFα的单结构域抗体治疗免疫病症的方法 |
JP5908972B2 (ja) | 2011-04-07 | 2016-04-26 | アムジエン・インコーポレーテツド | 新規な抗原結合タンパク質 |
EP2696898A4 (en) | 2011-04-07 | 2014-10-01 | Univ Emory | COMPOSITIONS COMPRISING SACCHARIDE BINDING FRACTIONS AND METHODS FOR TARGETED THERAPY |
WO2012142164A1 (en) | 2011-04-12 | 2012-10-18 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii |
DK2699264T3 (en) | 2011-04-20 | 2018-06-25 | Medimmune Llc | ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1 |
WO2012149197A2 (en) | 2011-04-27 | 2012-11-01 | Abbott Laboratories | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
CN107936121B (zh) | 2011-05-16 | 2022-01-14 | 埃泰美德(香港)有限公司 | 多特异性fab融合蛋白及其使用方法 |
WO2012158989A2 (en) | 2011-05-19 | 2012-11-22 | The Regents Of The University Of Michigan | Integrin alpha-2 binding agents and use thereof to inhibit cancer cell proliferation |
NZ618016A (en) | 2011-05-21 | 2015-05-29 | Macrogenics Inc | Deimmunized serum-binding domains and their use for extending serum half-life |
EP2714738B1 (en) | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
AR086543A1 (es) | 2011-05-25 | 2014-01-08 | Bg Medicine Inc | Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica |
JP6104897B2 (ja) | 2011-06-02 | 2017-04-05 | ダイアックス コーポレーション | Fcレセプター結合タンパク質 |
EP2714094B1 (en) | 2011-06-02 | 2016-02-24 | The University of Louisville Research Foundation, Inc. | Anti-nucleolin agent-conjugated nanoparticles |
HRP20211582T1 (hr) | 2011-06-03 | 2022-01-07 | Xoma Technology Ltd. | Protutijela specifična za tgf-beta |
EP3424953B1 (en) | 2011-06-06 | 2020-08-05 | Novo Nordisk A/S | Therapeutic antibodies |
CA2836373A1 (en) | 2011-06-06 | 2012-12-13 | Neotope Biosciences Limited | Mcam antagonists and methods of treatment |
WO2012168259A1 (en) | 2011-06-06 | 2012-12-13 | Novartis Forschungsstiftung, Zweigniederlassung | Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and triple-negative breast cancer |
US9574002B2 (en) | 2011-06-06 | 2017-02-21 | Amgen Inc. | Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor |
US9244074B2 (en) | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
US9561274B2 (en) | 2011-06-07 | 2017-02-07 | University Of Hawaii | Treatment and prevention of cancer with HMGB1 antagonists |
RS57024B1 (sr) | 2011-06-10 | 2018-05-31 | Medimmune Ltd | Anti-pseudomonas psl vezujući molekuli i njihova upotreba |
US20140227265A1 (en) | 2011-06-17 | 2014-08-14 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using clec-2 |
US20140120555A1 (en) | 2011-06-20 | 2014-05-01 | Pierre Fabre Medicament | Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer |
JP2013040160A (ja) | 2011-07-01 | 2013-02-28 | Genentech Inc | 自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用 |
JP2014520847A (ja) | 2011-07-13 | 2014-08-25 | アッヴィ・インコーポレイテッド | 抗il−13抗体を使用して喘息を治療するための方法および組成物 |
US20140234330A1 (en) | 2011-07-22 | 2014-08-21 | Amgen Inc. | Il-17 receptor a is required for il-17c biology |
AU2012290121B2 (en) | 2011-08-01 | 2015-11-26 | Genentech, Inc. | Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors |
SG10201914002RA (en) | 2011-08-05 | 2020-03-30 | Regeneron Pharma | Humanized universal light chain mice |
EP2756094B1 (en) | 2011-08-15 | 2017-12-27 | Medlmmune, LLC | Anti-b7-h4 antibodies and their uses |
CN103890008A (zh) | 2011-08-17 | 2014-06-25 | 霍夫曼-拉罗奇有限公司 | 在顽固性肿瘤中抑制血管发生 |
EP2753933B1 (en) | 2011-09-09 | 2017-08-09 | Amgen Inc. | Use of human papillomavirus status in establishing use of an agent that binds egfr in the treatment of cancer |
EP2753356B1 (en) | 2011-09-09 | 2021-12-22 | Medimmune Limited | Anti-siglec-15 antibodies and uses thereof |
CA2846319A1 (en) * | 2011-09-19 | 2013-03-28 | Kymab Limited | Antibodies, variable domains & chains tailored for human use |
ES2953393T3 (es) | 2011-09-20 | 2023-11-10 | Icahn School Med Mount Sinai | Vacunas contra el virus de la influenza y sus usos |
WO2013042426A1 (ja) | 2011-09-21 | 2013-03-28 | 富士レビオ株式会社 | 親和性複合体に対する抗体 |
EA201790757A1 (ru) | 2011-09-22 | 2017-07-31 | Эмджен Инк. | Связывающие антиген cd27l белки |
EP2758438A1 (en) | 2011-09-23 | 2014-07-30 | Amgen Research (Munich) GmbH | Bispecific binding molecules for 5t4 and cd3 |
EP2761008A1 (en) | 2011-09-26 | 2014-08-06 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
PE20142361A1 (es) | 2011-09-30 | 2015-01-16 | Dana Farber Cancer Inst Inc | Peptidos terapeuticos |
BR112014008212A2 (pt) | 2011-10-05 | 2017-06-13 | Genentech Inc | método para tratar uma condição hepática, método de indução por diferenciação hepática e método de redução de proliferação anormal do ducto biliar |
CN108200885B (zh) | 2011-10-17 | 2021-12-14 | 瑞泽恩制药公司 | 受限制的免疫球蛋白重链基因座 |
RU2014120755A (ru) | 2011-10-24 | 2015-12-10 | Эббви Инк. | Иммуносвязующие агенты, направленные против tnf |
RU2014120981A (ru) | 2011-10-24 | 2015-12-10 | Эббви Инк. | Иммунные связывающие агенты против склеростина |
PT3424947T (pt) | 2011-10-28 | 2021-03-01 | Regeneron Pharma | Ratinhos com recetores de células t geneticamente modificados |
JP6285361B2 (ja) | 2011-10-28 | 2018-02-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | キメラ主要組織適合複合体(mhc)ii分子を発現する遺伝子改変されたマウス |
US9272002B2 (en) | 2011-10-28 | 2016-03-01 | The Trustees Of The University Of Pennsylvania | Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting |
US9591835B2 (en) | 2011-10-28 | 2017-03-14 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
PT3262932T (pt) | 2011-10-28 | 2019-08-26 | Regeneron Pharma | Ratinhos de complexo principal de histocompatibilidade modificados geneticamente |
US9043996B2 (en) | 2011-10-28 | 2015-06-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
EP3091029B1 (en) | 2011-10-31 | 2022-12-28 | F. Hoffmann-La Roche AG | Anti-il13 antibody formulations |
WO2013067060A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Anti-gpr49 antibodies |
JP2014533247A (ja) | 2011-11-01 | 2014-12-11 | バイオノミクス インコーポレイテッド | 抗体および癌を治療する方法 |
US9220774B2 (en) | 2011-11-01 | 2015-12-29 | Bionomics Inc. | Methods of treating cancer by administering anti-GPR49 antibodies |
ES2697674T3 (es) | 2011-11-01 | 2019-01-25 | Bionomics Inc | Procedimientos para bloquear el crecimiento de células madre cancerosas |
EP2773651B1 (en) | 2011-11-03 | 2020-12-23 | The Trustees of the University of Pennsylvania | Isolated b7-h4 specific compositions and methods of use thereof |
US20140314787A1 (en) | 2011-11-08 | 2014-10-23 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute | Treatment for neurodegenerative diseases |
BR112014011115A2 (pt) | 2011-11-08 | 2017-06-13 | Pfizer | métodos para tratamento de distúrbios inflamatórios usando anticorpos anti-m-csf |
WO2013070468A1 (en) | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
WO2013068432A1 (en) | 2011-11-08 | 2013-05-16 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | Early diagnostic of neurodegenerative diseases |
WO2013070821A1 (en) | 2011-11-08 | 2013-05-16 | Quark Pharmaceuticals, Inc. | Methods and compositions for treating diseases, disorders or injury of the nervous system |
TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對bcma之e3以及cd3的結合分子 |
MX2014005957A (es) | 2011-11-16 | 2015-02-04 | Amgen Inc | Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico. |
CN103987405B (zh) | 2011-11-28 | 2017-03-29 | 默克专利股份公司 | 抗pd‑l1抗体及其用途 |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
SG11201402887SA (en) | 2011-12-08 | 2014-07-30 | Biotest Ag | Uses of immunoconjugates targeting cd138 |
CN104220460A (zh) | 2011-12-08 | 2014-12-17 | 安姆根有限公司 | 激动人lcat抗原结合蛋白和它们在疗法中的用途 |
WO2013090633A2 (en) | 2011-12-14 | 2013-06-20 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
CN104144947B (zh) | 2011-12-14 | 2017-10-27 | 艾伯维德国有限责任两合公司 | 用于诊断和治疗铁相关病症的组合物和方法 |
CN104144946A (zh) | 2011-12-19 | 2014-11-12 | 爱克索马美国有限责任公司 | 治疗痤疮的方法 |
AU2012323987B2 (en) | 2011-12-20 | 2015-07-09 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
US11147852B2 (en) | 2011-12-23 | 2021-10-19 | Pfizer Inc. | Engineered antibody constant regions for site-specific conjugation and methods and uses therefor |
CN104159920A (zh) | 2011-12-30 | 2014-11-19 | 艾伯维公司 | 针对il-13和/或il-17的双重可变结构域免疫球蛋白 |
EP2800583A1 (en) | 2012-01-02 | 2014-11-12 | Novartis AG | Cdcp1 and breast cancer |
EP3663314A1 (en) | 2012-01-09 | 2020-06-10 | The Scripps Research Institute | Humanized antibodies with ultralong cdr3s |
EP2802603A4 (en) | 2012-01-09 | 2015-11-04 | Scripps Research Inst | REGIONS DETERMINING ULTRALONGUAL COMPLEMENTARYITY AND USES THEREOF |
US10800847B2 (en) | 2012-01-11 | 2020-10-13 | Dr. Mepur Ravindranath | Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use |
US20130177574A1 (en) | 2012-01-11 | 2013-07-11 | Paul I. Terasaki Foundation Laboratory | ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE |
WO2013106765A1 (en) | 2012-01-13 | 2013-07-18 | Genentech, Inc. | Biological markers for identifying patients for treatment with vegf antagonists |
WO2013107290A1 (en) | 2012-01-20 | 2013-07-25 | The Government of the Hong Kong Special Administrative Region of the People's Republic of China | A novel paramyxovirus and uses thereof |
DK2807192T3 (en) | 2012-01-27 | 2018-07-23 | Abbvie Deutschland | COMPOSITION AND PROCEDURE FOR DIAGNOSTICATION AND TREATMENT OF DISEASES RELATED TO NEURITE DEGENERATION |
BR112014018471A2 (pt) | 2012-01-31 | 2017-07-04 | Genentech Inc | anticorpos anti-ige m1' e métodos para o seu uso |
EP2812443B1 (en) | 2012-02-06 | 2019-05-29 | Inhibrx, Inc. | Cd47 antibodies and methods of use thereof |
GB201202268D0 (en) | 2012-02-09 | 2012-03-28 | Medical Res Council | Intracellular immunity |
WO2013119990A2 (en) | 2012-02-10 | 2013-08-15 | Seattle Genetics, Inc. | Detection and treatment of cd30+ cancers |
US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
EP2814842B1 (en) | 2012-02-15 | 2018-08-22 | Novo Nordisk A/S | Antibodies that bind peptidoglycan recognition protein 1 |
US9000127B2 (en) | 2012-02-15 | 2015-04-07 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
ES2732243T3 (es) | 2012-02-16 | 2019-11-21 | Santarus Inc | Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A) |
US20150201588A1 (en) | 2012-02-22 | 2015-07-23 | Amgen Inc. | Autologous Mammalian Models Derived from Induced Pluripotent Stem Cells and Related Methods |
JP6407726B2 (ja) | 2012-03-01 | 2018-10-24 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH | 長寿命ポリペプチド結合分子 |
US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
US20130259867A1 (en) | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
WO2013148232A1 (en) | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
WO2013144240A1 (en) | 2012-03-29 | 2013-10-03 | Friedrich Miescher Institute For Biomedical Research | Inhibition of interleukin- 8 and/or its receptor cxcrl in the treatment her2/her3 -overexpressing breast cancer |
SG11201406184XA (en) | 2012-03-30 | 2014-10-30 | Genentech Inc | Diagnostic methods and compositions for treatment of cancer |
WO2013151649A1 (en) | 2012-04-04 | 2013-10-10 | Sialix Inc | Glycan-interacting compounds |
US9534059B2 (en) | 2012-04-13 | 2017-01-03 | Children's Medical Center Corporation | TIKI inhibitors |
US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
US9505833B2 (en) | 2012-04-20 | 2016-11-29 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
DK2841456T3 (en) | 2012-04-27 | 2018-08-13 | Novo Nordisk As | HUMAN CD30 LIGAND ANTI-BINDING PROTEINS |
US9980942B2 (en) | 2012-05-02 | 2018-05-29 | Children's Hospital Medical Center | Rejuvenation of precursor cells |
US9480449B2 (en) | 2012-05-03 | 2016-11-01 | Fibrogen, Inc. | Methods for treating idiopathic pulmonary fibrosis |
EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
WO2013166290A1 (en) | 2012-05-04 | 2013-11-07 | Abbvie Biotherapeutics Inc. | P21 biomarker assay |
EP2847219A1 (en) | 2012-05-07 | 2015-03-18 | Amgen Inc. | Anti-erythropoietin antibodies |
CA2873623C (en) | 2012-05-14 | 2021-11-09 | Biogen Idec Ma Inc. | Lingo-2 antagonists for treatment of conditions involving motor neurons |
EP2849786B1 (en) | 2012-05-15 | 2019-11-06 | Eisai Inc. | Methods for treatment of gastric cancer |
AU2013263349B2 (en) | 2012-05-17 | 2016-09-08 | Extend Biosciences, Inc | Carriers for improved drug delivery |
CA2872018A1 (en) | 2012-05-17 | 2013-11-21 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind egfr |
JO3623B1 (ar) | 2012-05-18 | 2020-08-27 | Amgen Inc | البروتينات المرتبطة بمولد المستضاد st2 |
US9249182B2 (en) | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
WO2013177386A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Biotherapeutics Inc. | Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy |
WO2013181452A1 (en) | 2012-05-31 | 2013-12-05 | Genentech, Inc. | Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists |
EP2859018B1 (en) | 2012-06-06 | 2021-09-22 | Zoetis Services LLC | Caninized anti-ngf antibodies and methods thereof |
LT2858487T (lt) * | 2012-06-12 | 2019-12-27 | Regeneron Pharmaceuticals, Inc. | Gyvūnai, išskyrus žmogų, kurie yra humanizuoti ir turi redukuotą imunoglobulino sunkiosios grandinės lokusą |
AU2013278075B2 (en) | 2012-06-22 | 2018-05-17 | Cytomx Therapeutics, Inc. | Anti-jagged 1/Jagged 2 cross-reactive antibodies, activatable anti-Jagged antibodies and methods of use thereof |
JP6103832B2 (ja) | 2012-06-25 | 2017-03-29 | Hoya株式会社 | Egfr結合性ペプチド |
WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
US20150218238A1 (en) | 2012-06-29 | 2015-08-06 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear | Treating diseases by modulating a specific isoform of mkl1 |
US20150184154A1 (en) | 2012-07-05 | 2015-07-02 | Novartis Forschungsstiftung, Zweigniederlassung Friedrich Miescher Institute For Biomedical Resear | New treatment for neurodegenerative diseases |
US10656156B2 (en) | 2012-07-05 | 2020-05-19 | Mepur Ravindranath | Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E |
WO2014006115A1 (en) | 2012-07-06 | 2014-01-09 | Novartis Ag | Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the il-8/cxcr interaction |
AR091755A1 (es) | 2012-07-12 | 2015-02-25 | Abbvie Inc | Proteinas de union a il-1 |
ES2786263T3 (es) | 2012-07-13 | 2020-10-09 | Univ Pennsylvania | Mejora de la actividad de los CAR de linfocitos T mediante la introducción conjunta de un anticuerpo biespecífico |
US10413620B2 (en) | 2012-08-17 | 2019-09-17 | The Regents Of The University Of Colorado, A Body Corporate | Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging |
WO2014028865A1 (en) | 2012-08-17 | 2014-02-20 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for detecting complement activation |
CA2880701A1 (en) | 2012-08-18 | 2014-02-27 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
AU2013305827A1 (en) | 2012-08-21 | 2015-03-05 | Academia Sinica | Benzocyclooctyne compounds and uses thereof |
RS60217B1 (sr) | 2012-08-31 | 2020-06-30 | Immunogen Inc | Dijagnostički testovi i kompleti za detekciju folatnog receptora 1 |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
US9206390B2 (en) | 2012-09-02 | 2015-12-08 | Abbvie, Inc. | Methods to control protein heterogeneity |
TWI660972B (zh) | 2012-09-10 | 2019-06-01 | 愛爾蘭商尼歐托普生物科學公司 | 抗mcam抗體及相關使用方法 |
EP2904106A4 (en) | 2012-10-01 | 2016-05-11 | Univ Pennsylvania | COMPOSITIONS AND METHODS FOR TARGETING STROMAL CELLS FOR THE TREATMENT OF CANCER |
NO2760138T3 (ja) | 2012-10-01 | 2018-08-04 | ||
WO2014055771A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Human alpha-folate receptor chimeric antigen receptor |
WO2014063205A1 (en) | 2012-10-26 | 2014-05-01 | The University Of Queensland | Use of endocytosis inhibitors and antibodies for cancer therapy |
JP6109952B2 (ja) | 2012-11-01 | 2017-04-05 | アッヴィ・インコーポレイテッド | 抗vegf/dll4二重可変ドメイン免疫グロブリンおよびこれらの使用 |
US20140154255A1 (en) | 2012-11-30 | 2014-06-05 | Abbvie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
US10342869B2 (en) | 2012-12-07 | 2019-07-09 | The Regents Of The University Of California | Compositions comprising anti-CD38 antibodies and lenalidomide |
US9383357B2 (en) | 2012-12-07 | 2016-07-05 | Northwestern University | Biomarker for replicative senescence |
TW201425336A (zh) | 2012-12-07 | 2014-07-01 | Amgen Inc | Bcma抗原結合蛋白質 |
UA118255C2 (uk) | 2012-12-07 | 2018-12-26 | Санофі | Композиція, яка містить антитіло до cd38 і леналідомід |
JP6490591B2 (ja) | 2012-12-10 | 2019-03-27 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | 抗血液樹状細胞抗原2抗体およびその使用 |
PT3653049T (pt) * | 2012-12-14 | 2023-11-14 | Omniab Inc | Polinucleótidos que codificam anticorpos de roedores com idiótipos humanos e animais que os compreendem |
BR112015014482A2 (pt) | 2012-12-18 | 2017-11-21 | Icahn School Med Mount Sinai | vacinas para vírus influenza e seus usos |
WO2014100483A1 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | Anti-human b7-h4 antibodies and their uses |
JP6359031B2 (ja) | 2012-12-21 | 2018-07-18 | メディミューン,エルエルシー | 抗h7cr抗体 |
US10717965B2 (en) | 2013-01-10 | 2020-07-21 | Gloriana Therapeutics, Inc. | Mammalian cell culture-produced neublastin antibodies |
JO3519B1 (ar) | 2013-01-25 | 2020-07-05 | Amgen Inc | تركيبات أجسام مضادة لأجل cdh19 و cd3 |
US9920121B2 (en) | 2013-01-25 | 2018-03-20 | Amgen Inc. | Antibodies targeting CDH19 for melanoma |
US9834610B2 (en) | 2013-01-31 | 2017-12-05 | Thomas Jefferson University | Fusion proteins for modulating regulatory and effector T cells |
KR102170196B1 (ko) | 2013-02-06 | 2020-10-26 | 인히브릭스, 인크. | 비-혈소판 및 비-적혈구 세포 격감성 cd47 항체 및 이를 이용하는 방법 |
WO2014129895A1 (en) | 2013-02-19 | 2014-08-28 | Stichting Vu-Vumc | Means and method for increasing the sensitivity of cancers for radiotherapy |
AU2014218915B2 (en) | 2013-02-20 | 2017-01-19 | Regeneron Pharmaceuticals, Inc. | Non-human animals with modified immunoglobulin heavy chain sequences |
JP6444895B2 (ja) | 2013-02-20 | 2018-12-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | ヒト化t細胞補助受容体を発現するマウス |
US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
DK2958937T3 (en) | 2013-02-22 | 2018-11-26 | Regeneron Pharma | Mice expressing humanized major histocompatibility complex |
EP2959014B1 (en) | 2013-02-25 | 2019-11-13 | Genentech, Inc. | Methods and compositions for detecting and treating drug resistant akt mutant |
EP2968460B1 (en) | 2013-03-11 | 2021-01-06 | Amgen Inc. | Protein formulations |
SG10201705525VA (en) | 2013-03-13 | 2017-08-30 | Genentech Inc | Formulations with reduced oxidation |
AR095399A1 (es) | 2013-03-13 | 2015-10-14 | Genentech Inc | Formulaciones con oxidación reducida, método |
NZ711567A (en) | 2013-03-13 | 2020-04-24 | Genentech Inc | Antibody formulations |
US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
EP2968468B1 (en) | 2013-03-13 | 2021-07-14 | Buzzard Pharmaceuticals AB | Chimeric cytokine formulations for ocular delivery |
AR095398A1 (es) | 2013-03-13 | 2015-10-14 | Genentech Inc | Formulaciones con oxidación reducida |
BR112015022475A8 (pt) | 2013-03-13 | 2019-11-26 | Genentech Inc | formulação líquida e método para impedir a oxidação de uma proteína em uma formulação de proteína |
WO2014159911A1 (en) | 2013-03-13 | 2014-10-02 | Sanofi | Compositions comprising anti-cd38 antibodies and carfilzomib |
US9908930B2 (en) | 2013-03-14 | 2018-03-06 | Icahn School Of Medicine At Mount Sinai | Antibodies against influenza virus hemagglutinin and uses thereof |
WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
MX362075B (es) | 2013-03-14 | 2019-01-07 | Abbott Lab | Ensayo de combinación de antígeno-anticuerpo del virus de la hepatitis c (vhc) y métodos y composiciones para usarlo. |
CN105378099B (zh) | 2013-03-14 | 2021-05-11 | 雅培制药有限公司 | Hcv核心脂质结合结构域单克隆抗体 |
EP2967012B1 (en) | 2013-03-14 | 2020-09-16 | Erasmus University Medical Center Rotterdam | Transgenic non-human mammal for antibody production |
US9790478B2 (en) | 2013-03-14 | 2017-10-17 | Abbott Laboratories | HCV NS3 recombinant antigens and mutants thereof for improved antibody detection |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
CA2904337A1 (en) | 2013-03-14 | 2014-10-02 | Amgen Inc. | Chrdl-1 antigen binding proteins and methods of treatment |
PE20151893A1 (es) | 2013-03-14 | 2015-12-30 | Parkash Gill | Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
CN105246510A (zh) | 2013-03-15 | 2016-01-13 | 豪夫迈·罗氏有限公司 | 细胞培养培养基和抗体生产方法 |
CA2903546A1 (en) | 2013-03-15 | 2014-09-25 | Biogen Ma Inc. | Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies |
US10993420B2 (en) | 2013-03-15 | 2021-05-04 | Erasmus University Medical Center | Production of heavy chain only antibodies in transgenic mammals |
JP2016522793A (ja) | 2013-03-15 | 2016-08-04 | アッヴィ・インコーポレイテッド | IL−1βおよび/またはIL−17に対して指向された二重特異的結合タンパク質 |
US9920377B2 (en) | 2013-03-15 | 2018-03-20 | Sutter West Bay Hospitals | FALZ for use as a target for therapies to treat cancer |
US9505849B2 (en) | 2013-03-15 | 2016-11-29 | Amgen Research (Munich) Gmbh | Antibody constructs for influenza M2 and CD3 |
MX2015013163A (es) | 2013-03-15 | 2016-04-04 | Zyngenia Inc | Complejos multiespecificos multivalente y monovalentes y sus usos. |
WO2014144292A2 (en) | 2013-03-15 | 2014-09-18 | Sanofi Pasteur Biologics , Llc | Antibodies against clostridium difficile toxins and methods of using the same |
EP2970449B1 (en) | 2013-03-15 | 2019-09-25 | Amgen Research (Munich) GmbH | Single chain binding molecules comprising n-terminal abp |
RU2718986C2 (ru) | 2013-03-15 | 2020-04-15 | Дженентек, Инк. | Композиции клеточных культур с антиоксидантами и способы получения полипептидов |
EP2970436B1 (en) | 2013-03-15 | 2018-09-05 | AbbVie Biotherapeutics Inc. | Fc variants |
AU2014228924B2 (en) | 2013-03-15 | 2019-04-18 | Amgen Inc. | Human PAC1 antibodies |
WO2014151834A2 (en) | 2013-03-15 | 2014-09-25 | Amgen Inc. | Methods and compositions relating to anti-ccr7 antigen binding proteins |
BR112015021576A2 (pt) | 2013-03-15 | 2017-10-10 | Dana Farber Cancer Inst Inc | peptídeos terapêuticos |
EP3216804A3 (en) | 2013-03-15 | 2017-12-20 | AbbVie Biotechnology Ltd. | Anti-cd25 antibodies and their uses |
CA2904527A1 (en) | 2013-03-15 | 2014-09-18 | Abbvie Biotechnology Ltd. | Anti-cd25 antibodies and their uses |
WO2014144553A1 (en) | 2013-03-15 | 2014-09-18 | Amgen Inc. | Secreted frizzle-related protein 5 (sfrp5) binding proteins and methods of treatment |
US9469686B2 (en) | 2013-03-15 | 2016-10-18 | Abbott Laboratories | Anti-GP73 monoclonal antibodies and methods of obtaining the same |
CA2903576C (en) | 2013-03-15 | 2021-06-08 | Nai-Kong V. Cheung | High affinity anti-gd2 antibodies |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
WO2014165818A2 (en) | 2013-04-05 | 2014-10-09 | T Cell Therapeutics, Inc. | Compositions and methods for preventing and treating prostate cancer |
EP2983710B1 (en) | 2013-04-09 | 2019-07-31 | Annexon, Inc. | Methods of treatment for neuromyelitis optica |
TWI679019B (zh) | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | 抗il-4/抗il-13之雙特異性抗體調配物 |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
PT2981822T (pt) | 2013-05-06 | 2020-12-07 | Scholar Rock Inc | Composições e métodos para modulação do fator de crescimento |
WO2014182972A2 (en) | 2013-05-10 | 2014-11-13 | The Regents Of The University Of California | Diagnostic and monitoring system for huntington's disease |
SG11201509618QA (en) | 2013-05-24 | 2015-12-30 | Medimmune Llc | Anti-b7-h5 antibodies and their uses |
HUE040548T2 (hu) | 2013-05-30 | 2019-03-28 | Kiniksa Pharmaceuticals Ltd | Onkosztatin-M-receptor antigénjét kötõ fehérjék |
JP6824735B2 (ja) | 2013-06-06 | 2021-02-03 | ピエール、ファーブル、メディカマン | 抗C10orf54抗体およびその使用方法 |
WO2014197866A1 (en) | 2013-06-06 | 2014-12-11 | Igenica Biotherapeutics, Inc. | Modified antibodies and related compounds, compositions, and methods of use |
EP3632467B1 (en) | 2013-06-07 | 2023-09-27 | Duke University | Inhibitors of complement factor h |
MX2015017035A (es) | 2013-06-13 | 2016-04-25 | Fast Forward Pharmaceuticals B V | Inhibidor de la señalizacion de cd40 y un compuesto adicional, en donde el compuesto adicional es un acido labil, un derivado de acido labil, un agonista del receptor tgr5, un agonista del fxr o una combinacion de los mismos, para el tratamiento de inflamacion cronica, y la prevencion de cancer gastrointestinal o fibrosis. |
US9499628B2 (en) | 2013-06-14 | 2016-11-22 | Children's Hospital Medical Center | Method of boosting the immune response in neonates |
WO2014210397A1 (en) | 2013-06-26 | 2014-12-31 | Academia Sinica | Rm2 antigens and use thereof |
US9981030B2 (en) | 2013-06-27 | 2018-05-29 | Academia Sinica | Glycan conjugates and use thereof |
EP3013422A1 (en) | 2013-06-28 | 2016-05-04 | Amgen Inc. | Methods for treating homozygous familial hypercholesterolemia |
BR112016000106B1 (pt) | 2013-07-09 | 2023-11-21 | Annexon, Inc. | Anticorpos anti-c1q e usos dos mesmos, célula de hibridoma, composição farmacêutica e métodos de detecção de sinapses em uma amostra biológica referências cruzadas a pedidos relacionados |
CA2916681A1 (en) | 2013-07-16 | 2015-01-22 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
EP3022224A2 (en) | 2013-07-18 | 2016-05-25 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
AU2014290361B2 (en) | 2013-07-18 | 2019-04-18 | Taurus Biosciences, Llc | Humanized antibodies with ultralong complementarity determining regions |
WO2015021308A1 (en) | 2013-08-07 | 2015-02-12 | Astute Medical, Inc. | Assays for timp2 having improved performance in biological samples |
ES2761587T3 (es) | 2013-08-07 | 2020-05-20 | Friedrich Miescher Institute For Biomedical Res | Nuevo método de cribado para el tratamiento de la ataxia de Friedreich |
WO2015023851A1 (en) | 2013-08-14 | 2015-02-19 | The Governing Council Of The University Of Toronto | Antibodies against frizzled proteins and methods of use thereof |
EP3036320B2 (en) | 2013-08-19 | 2024-04-03 | Biogen MA Inc. | Control of protein glycosylation by culture medium supplementation and cell culture process parameters |
US10617755B2 (en) | 2013-08-30 | 2020-04-14 | Genentech, Inc. | Combination therapy for the treatment of glioblastoma |
TW201605896A (zh) | 2013-08-30 | 2016-02-16 | 安美基股份有限公司 | Gitr抗原結合蛋白 |
US10456470B2 (en) | 2013-08-30 | 2019-10-29 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
WO2015035044A2 (en) | 2013-09-04 | 2015-03-12 | Abbvie Biotherapeutics Inc. | Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY |
WO2015035337A1 (en) | 2013-09-06 | 2015-03-12 | Academia Sinica | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS |
CA2925310C (en) | 2013-09-27 | 2022-12-06 | Genentech, Inc. | Anti-pdl1 antibody formulations |
CA2925723A1 (en) | 2013-10-01 | 2015-04-09 | Kymab Limited | Animal models and therapeutic molecules |
WO2015051293A2 (en) | 2013-10-04 | 2015-04-09 | Abbvie, Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
CN105934252B (zh) | 2013-10-10 | 2020-11-10 | 贝思以色列女会吏医学中心公司 | Tm4sf1结合蛋白及其使用方法 |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
CN111443069A (zh) | 2013-10-28 | 2020-07-24 | 多茨技术公司 | 过敏原检测 |
TN2016000142A1 (en) | 2013-10-31 | 2017-10-06 | Sanofi Sa | Specific anti-cd38 antibodies for treating human cancers. |
CA3185700A1 (en) | 2013-11-06 | 2015-05-14 | Astute Medical, Inc. | Assays for igfbp7 having improved performance in biological samples |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
CA2932767A1 (en) | 2013-12-06 | 2015-06-11 | Dana-Farber Cancer Institute, Inc. | Therapeutic peptides |
CN106459187A (zh) | 2013-12-09 | 2017-02-22 | 纽约大学 | 用于抗葡萄球菌剂的吞噬细胞递送的组合物和方法 |
EP3080160B1 (en) | 2013-12-13 | 2022-07-06 | Rijksuniversiteit Groningen | Antibodies against staphylococcus aureus and uses thereof |
US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
US9023359B1 (en) | 2014-07-15 | 2015-05-05 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
CA2933883A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies |
US9051378B1 (en) | 2014-07-15 | 2015-06-09 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
SG11201604979WA (en) | 2013-12-17 | 2016-07-28 | Genentech Inc | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
SG11201604875PA (en) | 2013-12-17 | 2016-07-28 | Genentech Inc | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US9045548B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment |
US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
JP6779785B2 (ja) | 2013-12-19 | 2020-11-04 | ノバルティス アーゲー | ヒトメソテリンキメラ抗原受容体およびその使用 |
CA3204788A1 (en) | 2013-12-20 | 2015-06-25 | Genentech, Inc. | Antibodies comprising an antigen-binding site that specifically binds to two different epitopes and methods of making them |
WO2015095809A1 (en) | 2013-12-20 | 2015-06-25 | Biogen Idec Ma Inc. | Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality |
DK3087098T3 (da) | 2013-12-24 | 2020-06-08 | Janssen Pharmaceutica Nv | Anti-Vista-antistoffer og -fragmenter |
EP2893939A1 (en) | 2014-01-10 | 2015-07-15 | Netris Pharma | Anti-netrin-1 antibody |
WO2016114819A1 (en) | 2015-01-16 | 2016-07-21 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
CA2937123A1 (en) | 2014-01-16 | 2015-07-23 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
WO2015116902A1 (en) | 2014-01-31 | 2015-08-06 | Genentech, Inc. | G-protein coupled receptors in hedgehog signaling |
US20170044232A1 (en) | 2014-02-04 | 2017-02-16 | Genentech, Inc. | Mutant smoothened and methods of using the same |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
CA2939006A1 (en) | 2014-03-14 | 2015-09-17 | Dana-Farber Cancer Institute, Inc. | Vaccine compositions and methods for restoring nkg2d pathway function against cancers |
JP2017510273A (ja) | 2014-03-21 | 2017-04-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | 異なる結合特性を示すvl抗原結合タンパク質 |
KR102601491B1 (ko) | 2014-03-21 | 2023-11-13 | 리제너론 파마슈티칼스 인코포레이티드 | 단일 도메인 결합 단백질을 생산하는 비-인간 동물 |
EP3122869B2 (en) | 2014-03-24 | 2022-08-10 | Biogen MA Inc. | Methods for overcoming glutamine deprivation during mammalian cell culture |
BR112016021739B1 (pt) | 2014-03-25 | 2021-11-03 | Genentech, Inc | Método para preparar um poloxâmero para uso em um meio de cultura de célula |
WO2015148915A1 (en) | 2014-03-27 | 2015-10-01 | Academia Sinica | Reactive labelling compounds and uses thereof |
CA2943834A1 (en) | 2014-03-31 | 2015-10-08 | Genentech, Inc. | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
EP3126397B1 (en) | 2014-04-04 | 2020-01-29 | Bionomics, Inc. | Humanized antibodies that bind lgr5 |
AU2015249946A1 (en) | 2014-04-25 | 2016-11-17 | The Brigham And Women's Hospital Inc. | Methods to manipulate alpha-fetoprotein (AFP) |
JP6832709B2 (ja) | 2014-05-16 | 2021-02-24 | メディミューン,エルエルシー | 新生児Fc受容体結合が改変されて治療および診断特性が強化された分子 |
EP3145953A1 (en) | 2014-05-21 | 2017-03-29 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer with anti bip or anti mica antibodies |
US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
CN106573971A (zh) | 2014-05-27 | 2017-04-19 | 中央研究院 | 抗cd20醣抗体及其用途 |
CN106661099A (zh) | 2014-05-27 | 2017-05-10 | 中央研究院 | 抗her2醣抗体及其用途 |
TWI717319B (zh) | 2014-05-27 | 2021-02-01 | 中央研究院 | 得自類桿菌屬之岩藻糖苷酶及其用途 |
AU2015267044A1 (en) | 2014-05-28 | 2016-12-15 | Academia Sinica | Anti-TNF-alpha glycoantibodies and uses thereof |
IL249092B (en) | 2014-05-28 | 2022-07-01 | Agenus Inc | Anti-gitr antibodies and methods of using them |
WO2015189816A1 (en) | 2014-06-13 | 2015-12-17 | Friedrich Miescher Institute For Biomedical Research | New treatment against influenza virus |
TWI695011B (zh) | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗her2表位之單株抗體及其使用之方法 |
EP3157535A1 (en) | 2014-06-23 | 2017-04-26 | Friedrich Miescher Institute for Biomedical Research | Methods for triggering de novo formation of heterochromatin and or epigenetic silencing with small rnas |
WO2016001830A1 (en) | 2014-07-01 | 2016-01-07 | Friedrich Miescher Institute For Biomedical Research | Combination of a brafv600e inhibitor and mertk inhibitor to treat melanoma |
AU2015287760B2 (en) | 2014-07-09 | 2019-06-20 | Genentech, Inc. | pH adjustment to improve thaw recovery of cell banks |
WO2016011052A1 (en) | 2014-07-14 | 2016-01-21 | Genentech, Inc. | Diagnostic methods and compositions for treatment of glioblastoma |
MX2017000546A (es) | 2014-07-15 | 2017-03-08 | Genentech Inc | Composiciones para el tratamiento del cancer mediante el uso de antagonistas de union al eje de pd-1 e inhibidores de mek. |
US9150660B1 (en) | 2014-07-15 | 2015-10-06 | Kymab Limited | Precision Medicine by targeting human NAV1.8 variants for treatment of pain |
US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
US10179814B2 (en) | 2014-07-17 | 2019-01-15 | Novo Nordisk A/S | Site directed mutagenesis of TREM-1 antibodies for decreasing viscosity |
AR101400A1 (es) | 2014-07-31 | 2016-12-14 | Amgen Res (Munich) Gmbh | Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido |
JP6749312B2 (ja) | 2014-07-31 | 2020-09-02 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハーAMGEN Research(Munich)GmbH | 最適化された種間特異的二重特異性単鎖抗体コンストラクト |
UY36245A (es) | 2014-07-31 | 2016-01-29 | Amgen Res Munich Gmbh | Constructos de anticuerpos para cdh19 y cd3 |
SG11201700901SA (en) | 2014-08-08 | 2017-03-30 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
CA2958200A1 (en) | 2014-08-14 | 2016-02-18 | Novartis Ag | Treatment of cancer using a gfr alpha-4 chimeric antigen receptor |
EP3183002B1 (en) | 2014-08-21 | 2021-03-03 | Walter Reed Army Institute of Research | Monoclonal antibodies for treatment of microbial infections |
EP3188761A4 (en) | 2014-09-02 | 2018-04-18 | ImmunoGen, Inc. | Methods for formulating antibody drug conjugate compositions |
US9879042B2 (en) | 2014-09-08 | 2018-01-30 | Academia Sinica | Human iNKT cell activation using glycolipids |
WO2016040767A2 (en) | 2014-09-12 | 2016-03-17 | Amgen Inc. | Chrdl-1 epitopes and antibodies |
WO2016044224A1 (en) | 2014-09-15 | 2016-03-24 | Amgen Inc. | Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof |
WO2016044334A1 (en) | 2014-09-15 | 2016-03-24 | Genentech, Inc. | Antibody formulations |
US10080790B2 (en) | 2014-09-19 | 2018-09-25 | The Regents Of The University Of Michigan | Staphylococcus aureus materials and methods |
EP3193592A1 (en) | 2014-09-19 | 2017-07-26 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors |
WO2016046768A1 (en) | 2014-09-24 | 2016-03-31 | Friedrich Miescher Institute For Biomedical Research | Lats and breast cancer |
EP3207146B1 (en) | 2014-10-15 | 2021-09-29 | Amgen Inc. | Promoter and regulatory elements for improved expression of heterologous genes in host cells |
MA41685A (fr) | 2014-10-17 | 2017-08-22 | Biogen Ma Inc | Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère |
US9616109B2 (en) | 2014-10-22 | 2017-04-11 | Extend Biosciences, Inc. | Insulin vitamin D conjugates |
CA2964463C (en) | 2014-10-22 | 2024-02-13 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
AU2015339012B2 (en) | 2014-10-31 | 2020-11-05 | Abbvie Biotherapeutics Inc. | Anti-CS1 antibodies and antibody drug conjugates |
EP3215168B1 (en) | 2014-10-31 | 2023-08-02 | The Trustees of the University of Pennsylvania | Altering gene expression in modified t cells and uses thereof |
KR20230141922A (ko) | 2014-10-31 | 2023-10-10 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | T 세포를 자극 및 증대시키는 조성물 및 방법 |
MA40864A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères |
CN107207587B (zh) | 2014-11-05 | 2022-04-19 | 安尼艾克松股份有限公司 | 人源化抗-补体因子c1q抗体及其应用 |
US10066002B2 (en) | 2014-11-05 | 2018-09-04 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
CA2966558C (en) | 2014-11-05 | 2024-03-12 | Genentech, Inc. | Methods of producing two chain proteins in bacteria |
BR112017008628A2 (pt) | 2014-11-06 | 2018-01-30 | Genentech Inc | terapia de combinação compreendendo agonistas de ligação a ox40 e inibidores de tigit |
WO2016073157A1 (en) | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Anti-ang2 antibodies and methods of use thereof |
US9879087B2 (en) | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
CA2967595A1 (en) | 2014-11-12 | 2016-05-19 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
RU2017121096A (ru) | 2014-11-17 | 2018-12-19 | Дженентек, Инк. | Комбинированная терапия, включающая применение ох40-связывающих агонистов и антагонистов связывания оси pd-1 |
CN107406503B (zh) | 2014-11-18 | 2021-07-16 | 詹森药业有限公司 | Cd47抗体、方法和用途 |
EP3221340A1 (en) | 2014-11-19 | 2017-09-27 | Koninklijke Philips N.V. | Diagnostic method employing hnl |
EP3221445B1 (en) | 2014-11-20 | 2021-07-14 | The Regents of The University of California | Compositions and methods related to hematologic recovery |
EP3220900B1 (en) | 2014-11-21 | 2020-09-23 | University of Maryland, Baltimore | Targeted structure-specific particulate delivery systems |
EP3227337A1 (en) | 2014-12-05 | 2017-10-11 | F. Hoffmann-La Roche AG | Methods and compositions for treating cancer using pd-1 axis antagonists and hpk1 antagonists |
JP2018506509A (ja) | 2014-12-09 | 2018-03-08 | アッヴィ・インコーポレイテッド | 細胞透過性Bcl−xL阻害剤との抗体薬物コンジュゲート |
US20160339117A1 (en) | 2014-12-09 | 2016-11-24 | Abbvie Inc. | BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same |
DK3229838T3 (da) | 2014-12-11 | 2020-10-19 | Pf Medicament | Anti-C10orf54-antistoffer og anvendelser deraf |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
WO2016097420A1 (en) | 2014-12-19 | 2016-06-23 | Universite De Nantes | Anti il-34 antibodies |
CA2972048C (en) | 2014-12-22 | 2023-03-07 | The Rockefeller University | Anti-mertk agonistic antibodies and uses thereof |
MX2017009038A (es) | 2015-01-08 | 2017-10-25 | Biogen Ma Inc | Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes. |
GB2557389B (en) | 2015-01-14 | 2020-12-23 | Brigham & Womens Hospital Inc | Treatment of cancer with anti-lap monoclonal antibodies |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
WO2016118937A1 (en) | 2015-01-23 | 2016-07-28 | Icahn School Of Medicine At Mount Sinai | Influenza virus vaccination regimens |
EP3789766A1 (en) | 2015-01-24 | 2021-03-10 | Academia Sinica | Novel glycan conjugates and methods of use thereof |
TWI710571B (zh) | 2015-01-24 | 2020-11-21 | 中央研究院 | 腫瘤標記及其使用方法 |
WO2016123329A2 (en) | 2015-01-28 | 2016-08-04 | Genentech, Inc. | Gene expression markers and treatment of multiple sclerosis |
CN114702581A (zh) | 2015-01-30 | 2022-07-05 | 台湾地区“中央研究院” | 增进抗体功效的通用糖型组合物及方法 |
ES2947589T3 (es) | 2015-01-31 | 2023-08-11 | Univ Pennsylvania | Composiciones y métodos para el suministro de moléculas terapéuticas a linfocitos T |
US10330683B2 (en) | 2015-02-04 | 2019-06-25 | Genentech, Inc. | Mutant smoothened and methods of using the same |
ES2789573T3 (es) | 2015-02-09 | 2020-10-26 | Memorial Sloan Kettering Cancer Center | Anticuerpos multiespecíficos con afinidad por el antígeno A33 humano y el complejo metálico de DOTA |
SG10201810615VA (en) | 2015-02-26 | 2019-01-30 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for the treatment of cancer |
EP3265491A1 (en) | 2015-03-03 | 2018-01-10 | Xoma (Us) Llc | Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery |
DE112016001013T5 (de) | 2015-03-03 | 2017-12-21 | Kymab Limited | Antikörper, verwendungen und verfahren |
WO2016142288A1 (en) | 2015-03-06 | 2016-09-15 | Csl Behring Recombinant Facility Ag | Modified von willebrand factor having improved half-life |
JP6968698B2 (ja) | 2015-03-17 | 2021-11-24 | メモリアル スローン ケタリング キャンサー センター | 抗muc16抗体及びその使用 |
CN107438622A (zh) | 2015-03-19 | 2017-12-05 | 瑞泽恩制药公司 | 选择结合抗原的轻链可变区的非人动物 |
WO2016151558A1 (en) | 2015-03-25 | 2016-09-29 | Alexion Pharmaceuticals, Inc. | A method for measuring the protease activity of factor d of the alternative complement pathway |
EP3274468B1 (en) | 2015-03-25 | 2019-02-20 | Alexion Pharmaceuticals, Inc. | A method for measuring the protease activity of c3 and c5 convertase of the alternative complement pathway |
CN116327915A (zh) | 2015-04-03 | 2023-06-27 | 佐马技术有限公司 | 使用TGF-β抑制剂和PD-1抑制剂治疗癌症 |
EP3277823B1 (en) * | 2015-04-03 | 2023-09-13 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
SI3280257T1 (sl) | 2015-04-06 | 2023-10-30 | Regeneron Pharmaceuticals, Inc., | S humaniziranimi t-celicami posredovani imunski odzivi pri nehumanih živalih |
US10849992B1 (en) | 2015-04-07 | 2020-12-01 | Alector Llc | Methods of screening for sortilin binding antagonists |
SG10201912087SA (en) | 2015-04-07 | 2020-02-27 | Alector Llc | Anti-sortilin antibodies and methods of use thereof |
CA2982682A1 (en) | 2015-04-17 | 2016-10-20 | Amgen Research (Munich) Gmbh | Bispecific antibody constructs for cdh3 and cd3 |
JOP20200116A1 (ar) | 2015-04-24 | 2017-06-16 | Amgen Inc | طرق لعلاج أو الوقاية من الصداع النصفي |
CA3020885A1 (en) | 2015-05-05 | 2016-11-10 | Mohammad Tariq MALIK | Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents |
TWI820377B (zh) | 2015-05-07 | 2023-11-01 | 美商艾吉納斯公司 | 抗ox40抗體及其使用方法 |
EP3294771A1 (en) | 2015-05-11 | 2018-03-21 | H. Hoffnabb-La Roche Ag | Compositions and methods of treating lupus nephritis |
PT3294770T (pt) | 2015-05-12 | 2020-12-04 | Hoffmann La Roche | Métodos terapêuticos e diagnósticos para o cancro |
EP4292664A2 (en) | 2015-05-15 | 2023-12-20 | The General Hospital Corporation | Antagonistic anti-tumor necrosis factor receptor superfamily antibodies |
WO2016191397A1 (en) | 2015-05-22 | 2016-12-01 | Td2 Inc. | Benzamide and active compound compositions and methods of use |
IL255372B (en) | 2015-05-29 | 2022-07-01 | Genentech Inc | Therapeutic and diagnostic methods for cancer |
SG10201913500TA (en) | 2015-05-29 | 2020-03-30 | Agenus Inc | Anti-ctla-4 antibodies and methods of use thereof |
US10174121B2 (en) | 2015-05-29 | 2019-01-08 | Abbvie, Inc. | Anti-CD40 antibodies |
WO2016191811A1 (en) | 2015-06-03 | 2016-12-08 | The University Of Queensland | Mobilizing agents and uses therefor |
SG10201912085WA (en) | 2015-06-12 | 2020-02-27 | Alector Llc | Anti-cd33 antibodies and methods of use thereof |
JP2018518491A (ja) | 2015-06-12 | 2018-07-12 | アレクトル エルエルシー | 抗cd33抗体及びその使用方法 |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
IL256245B (en) | 2015-06-16 | 2022-09-01 | Merck Patent Gmbh | Treatments that combine a pd-l1 antagonist |
MX2017016353A (es) | 2015-06-17 | 2018-05-02 | Genentech Inc | Metodos para tratar canceres de mama metastasicos o localmente avanzados con antagonistas de union al eje de pd-1 y taxanos. |
CN107922497B (zh) | 2015-06-24 | 2022-04-12 | 詹森药业有限公司 | 抗vista抗体和片段 |
AU2016285596A1 (en) | 2015-06-29 | 2018-01-18 | Genentech, Inc. | Type II anti-CD20 antibody for use in organ transplantation |
TWI717375B (zh) | 2015-07-31 | 2021-02-01 | 德商安美基研究(慕尼黑)公司 | Cd70及cd3抗體構築體 |
TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Msln及cd3抗體構築體 |
TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究(慕尼黑)公司 | Egfrviii及cd3抗體構築體 |
TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Flt3及cd3抗體構築體 |
TWI793062B (zh) | 2015-07-31 | 2023-02-21 | 德商安美基研究(慕尼黑)公司 | Dll3及cd3抗體構築體 |
TW202330904A (zh) | 2015-08-04 | 2023-08-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
CA2994841A1 (en) | 2015-08-06 | 2017-02-09 | Xoma (Us) Llc | Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia |
CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
US11384138B2 (en) | 2015-08-19 | 2022-07-12 | Rutgers, The State University Of New Jersey | Methods of generating antibodies |
EP3338094B1 (en) | 2015-08-20 | 2019-05-08 | H. Hoffnabb-La Roche Ag | Particle-based immunoassay using a pegylated analyte-specific binding agent |
CN108138200A (zh) | 2015-08-24 | 2018-06-08 | 特里安尼公司 | 增强的免疫球蛋白产生 |
US10590198B2 (en) | 2015-08-28 | 2020-03-17 | Alector Llc | Anti-siglec-7 antibodies and methods of use thereof |
EA038329B1 (ru) | 2015-08-28 | 2021-08-10 | Амьюникс Фармасьютикалз, Инк. | Химерный полипептидный комплекс и способы его получения и применения |
PE20181322A1 (es) | 2015-09-01 | 2018-08-14 | Agenus Inc | Anticuerpo anti-pd1 y sus metodos de uso |
AR105910A1 (es) | 2015-09-04 | 2017-11-22 | Obi Pharma Inc | Matrices de glicano y método de uso |
MA42821A (fr) | 2015-09-15 | 2018-07-25 | Amgen Inc | Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci |
CN113912724A (zh) | 2015-09-25 | 2022-01-11 | 豪夫迈·罗氏有限公司 | 抗tigit抗体和使用方法 |
CA2997444A1 (en) | 2015-09-29 | 2017-04-06 | Amgen Inc. | Asgr inhibitors for reducing cholesterol levels |
WO2017058780A1 (en) | 2015-09-30 | 2017-04-06 | Merck Patent Gmbh | Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer |
CN108738323B (zh) | 2015-10-06 | 2023-05-26 | 艾利妥 | 抗trem2抗体及其使用方法 |
EP3368566A1 (en) | 2015-10-28 | 2018-09-05 | Friedrich Miescher Institute for Biomedical Research | Tenascin-w and biliary tract cancers |
CN108431041B (zh) | 2015-10-29 | 2022-08-16 | 艾利妥 | 抗siglec-9抗体及其使用方法 |
AR106543A1 (es) | 2015-11-02 | 2018-01-24 | Netris Pharma | Terapia de combinación de agente neutralizante de ntn1 con fármacos que inhiben el control epigenético |
JP2019500011A (ja) | 2015-11-03 | 2019-01-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 腫瘍選択性及び阻害性が増強された二重特異性抗体及びその使用 |
CA3002097A1 (en) | 2015-11-12 | 2017-05-18 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
US20170189548A1 (en) | 2015-11-25 | 2017-07-06 | Immunogen, Inc. | Pharmaceutical formulations and methods of use thereof |
WO2017095805A1 (en) | 2015-11-30 | 2017-06-08 | Abbvie Inc. | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE |
EP3383910A1 (en) | 2015-11-30 | 2018-10-10 | AbbVie Inc. | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE |
JP7227007B2 (ja) | 2015-12-02 | 2023-02-21 | ストサイエンシス, インコーポレイテッド | グリコシル化btla(b-及びt-リンパ球減弱因子)に特異的な抗体 |
CA3006769A1 (en) | 2015-12-02 | 2017-06-08 | Stcube & Co., Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
US10813346B2 (en) | 2015-12-03 | 2020-10-27 | Trianni, Inc. | Enhanced immunoglobulin diversity |
EP3390447A1 (en) | 2015-12-15 | 2018-10-24 | Amgen Inc. | Pacap antibodies and uses thereof |
CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
US10294303B2 (en) | 2015-12-23 | 2019-05-21 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists |
EP3184544A1 (en) | 2015-12-23 | 2017-06-28 | Julius-Maximilians-Universität Würzburg | Glycoprotein v inhibitors for use as coagulants |
EP3397287A1 (en) | 2015-12-30 | 2018-11-07 | Genentech, Inc. | Formulations with reduced degradation of polysorbate |
MX2018008063A (es) | 2015-12-30 | 2018-11-29 | Genentech Inc | Uso de derivados de triptofano para formulaciones de proteina. |
KR102477179B1 (ko) | 2015-12-31 | 2022-12-13 | 프로가스트린 에 캔서스 에스.에이 알.엘. | 위암의 검출 및 치료를 위한 조성물 및 방법 |
AU2017204686B2 (en) | 2015-12-31 | 2020-04-30 | Progastrine Et Cancers S.À R.L. | Compositions and methods for detecting and treating esophageal cancer |
BR112018013271A2 (pt) | 2015-12-31 | 2018-12-11 | Progastrine Et Cancers S A R L | composições e métodos para detectar e tratar câncer de ovário |
AU2017204683B2 (en) | 2015-12-31 | 2023-03-16 | Syncerus S.À R.L. | Compositions and methods for assessing the risk of cancer occurrence |
US10596257B2 (en) | 2016-01-08 | 2020-03-24 | Hoffmann-La Roche Inc. | Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies |
WO2017120536A1 (en) | 2016-01-08 | 2017-07-13 | Apg Therapeutics, Inc. | Polyethylenimine (pei)-polypeptide conjugates and methods of use thereof |
CN109311979A (zh) | 2016-02-03 | 2019-02-05 | 安进研发(慕尼黑)股份有限公司 | Psma和cd3双特异性t细胞接合抗体构建体 |
EA039859B1 (ru) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
DK3411402T3 (da) | 2016-02-03 | 2022-02-07 | Amgen Res Munich Gmbh | Bcma- og cd3-bispecifikke t-celle-engagerende antistofkonstruktioner |
WO2017136734A1 (en) | 2016-02-04 | 2017-08-10 | Trianni, Inc. | Enhanced production of immunoglobulins |
JP2019509721A (ja) | 2016-02-04 | 2019-04-11 | キュリス,インコーポレイテッド | 突然変異体スムースンド及びその使用方法 |
CN109069626A (zh) | 2016-02-12 | 2018-12-21 | 詹森药业有限公司 | 抗-vista(b7h5)抗体 |
AU2017225854B2 (en) | 2016-02-29 | 2020-11-19 | Foundation Medicine, Inc. | Therapeutic and diagnostic methods for cancer |
JP7023853B2 (ja) | 2016-03-04 | 2022-02-22 | アレクトル エルエルシー | 抗trem1抗体及びその使用方法 |
EP3426691A4 (en) | 2016-03-07 | 2019-09-25 | Charlestonpharma, LLC | ANTI-NUCLEOLIN ANTIBODIES |
EP3426693A4 (en) | 2016-03-08 | 2019-11-13 | Academia Sinica | PROCESS FOR MODULAR SYNTHESIS OF N-GLYCANES AND ARRANGEMENTS THEREOF |
WO2017159699A1 (en) | 2016-03-15 | 2017-09-21 | Chugai Seiyaku Kabushiki Kaisha | Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies |
KR102413037B1 (ko) | 2016-03-15 | 2022-06-23 | 메르사나 테라퓨틱스, 인코포레이티드 | Napi2b 표적화된 항체-약물 접합체 및 이의 사용 방법 |
AU2017233121B2 (en) | 2016-03-15 | 2023-12-21 | Itabmed (Hk) Limited | Multispecific Fab fusion proteins and use thereof |
SG11201808041UA (en) | 2016-03-17 | 2018-10-30 | Numab Innovation Ag | ANTI-TNFa-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF |
RS61412B1 (sr) | 2016-03-17 | 2021-03-31 | Tillotts Pharma Ag | Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti |
MA43715A (fr) | 2016-03-17 | 2018-11-28 | Numab Innovation Ag | Anticorps anti-tnf et fragments fonctionnels correspondants |
MA43716A (fr) | 2016-03-17 | 2018-11-28 | Numab Innovation Ag | Anticorps anti-tnf et fragments fonctionnels de ceux-ci |
PL3219726T3 (pl) | 2016-03-17 | 2021-07-19 | Tillotts Pharma Ag | Przeciwciała anty-tnf alfa i ich funkcjonalne fragmenty |
AU2017239038A1 (en) | 2016-03-22 | 2018-10-04 | Bionomics Inc | Administration of an anti-LGR5 monoclonal antibody |
US11549099B2 (en) | 2016-03-23 | 2023-01-10 | Novartis Ag | Cell secreted minibodies and uses thereof |
CA3019164A1 (en) | 2016-03-29 | 2017-10-05 | Janssen Biotech, Inc. | Method of treating psoriasis with increased interval dosing of anti-il12/23 antibody |
US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
TWI780045B (zh) | 2016-03-29 | 2022-10-11 | 台灣浩鼎生技股份有限公司 | 抗體、醫藥組合物及方法 |
WO2017175058A1 (en) | 2016-04-07 | 2017-10-12 | Janssen Pharmaceutica Nv | Anti-vista antibodies and fragments, uses thereof, and methods of identifying same |
WO2017181079A2 (en) | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Methods for monitoring and treating cancer |
CA3019921A1 (en) | 2016-04-15 | 2017-10-19 | Genentech, Inc. | Methods for monitoring and treating cancer |
JOP20170091B1 (ar) | 2016-04-19 | 2021-08-17 | Amgen Res Munich Gmbh | إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية |
TWI697333B (zh) | 2016-04-22 | 2020-07-01 | 台灣浩鼎生技股份有限公司 | 經由Globo系列抗原之免疫活化或免疫調節之癌症免疫療法 |
EP3455364A2 (en) | 2016-05-10 | 2019-03-20 | H. Hoffnabb-La Roche Ag | Methods of decreasing trisulfide bonds during recombinant production of polypeptides |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
TW201808336A (zh) | 2016-05-11 | 2018-03-16 | 賽諾菲公司 | 用抗muc1類美登素免疫綴合物抗體治療腫瘤的治療方案 |
US20170348429A1 (en) | 2016-05-17 | 2017-12-07 | Abbvie Biotherapeutics Inc. | ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE |
WO2017205465A2 (en) | 2016-05-24 | 2017-11-30 | Griswold Karl Edwin | Antibodies and methods of making same |
CN109195989A (zh) | 2016-05-26 | 2019-01-11 | 默克专利股份有限公司 | 用于癌症治疗的pd-1/pd-l1抑制剂 |
ES2901722T3 (es) | 2016-05-27 | 2022-03-23 | Abbvie Biotherapeutics Inc | Anticuerpos anti-CD40 y sus usos |
WO2017205721A1 (en) | 2016-05-27 | 2017-11-30 | Agenus Inc. | Anti-tim-3 antibodies and methods of use thereof |
EP3464362B1 (en) | 2016-05-27 | 2020-12-09 | AbbVie Biotherapeutics Inc. | Anti-4-1bb antibodies and their uses |
IL263160B2 (en) | 2016-06-03 | 2024-01-01 | Regeneron Pharma | Non-human animals expressing exogenous terminal deoxynucleotidyl transferase |
RS61828B1 (sr) | 2016-06-08 | 2021-06-30 | Abbvie Inc | Anti-b7-h3 antitela i antitelske konjugacije lekova |
KR20210084680A (ko) | 2016-06-13 | 2021-07-07 | 아이-맵 바이오파마 유에스 리미티드 | 항-pd-l1 항체 및 이것의 사용 |
EP3471767A4 (en) | 2016-06-15 | 2020-01-15 | Icahn School of Medicine at Mount Sinai | INFLUENZA VIRUS HEMAGGLUTININS AND USES THEREOF |
WO2018007999A1 (en) | 2016-07-08 | 2018-01-11 | Staten Biotechnology B.V. | Anti-apoc3 antibodies and methods of use thereof |
WO2018014260A1 (en) | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
US11312745B2 (en) | 2016-07-22 | 2022-04-26 | Amgen Inc. | Methods of purifying Fc-containing proteins |
EP3487880A1 (en) | 2016-07-25 | 2019-05-29 | Biogen MA Inc. | Anti-hspa5 (grp78) antibodies and uses thereof |
AU2017302038B2 (en) | 2016-07-27 | 2024-03-21 | Obi Pharma, Inc. | Immunogenic/therapeutic glycan compositions and uses thereof |
NL2017267B1 (en) | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
US11643456B2 (en) | 2016-07-29 | 2023-05-09 | Obi Pharma, Inc. | Human antibodies, pharmaceutical compositions and methods |
WO2018026748A1 (en) | 2016-08-01 | 2018-02-08 | Xoma (Us) Llc | Parathyroid hormone receptor 1 (pth1r) antibodies and uses thereof |
NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
CN109476748B (zh) | 2016-08-08 | 2023-05-23 | 豪夫迈·罗氏有限公司 | 用于癌症的治疗和诊断方法 |
JP2019524820A (ja) | 2016-08-12 | 2019-09-05 | ジェネンテック, インコーポレイテッド | Mek阻害剤、pd−1軸阻害剤及びvegf阻害剤での組合せ療法 |
CA3034057A1 (en) | 2016-08-22 | 2018-03-01 | CHO Pharma Inc. | Antibodies, binding fragments, and methods of use |
US11168148B2 (en) | 2016-09-07 | 2021-11-09 | The Regents Of The University Of California | Antibodies to oxidation-specific epitopes |
WO2018049261A1 (en) | 2016-09-09 | 2018-03-15 | Icellhealth Consulting Llc | Oncolytic virus expressing immune checkpoint modulators |
SI3512547T1 (sl) | 2016-09-14 | 2021-01-29 | Abbvie Biotherapeutics Inc. | Anti-PD-1 protitelesa |
PT3328887T (pt) | 2016-09-19 | 2021-10-19 | I Mab Biopharma Hangzhou Co Ltd | Anticorpos anti-gm-csf e suas utilizações |
CA3033571A1 (en) | 2016-09-21 | 2018-03-29 | Nextcure, Inc. | Antibodies for siglec-15 and methods of use thereof |
EP4360714A2 (en) | 2016-09-21 | 2024-05-01 | Nextcure, Inc. | Antibodies for siglec-15 and methods of use thereof |
JOP20190009A1 (ar) | 2016-09-21 | 2019-01-27 | Alx Oncology Inc | أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها |
AU2017335771A1 (en) | 2016-09-28 | 2019-02-28 | Musc Foundation For Research Development | Antibodies that bind interleukin-2 and uses thereof |
JP2019534251A (ja) | 2016-09-29 | 2019-11-28 | ジェネンテック, インコーポレイテッド | Mek阻害剤、pd−1軸阻害剤、及びタキサンを用いた併用療法 |
MA46366A (fr) | 2016-09-30 | 2019-08-07 | Janssen Biotech Inc | Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique contre l'il-23 |
CN110249226B (zh) | 2016-10-03 | 2023-08-25 | 雅培实验室 | 评估患者样品中gfap状态的改进方法 |
JP2019530704A (ja) | 2016-10-06 | 2019-10-24 | ファイザー・インコーポレイテッド | がんの処置のためのアベルマブの投与レジメン |
CA3038712A1 (en) | 2016-10-06 | 2018-04-12 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
CA3037380A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
WO2018081531A2 (en) | 2016-10-28 | 2018-05-03 | Ariad Pharmaceuticals, Inc. | Methods for human t-cell activation |
WO2018081578A1 (en) | 2016-10-28 | 2018-05-03 | Astute Medical, Inc. | Use of antibodies to timp-2 for the improvement of renal function |
RU2019114863A (ru) | 2016-11-02 | 2020-12-03 | Иммуноджен, Инк. | Комбинированное лечение конъюгатами антитело-лекарственное средство и ингибиторами parp |
US11779604B2 (en) | 2016-11-03 | 2023-10-10 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses and methods |
JP7045724B2 (ja) | 2016-11-07 | 2022-04-01 | ニューラクル サイエンス カンパニー リミテッド | 配列類似性を持つ抗ファミリー19、メンバーa5抗体及びその用途 |
EP3538550A1 (en) | 2016-11-10 | 2019-09-18 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Or10h1 modulators and uses thereof |
WO2018090052A1 (en) | 2016-11-14 | 2018-05-17 | Amgen Inc. | Bispecific or biparatopic antigen binding proteins and uses thereof |
KR20190078648A (ko) | 2016-11-16 | 2019-07-04 | 얀센 바이오테크 인코포레이티드 | 항-il23 특이적 항체로 건선을 치료하는 방법 |
US11401330B2 (en) | 2016-11-17 | 2022-08-02 | Seagen Inc. | Glycan-interacting compounds and methods of use |
WO2018094414A1 (en) | 2016-11-21 | 2018-05-24 | Obi Pharma, Inc. | Conjugated biological molecules, pharmaceutical compositions and methods |
WO2018098401A1 (en) | 2016-11-23 | 2018-05-31 | Translational Drug Development, Llc | Benzamide and active compound compositions and methods of use |
WO2018106864A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Antibodies and methods of use thereof |
WO2018106862A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
CN110573527A (zh) | 2016-12-15 | 2019-12-13 | 艾伯维生物制药股份有限公司 | 抗ox40抗体及其用途 |
KR102413013B1 (ko) | 2016-12-27 | 2022-06-23 | 에프. 호프만-라 로슈 아게 | 신규한 비오틴-특이적 단일클론 항체 및 그 용도 |
BR112019011131A2 (pt) | 2016-12-27 | 2019-12-31 | Hoffmann La Roche | anticorpo monoclonal, métodos para medir um analito em uma amostra e para produzir um anticorpo, uso de um anticorpo, kit de teste de imunoensaio e imunógeno |
KR20210126135A (ko) | 2016-12-27 | 2021-10-19 | 에프. 호프만-라 로슈 아게 | 신규한 비오틴-특이적 단일클론 항체 및 그 용도 |
EA039433B1 (ru) | 2017-01-05 | 2022-01-27 | Нетрис Фарма | Комбинированное лечение лекарственными средствами, интерферирующими с нетрином-1, и лекарственными средствами, ингибиторами контрольных точек иммуного ответа |
JOP20190177A1 (ar) | 2017-01-17 | 2019-07-16 | Amgen Inc | طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr) |
CN117586401A (zh) | 2017-01-20 | 2024-02-23 | 大有华夏生物医药集团有限公司 | 抗pd-1抗体及其用途 |
BR112019012040A2 (pt) | 2017-01-24 | 2019-11-12 | I Mab | anticorpo isolado ou fragmento do mesmo, composição, célula isolada, e, métodos para tratamento de câncer, para detecção da expressão de cd73 em uma amostra e para identificação de um paciente com câncer adequado para o tratamento com uma terapia anti-cd73. |
WO2018140510A1 (en) | 2017-01-25 | 2018-08-02 | Biogen Ma Inc. | Compositions and methods for treatment of stroke and other cns disorders |
CA3051484A1 (en) | 2017-01-27 | 2018-08-02 | Memorial Sloan Kettering Cancer Center | Bispecific her2 and cd3 binding molecules |
KR20240038146A (ko) | 2017-01-30 | 2024-03-22 | 얀센 바이오테크 인코포레이티드 | 활성 건선성 관절염의 치료를 위한 항-tnf 항체, 조성물, 및 방법 |
JOP20190189A1 (ar) | 2017-02-02 | 2019-08-01 | Amgen Res Munich Gmbh | تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t |
CN110234995A (zh) | 2017-02-02 | 2019-09-13 | 豪夫迈·罗氏有限公司 | 使用至少两种聚乙二醇化的分析物特异性结合试剂的免疫测定 |
KR20190115042A (ko) | 2017-02-07 | 2019-10-10 | 얀센 바이오테크 인코포레이티드 | 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법 |
CN108456251A (zh) | 2017-02-21 | 2018-08-28 | 上海君实生物医药科技股份有限公司 | 抗pd-l1抗体及其应用 |
WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
WO2018160841A1 (en) | 2017-03-01 | 2018-09-07 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
BR112019018043A2 (pt) | 2017-03-03 | 2020-04-07 | Seattle Genetics Inc | método de tratamento de câncer, e, conjugado de anticorpo-fármaco |
TWI808963B (zh) | 2017-03-22 | 2023-07-21 | 法商賽諾菲公司 | 使用人類化抗cxcr5抗體治療狼瘡 |
JP7346300B2 (ja) | 2017-03-23 | 2023-09-19 | アボット・ラボラトリーズ | 早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼl1を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法 |
BR112019020412A2 (pt) | 2017-03-30 | 2020-06-09 | Ecs Progastrin Sa | composições e métodos para detectar câncer de pulmão |
SG11201908998XA (en) | 2017-03-30 | 2019-10-30 | Progastrine Et Cancers S A R L | Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule |
MX2019011599A (es) | 2017-03-30 | 2019-12-19 | Univ Queensland | Moleculas quimericas y usos de las mismas. |
EP3600410A1 (en) | 2017-03-30 | 2020-02-05 | Merck Patent GmbH | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer |
JP7315466B2 (ja) | 2017-04-05 | 2023-07-26 | アスチュート メディカル,インコーポレイテッド | 生体試料中において改善した性能を有する、timp2に関するアッセイ |
EP3606555A4 (en) | 2017-04-07 | 2021-08-04 | Icahn School of Medicine at Mount Sinai | INFLUENZA VIRUS TYPE B ANTI-NEURAMINIDASE ANTIBODIES AND THEIR USES |
MX2019012223A (es) | 2017-04-13 | 2019-12-09 | Agenus Inc | Anticuerpos anti-cd137 y metodos de uso de los mismos. |
CA3053409A1 (en) | 2017-04-15 | 2018-10-18 | Abbott Laboratories | Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers |
KR20190141659A (ko) | 2017-04-21 | 2019-12-24 | 스태튼 바이오테크놀로지 비.브이. | 항-apoc3 항체 및 이의 사용 방법 |
JP2020517271A (ja) | 2017-04-22 | 2020-06-18 | イミュノミック セラピューティックス, インコーポレイテッドImmunomic Therapeutics, Inc. | 改良lamp構築物 |
US20230140818A1 (en) | 2017-04-27 | 2023-05-04 | The University Of Hong Kong | Use of hcn inhibitors for treatment of cancer |
WO2018200823A1 (en) | 2017-04-28 | 2018-11-01 | Abbott Laboratories | Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject |
LT3618863T (lt) | 2017-05-01 | 2023-10-10 | Agenus Inc. | Anti-tigit antikūnai ir jų panaudojimo būdai |
IL297073B2 (en) | 2017-05-02 | 2023-12-01 | Immunomic Therapeutics Inc | LAMP constructs containing cancer antigens |
US10865238B1 (en) | 2017-05-05 | 2020-12-15 | Duke University | Complement factor H antibodies |
CN110913904A (zh) | 2017-05-05 | 2020-03-24 | 美国安进公司 | 用于改善的储存和施用的包含双特异性抗体构建体的药物组合物 |
JOP20190256A1 (ar) | 2017-05-12 | 2019-10-28 | Icahn School Med Mount Sinai | فيروسات داء نيوكاسل واستخداماتها |
EP3625258A1 (en) | 2017-05-16 | 2020-03-25 | Alector LLC | Anti-siglec-5 antibodies and methods of use thereof |
US10914729B2 (en) | 2017-05-22 | 2021-02-09 | The Trustees Of Princeton University | Methods for detecting protein binding sequences and tagging nucleic acids |
EP3630830A1 (en) | 2017-05-23 | 2020-04-08 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Novel cd73 antibody, preparation and uses thereof |
US10866251B2 (en) | 2017-05-25 | 2020-12-15 | Abbott Laboratories | Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers |
AU2018275235A1 (en) | 2017-05-30 | 2019-10-31 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I and early biomarkers |
JOP20190259A1 (ar) | 2017-05-31 | 2019-10-31 | Amgen Inc | بروتينات ربط مولد ضد مضادة لـ jagged1 |
CN111051346A (zh) | 2017-05-31 | 2020-04-21 | 斯特库伯株式会社 | 使用免疫特异性结合btn1a1的抗体和分子治疗癌症的方法 |
US20200148768A1 (en) | 2017-05-31 | 2020-05-14 | Stcube & Co., Inc. | Antibodies and molecules that immunospecifically bind to btn1a1 and the therapeutic uses thereof |
WO2018226671A1 (en) | 2017-06-06 | 2018-12-13 | Stcube & Co., Inc. | Methods of treating cancer using antibodies and molecules that bind to btn1a1 or btn1a1-ligands |
MX2019013919A (es) | 2017-06-20 | 2020-01-21 | Amgen Inc | Metodo para tratar o mejorar trastornos metabolicos con proteinas de union para el receptor peptidico inhibidor gastrico (gipr) en combinacion con agonistas de glp-1. |
WO2019000223A1 (en) | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF |
SG11202000298VA (en) | 2017-07-14 | 2020-02-27 | Pfizer | Antibodies to madcam |
JP2020527351A (ja) | 2017-07-21 | 2020-09-10 | ジェネンテック, インコーポレイテッド | がんの治療法及び診断法 |
AU2018302343B2 (en) | 2017-07-21 | 2020-11-26 | Trianni, Inc. | Single chain vh and heavy chain antibodies |
SG11202000634UA (en) | 2017-07-27 | 2020-02-27 | Nomocan Pharmaceuticals Llc | Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer |
WO2019028292A1 (en) | 2017-08-03 | 2019-02-07 | Alector Llc | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
BR112020002013B1 (pt) | 2017-08-03 | 2023-01-24 | Amgen Inc | Muteínas de il-21, método de preparação das mesmas, ácido nucleico, vetor, célula hospedeira, kit, uso dos mesmos e composição farmacêutica |
BR112019023789A2 (pt) | 2017-08-03 | 2020-07-28 | Alector Llc | anticorpos anti-cd33 e métodos de uso dos mesmos |
EP3661562A1 (en) | 2017-08-04 | 2020-06-10 | Amgen Inc. | Method of conjugation of cys-mabs |
JP7324744B2 (ja) | 2017-08-21 | 2023-08-10 | アダジーン インコーポレイテッド | ダイナミックヒト抗体軽鎖ライブラリー |
US11578426B2 (en) | 2017-08-21 | 2023-02-14 | Adagene Inc. | Dynamic human heavy chain antibody libraries |
CN111133005A (zh) | 2017-09-07 | 2020-05-08 | 奥古斯塔大学研究所公司 | 程序性细胞死亡蛋白1抗体 |
SG11202001499WA (en) | 2017-09-08 | 2020-03-30 | Amgen Inc | Inhibitors of kras g12c and methods of using the same |
US20200216542A1 (en) | 2017-09-20 | 2020-07-09 | Chugai Seiyaku Kabushiki Kaisha | Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agent |
MX2020003193A (es) | 2017-09-22 | 2020-07-29 | Hoffmann La Roche | Anticuerpos recombinantes mono- o biespecificos multivalentes para fines analiticos. |
TW201922780A (zh) | 2017-09-25 | 2019-06-16 | 美商健生生物科技公司 | 以抗il12/il23抗體治療狼瘡之安全且有效之方法 |
US11230601B2 (en) | 2017-10-10 | 2022-01-25 | Tilos Therapeutics, Inc. | Methods of using anti-lap antibodies |
CA3185107A1 (en) | 2017-10-12 | 2019-04-18 | Immunowake Inc. | Vegfr-antibody light chain fusion protein |
US11826414B2 (en) | 2017-10-23 | 2023-11-28 | Cz Biohub Sf, Llc | Measurement of afucosylated IgG Fc glycans and related vaccination methods |
WO2019084460A1 (en) | 2017-10-26 | 2019-05-02 | The Regents Of The University Of California | INHIBITION OF OXIDATION-SPECIFIC EPITOPES TO TREAT ISCHEMIC REPERFUSION INJURY |
DK3476942T3 (da) | 2017-10-27 | 2022-04-19 | Trianni Inc | Lange kimlinje-dh-gener og antistoffer med lang hcdr3 |
WO2019089594A1 (en) | 2017-10-31 | 2019-05-09 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and cytarabine |
SG11202003980PA (en) | 2017-10-31 | 2020-05-28 | Staten Biotechnology B V | Anti-apoc3 antibodies and methods of use thereof |
CA3077664A1 (en) | 2017-11-06 | 2019-05-09 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
JP7165193B2 (ja) | 2017-11-27 | 2022-11-02 | パーデュー、ファーマ、リミテッド、パートナーシップ | ヒト組織因子を標的とするヒト化抗体 |
DK3720879T3 (da) | 2017-12-05 | 2022-06-20 | Progastrine Et Cancers S A R L | Kombinationsterapi mellem anti-progastrin-antistof og immunterapi til behandling af cancer |
US11051498B2 (en) * | 2017-12-05 | 2021-07-06 | Regeneron Pharmaceuticals, Inc. | Mouse having an engineered immunoglobulin lambda light chain |
AU2018378804A1 (en) | 2017-12-06 | 2020-06-11 | Ensoma, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
AU2018378971A1 (en) | 2017-12-09 | 2020-01-02 | Abbott Laboratories | Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (TBI), using glial fibrillary acidic protein (GFAP) and/or ubiquitin carboxy-terminal hydrolase l1 (UCH-L1) |
BR112020010085A2 (pt) | 2017-12-09 | 2020-10-13 | Abbott Laboratories | métodos para auxiliar no diagnóstico e avaliar uma lesão cerebral traumática em um indivíduo humano usando uma combinação de gfap e uch-l1 |
CN111315780A (zh) | 2017-12-11 | 2020-06-19 | 安进公司 | 双特异性抗体产品的连续制造工艺 |
RU2756100C1 (ru) | 2017-12-20 | 2021-09-28 | Харбор Байомед (Шанхай) Ко., Лтд | Антитела, связывающие ctla-4, и их применение |
TW201930358A (zh) | 2017-12-28 | 2019-08-01 | 大陸商南京傳奇生物科技有限公司 | 針對tigit之單域抗體及其變異體 |
TW201930350A (zh) | 2017-12-28 | 2019-08-01 | 大陸商南京傳奇生物科技有限公司 | 針對pd-l1之抗體及其變異體 |
WO2019133902A2 (en) | 2017-12-28 | 2019-07-04 | Astute Medical, Inc. | Antibodies and assays for ccl14 |
UY38041A (es) | 2017-12-29 | 2019-06-28 | Amgen Inc | Construcción de anticuerpo biespecífico dirigida a muc17 y cd3 |
EP3508499A1 (en) | 2018-01-08 | 2019-07-10 | iOmx Therapeutics AG | Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof |
CA3087273A1 (en) | 2018-01-12 | 2019-07-18 | Amgen Inc. | Anti-pd-1 antibodies and methods of treatment |
MX2020006976A (es) | 2018-01-12 | 2020-10-05 | Amgen Inc | Anticuerpos del receptor de tipo i del polipeptido activador de la adenilato?ciclasa hipofisaria (pac1) y sus usos. |
KR20200120641A (ko) | 2018-01-15 | 2020-10-21 | 난징 레전드 바이오테크 씨오., 엘티디. | Pd-1에 대한 단일-도메인 항체 및 이의 변이체 |
CN111954541A (zh) | 2018-01-25 | 2020-11-17 | Acm生物实验室私人有限公司 | 包含可溶性包封抗原的聚合物囊泡以及其制备方法和用途 |
TW201940881A (zh) | 2018-01-26 | 2019-10-16 | 瑞士商Ecs前胃泌激素公司 | 在癌症診斷中結合前胃泌激素檢測與其他癌症生物標記的技術 |
EP3759141A1 (en) | 2018-02-26 | 2021-01-06 | F. Hoffmann-La Roche AG | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
US20200400675A1 (en) | 2018-02-27 | 2020-12-24 | Ecs-Progastrin Sa | Progastrin as a biomarker for immunotherapy |
US20210002373A1 (en) | 2018-03-01 | 2021-01-07 | Nextcure, Inc. | KLRG1 Binding Compositions and Methods of Use Thereof |
NL2020520B1 (en) | 2018-03-02 | 2019-09-12 | Labo Bio Medical Invest B V | Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders |
US20190269757A1 (en) | 2018-03-05 | 2019-09-05 | Janssen Biotech, Inc. | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody |
MX2020009526A (es) | 2018-03-12 | 2020-10-28 | Zoetis Services Llc | Anticuerpos anti-ngf y metodos de estos. |
TW202003562A (zh) | 2018-03-14 | 2020-01-16 | 中國大陸商北京軒義醫藥科技有限公司 | 抗密連蛋白18.2(cldn18.2)抗體 |
CN112040979A (zh) | 2018-03-21 | 2020-12-04 | Alx肿瘤生物技术公司 | 针对信号调控蛋白α的抗体和使用方法 |
WO2019180272A1 (en) | 2018-03-23 | 2019-09-26 | Fundación Instituto De Investigación Sanitaria De Santiago De Compostela | Anti-leptin affinity reagents for use in the treatment of obesity and other leptin-resistance associated diseases |
BR112020019026A2 (pt) | 2018-03-24 | 2020-12-29 | Regeneron Pharmaceuticals, Inc. | Animal não humano geneticamente modificado, métodos para produzir o animal não humano geneticamente modificado, para geração de uma proteína de ligação a antígeno, para obtenção de um ácido nucleico, e, para obtenção de uma célula que expressa um domínio variável de cadeia pesada de imunoglobulina humana e/ou um domínio variável de cadeia leve de imunoglobulina humana, método in vitro de produção de um domínio variável de imunoglobulina humana, ácido nucleico, célula hospedeira, célula isolada, e, domínio variável de cadeia pesada de imunoglobulina humana |
CN116420679A (zh) | 2018-03-26 | 2023-07-14 | 瑞泽恩制药公司 | 用于测试治疗剂的人源化啮齿动物 |
PT3775909T (pt) | 2018-03-26 | 2023-07-19 | Glycanostics S R O | Meios e métodos para o glicoperfil de uma proteína |
US11958903B2 (en) | 2018-03-30 | 2024-04-16 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies against LAG-3 and uses thereof |
JP2021521273A (ja) | 2018-04-12 | 2021-08-26 | メディアファーマ エス.アール.エル. | Lgals3bp抗体−薬剤結合体及びがん治療のためのその使用 |
EP3784274A1 (en) | 2018-04-27 | 2021-03-03 | Fondazione Ebri Rita Levi-Montalcini | Antibody directed against a tau-derived neurotoxic peptide and uses thereof |
KR20210006405A (ko) | 2018-05-04 | 2021-01-18 | 메르크 파텐트 게엠베하 | 암의 치료를 위한 PD-1/PD-L1, TGFβ 및 DNA-PK의 조합 억제 |
JP2021523138A (ja) | 2018-05-11 | 2021-09-02 | ヤンセン バイオテツク,インコーポレーテツド | Il−23抗体を使用してうつを治療する方法 |
WO2019222130A1 (en) | 2018-05-15 | 2019-11-21 | Immunogen, Inc. | Combination treatment with antibody-drug conjugates and flt3 inhibitors |
WO2019222281A1 (en) | 2018-05-15 | 2019-11-21 | Immunomic Therapeutics, Inc | Improved lamp constructs comprising allergens |
AR115418A1 (es) | 2018-05-25 | 2021-01-13 | Alector Llc | ANTICUERPOS ANTI-SIRPA (PROTEÍNA REGULADORA DE SEÑALES a) Y MÉTODOS DE USO DE LOS MISMOS |
MA52783A (fr) | 2018-06-05 | 2021-04-14 | Amgen Inc | Modulation de la phagocytose cellulaire dépendant de l'anticorps |
JP7382970B2 (ja) | 2018-06-08 | 2023-11-17 | アレクトル エルエルシー | 抗Siglec-7抗体及びその使用方法 |
LT3629720T (lt) | 2018-06-14 | 2022-03-10 | Regeneron Pharmaceuticals, Inc. | Gyvūnai, išskyrus žmogų, gebantys vykdyti imunoglobulino sunkiosios grandinės koduojančių sekų dh-dh pertvarkymą |
KR20210040945A (ko) | 2018-06-21 | 2021-04-14 | 유마니티 테라퓨틱스, 인크. | 신경장애의 치료 및 예방을 위한 조성물 및 방법 |
JP7399895B2 (ja) | 2018-06-23 | 2023-12-18 | ジェネンテック, インコーポレイテッド | Pd-1軸結合拮抗薬、白金剤、およびトポイソメラーゼii阻害剤で肺癌を治療する方法 |
US11203645B2 (en) | 2018-06-27 | 2021-12-21 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
MX2020013923A (es) | 2018-06-29 | 2021-03-29 | Apitbio Inc | Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos. |
LT3618928T (lt) | 2018-07-13 | 2023-04-11 | Alector Llc | Anti-sortilino antikūnai ir jų panaudojimo būdai |
BR112021000673A2 (pt) | 2018-07-18 | 2021-04-20 | Genentech, Inc. | métodos para tratar um indivíduo com câncer de pulmão, kits, anticorpo anti-pd-l1 e composições |
US20200025776A1 (en) | 2018-07-18 | 2020-01-23 | Janssen Biotech, Inc. | Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody |
EP3824287A1 (en) | 2018-07-20 | 2021-05-26 | Pierre Fabre Médicament | Receptor for vista |
US20210301020A1 (en) | 2018-07-24 | 2021-09-30 | Amgen Inc. | Combination of lilrb1/2 pathway inhibitors and pd-1 pathway inhibitors |
EA202190183A1 (ru) | 2018-07-27 | 2021-05-18 | Алектор Ллс | Антитела к siglec-5 и способы их применения |
JP2021532140A (ja) | 2018-07-30 | 2021-11-25 | アムジェン リサーチ (ミュニック) ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cd33及びcd3に結合する二重特異性抗体コンストラクトの長期投与 |
MA53330A (fr) | 2018-08-03 | 2021-06-09 | Amgen Inc | Constructions d'anticorps pour cldn18.2 et cd3 |
CA3106537A1 (en) | 2018-08-08 | 2020-02-13 | Genentech, Inc. | Use of tryptophan derivatives and l-methionine for protein formulation |
AU2019327155A1 (en) | 2018-08-27 | 2021-03-18 | Affimed Gmbh | Cryopreserved NK cells preloaded with an antibody construct |
EP3850006A1 (en) | 2018-09-11 | 2021-07-21 | Amgen Inc. | Methods of modulating antibody-dependent cell-mediated cytotoxicity |
WO2020053325A1 (en) | 2018-09-12 | 2020-03-19 | Acm Biolabs Pte Ltd | Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof |
CA3111401A1 (en) | 2018-09-19 | 2020-03-26 | Genentech, Inc. | Therapeutic and diagnostic methods for bladder cancer |
ES2955032T3 (es) | 2018-09-21 | 2023-11-28 | Hoffmann La Roche | Métodos de diagnóstico para el cáncer de mama triple negativo |
SI3883606T1 (sl) | 2018-09-24 | 2023-10-30 | Janssen Biotech, Inc. | Varen in učinkovit postopek zdravljenja ulceroznega kolitisa s protitelesom proti IL12/IL23 |
BR112021004935A2 (pt) | 2018-09-26 | 2021-06-01 | Merck Patent Gmbh | combinação de antagonista de pd-1, inibidor de atr e agente de platinação para tratamento de câncer |
UY38393A (es) | 2018-09-28 | 2020-03-31 | Amgen Inc | Anticuerpos contra bcma soluble |
MA53811A (fr) | 2018-10-03 | 2022-03-16 | Staten Biotechnology B V | Anticorps spécifiques à l'apoc3 humaine et du cynomolgus et procédés pour leur utilisation |
WO2020076969A2 (en) | 2018-10-10 | 2020-04-16 | Tilos Therapeutics, Inc. | Anti-lap antibody variants and uses thereof |
JP2022512636A (ja) | 2018-10-11 | 2022-02-07 | アムジエン・インコーポレーテツド | 二重特異性抗体コンストラクトの下流プロセシング |
CA3116234A1 (en) | 2018-10-15 | 2020-04-23 | Merck Patent Gmbh | Combination therapy utilizing dna alkylating agents and atr inhibitors |
EP3867646A1 (en) | 2018-10-18 | 2021-08-25 | F. Hoffmann-La Roche AG | Diagnostic and therapeutic methods for sarcomatoid kidney cancer |
US20210401956A1 (en) | 2018-10-24 | 2021-12-30 | Deutsches Krebsforschungszentrum Stiftung des Öffentichen Rechts | Vaccination and antibody generation platform |
WO2020086408A1 (en) | 2018-10-26 | 2020-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A high-yield perfusion-based transient gene expression bioprocess |
WO2020092455A2 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Car t cell transcriptional atlas |
WO2020092937A1 (en) | 2018-11-02 | 2020-05-07 | Annexon, Inc. | Compositions and methods for treating brain injury |
TW202031899A (zh) | 2018-11-05 | 2020-09-01 | 美商建南德克公司 | 在原核宿主細胞中產生二鏈蛋白質之方法 |
KR102624804B1 (ko) | 2018-11-16 | 2024-01-12 | 에프. 호프만-라 로슈 아게 | 결합 쌍의 부재를 갖는 스트렙타비딘 코팅된 고체상 |
US11548941B2 (en) | 2018-11-20 | 2023-01-10 | Janssen Biotech, Inc. | Safe and effective method of treating psoriasis with anti-IL-23 specific antibody |
WO2020118011A1 (en) | 2018-12-06 | 2020-06-11 | Alexion Pharmaceuticals, Inc. | Anti-alk2 antibodies and uses thereof |
US20220026445A1 (en) | 2018-12-07 | 2022-01-27 | Georgia Tech Research Corporation | Antibodies that bind to natively folded myocilin |
WO2020128864A1 (en) | 2018-12-18 | 2020-06-25 | Janssen Biotech, Inc. | Safe and effective method of treating lupus with anti-il12/il23 antibody |
CN115120716A (zh) | 2019-01-14 | 2022-09-30 | 健泰科生物技术公司 | 用pd-1轴结合拮抗剂和rna疫苗治疗癌症的方法 |
JP2022518208A (ja) | 2019-01-15 | 2022-03-14 | ヤンセン バイオテツク,インコーポレーテツド | 若年性特発性関節炎の治療のための抗tnf抗体、組成物、及び方法 |
JP2022518250A (ja) | 2019-01-23 | 2022-03-14 | ヤンセン バイオテツク,インコーポレーテツド | 乾癬性関節炎の治療方法で使用するための抗tnf抗体組成物 |
CA3124515A1 (en) | 2019-01-23 | 2020-07-30 | Genentech, Inc. | Methods of producing multimeric proteins in eukaryotic host cells |
EP3917968A1 (en) | 2019-01-30 | 2021-12-08 | Nomocan Pharmaceuticals LLC | Antibodies to m(h)dm2/4 and their use in diagnosing and treating cancer |
EP3921443A1 (en) | 2019-02-08 | 2021-12-15 | F. Hoffmann-La Roche AG | Diagnostic and therapeutic methods for cancer |
JP2022530301A (ja) | 2019-02-22 | 2022-06-29 | 武▲漢▼友芝友生物制▲薬▼有限公司 | Cd3抗原結合性断片及びその使用 |
FI3930847T3 (fi) | 2019-02-26 | 2024-04-23 | Inspirna Inc | Korkea-affiinisia anti-MERTK-vasta-aineita ja niiden käyttöjä |
JP2022521773A (ja) | 2019-02-27 | 2022-04-12 | ジェネンテック, インコーポレイテッド | 抗tigit抗体と抗cd20抗体又は抗cd38抗体とによる処置のための投薬 |
JP2022525179A (ja) | 2019-03-14 | 2022-05-11 | ヤンセン バイオテツク,インコーポレーテツド | 抗tnf抗体組成物を産生するための産生方法 |
MA55283A (fr) | 2019-03-14 | 2022-01-19 | Janssen Biotech Inc | Procédés de production de compositions d'anticorps anti-tnf |
JP2022525145A (ja) | 2019-03-14 | 2022-05-11 | ヤンセン バイオテツク,インコーポレーテツド | 抗il12/il23抗体組成物を生成するための製造方法 |
MA55284A (fr) | 2019-03-14 | 2022-01-19 | Janssen Biotech Inc | Procédés de production de compositions d'anticorps anti-tnf |
EP3938401A4 (en) | 2019-03-15 | 2023-05-24 | Cartesian Therapeutics, Inc. | CHIMERA ANTI-BCMA ANTIGEN RECEPTORS |
JP2022526493A (ja) | 2019-03-18 | 2022-05-25 | ヤンセン バイオテツク,インコーポレーテツド | 抗il12/il23抗体を用いた小児被験者の乾癬の治療方法 |
TW202042824A (zh) | 2019-03-27 | 2020-12-01 | 賓夕法尼亞大學董事會 | Tn-MUC1嵌合抗原受體(CAR)T細胞療法 |
US20220169706A1 (en) | 2019-03-28 | 2022-06-02 | Danisco Us Inc | Engineered antibodies |
JP2022530026A (ja) | 2019-04-24 | 2022-06-27 | ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング | アマトキシン抗体薬物複合体及びその使用 |
AU2020270376A1 (en) | 2019-05-03 | 2021-10-07 | Genentech, Inc. | Methods of treating cancer with an anti-PD-L1 antibody |
US20200369759A1 (en) | 2019-05-23 | 2020-11-26 | Fibrogen, Inc. | Methods of treatment of muscular dystrophies |
US11780911B2 (en) | 2019-05-23 | 2023-10-10 | Janssen Biotech, Inc. | Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha |
EP3976643A2 (en) | 2019-05-30 | 2022-04-06 | Amgen Inc. | Engineering the hinge region to drive antibody dimerization |
BR112021024425A2 (pt) | 2019-06-03 | 2022-01-18 | Janssen Biotech Inc | Composições de anticorpo anti-tnf e métodos para o tratamento de artrite psoriática |
BR112021024401A2 (pt) | 2019-06-03 | 2022-04-19 | Janssen Biotech Inc | Anticorpos anti-tnf, composições e métodos para o tratamento de espondilite anquilosante ativa |
MX2021015045A (es) | 2019-06-07 | 2022-03-17 | Amgen Inc | Construcciones de unión biespecíficas. |
TW202045711A (zh) | 2019-06-13 | 2020-12-16 | 美商安進公司 | 生物製品製造中基於生物量之自動灌注控制 |
JP2022538232A (ja) | 2019-06-28 | 2022-09-01 | アムジエン・インコーポレーテツド | 抗cgrp受容体/抗pac1受容体二重特異性抗原結合タンパク質 |
WO2021001458A1 (en) | 2019-07-01 | 2021-01-07 | Tonix Pharma Holdings Limited | Anti-cd154 antibodies and uses thereof |
US20220369609A1 (en) | 2019-07-01 | 2022-11-24 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
US20210000087A1 (en) | 2019-07-01 | 2021-01-07 | Trianni, Inc. | Transgenic mammals and methods of use thereof |
EP3994171A1 (en) | 2019-07-05 | 2022-05-11 | iOmx Therapeutics AG | Antibodies binding igc2 of igsf11 (vsig3) and uses thereof |
EP3763737A1 (en) | 2019-07-12 | 2021-01-13 | Eberhard Karls Universität Tübingen | Binding compounds of penicillin binding protein 2 a |
JP2022542890A (ja) | 2019-07-26 | 2022-10-07 | アムジエン・インコーポレーテツド | 抗il13抗原結合タンパク質 |
WO2021028752A1 (en) | 2019-08-15 | 2021-02-18 | Janssen Biotech, Inc. | Anti-tfn antibodies for treating type i diabetes |
EP3785536B1 (en) | 2019-08-28 | 2022-01-26 | Trianni, Inc. | Adam6 knockin mice |
PE20221151A1 (es) | 2019-08-30 | 2022-07-18 | Agenus Inc | Anticuerpos anti-cd96 y sus metodos de uso |
EP4026846A4 (en) | 2019-09-03 | 2023-09-13 | Bio-Thera Solutions, Ltd. | ANTI-TIGITE IMMUNOSUPPRESSANT AND USE THEREOF |
AU2020341458A1 (en) | 2019-09-04 | 2022-04-21 | Genentech, Inc. | CD8 binding agents and uses thereof |
US20220306741A1 (en) | 2019-09-10 | 2022-09-29 | Amgen Inc. | Purification Method for Bispecific antigen-binding Polypeptides with Enhanced Protein L Capture Dynamic Binding Capacity |
CA3146616A1 (en) | 2019-09-12 | 2021-03-18 | Matthew Dominic CASCINO | Compositions and methods of treating lupus nephritis |
US20220411511A1 (en) | 2019-09-26 | 2022-12-29 | Stcube & Co. | Antibodies specific to glycosylated ctla-4 and methods of use thereof |
CR20220127A (es) | 2019-09-27 | 2022-05-27 | Genentech Inc | Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1 |
JP2022552282A (ja) | 2019-10-09 | 2022-12-15 | エスティーキューブ アンド カンパニー | グリコシル化lag3に対して特異的な抗体およびその使用方法 |
KR20220083773A (ko) | 2019-10-18 | 2022-06-20 | 이뮤노믹 쎄라퓨틱스, 인크. | 암 항원을 포함하는 개선된 lamp 구축물 |
EP4045044A1 (en) | 2019-10-18 | 2022-08-24 | The Regents Of The University Of California | Plxdc activators and their use in the treatment of blood vessel disorders |
US20220401481A1 (en) | 2019-11-01 | 2022-12-22 | Magenta Therapeutics, Inc. | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells |
BR112022007787A2 (pt) | 2019-11-01 | 2022-07-05 | Ares Trading Sa | Inibição combinada de pd-1, tgfss e atm juntamente com radioterapia para o tratamento de câncer |
CA3155219A1 (en) | 2019-11-05 | 2021-05-14 | Merck Patent Gmbh | Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer |
CN115066613A (zh) | 2019-11-06 | 2022-09-16 | 基因泰克公司 | 用于治疗血液癌症的诊断和治疗方法 |
MX2022005566A (es) | 2019-11-08 | 2022-07-19 | Amgen Inc | Genomanipulación de mutaciones de par de carga para el emparejamiento de moléculas hetero-lgg. |
AU2020381536A1 (en) | 2019-11-13 | 2022-04-21 | Amgen Inc. | Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules |
EP3822288A1 (en) | 2019-11-18 | 2021-05-19 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof |
AU2020386005A1 (en) | 2019-11-19 | 2022-05-26 | Amgen Inc. | Novel multispecific antibody format |
EP3825330A1 (en) | 2019-11-19 | 2021-05-26 | International-Drug-Development-Biotech | Anti-cd117 antibodies and methods of use thereof |
CN114901678A (zh) | 2019-12-02 | 2022-08-12 | 瑞泽恩制药公司 | 肽-mhc ii蛋白构建体及其用途 |
MX2022006073A (es) | 2019-12-05 | 2022-08-04 | Alector Llc | Metodos para utilizar anticuerpos anti-trem2. |
US11897950B2 (en) | 2019-12-06 | 2024-02-13 | Augusta University Research Institute, Inc. | Osteopontin monoclonal antibodies |
KR20220113414A (ko) | 2019-12-09 | 2022-08-12 | 제넨테크, 인크. | 항-pd-l1 항체 제제 |
US20230035072A1 (en) | 2019-12-12 | 2023-02-02 | Alector Llc | Methods of use of anti-cd33 antibodies |
WO2021127528A1 (en) | 2019-12-20 | 2021-06-24 | Amgen Inc. | Mesothelin-targeted cd40 agonistic multispecific antibody constructs for the treatment of solid tumors |
CA3160927A1 (en) | 2019-12-27 | 2021-07-01 | Affimed Gmbh | Method for the production of bispecific fcyriii x cd30 antibody construct |
CN115052663A (zh) | 2020-01-08 | 2022-09-13 | 辛瑟斯治疗股份有限公司 | Alk5抑制剂缀合物及其用途 |
WO2021150824A1 (en) | 2020-01-22 | 2021-07-29 | Amgen Research (Munich) Gmbh | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
WO2022050954A1 (en) | 2020-09-04 | 2022-03-10 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2021194481A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
BR112022015077A2 (pt) | 2020-01-31 | 2022-10-04 | Genentech Inc | Métodos para induzir células t cd8+ específicas de neoepítopos em um indivíduo com um tumor e para induzir o tráfico de células t cd8+, vacinas de rna, vacina de rna para uso e antagonistas de ligação |
CN113248611A (zh) | 2020-02-13 | 2021-08-13 | 湖南华康恒健生物技术有限公司 | 抗bcma抗体、其药物组合物及应用 |
WO2021173565A1 (en) | 2020-02-24 | 2021-09-02 | Alector Llc | Methods of use of anti-trem2 antibodies |
CA3174103A1 (en) | 2020-03-06 | 2021-09-10 | Go Therapeutics, Inc. | Anti-glyco-cd44 antibodies and their uses |
WO2021177980A1 (en) | 2020-03-06 | 2021-09-10 | Genentech, Inc. | Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist |
JP2023517889A (ja) | 2020-03-10 | 2023-04-27 | マサチューセッツ インスティテュート オブ テクノロジー | NPM1c陽性がんの免疫療法のための組成物および方法 |
EP4118113A1 (en) | 2020-03-12 | 2023-01-18 | Amgen Inc. | Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor |
MX2022011632A (es) | 2020-03-19 | 2022-10-13 | Amgen Inc | Anticuerpos contra mucina 17 y usos de los mismos. |
US20230203191A1 (en) | 2020-03-30 | 2023-06-29 | Danisco Us Inc | Engineered antibodies |
WO2021197340A1 (zh) | 2020-03-31 | 2021-10-07 | 百奥泰生物制药股份有限公司 | 用于治疗冠状病毒的抗体、融合蛋白及其应用 |
JP2023520516A (ja) | 2020-04-03 | 2023-05-17 | アレクトル エルエルシー | 抗trem2抗体の使用方法 |
WO2021202959A1 (en) | 2020-04-03 | 2021-10-07 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
US20230272056A1 (en) | 2020-04-09 | 2023-08-31 | Merck Sharp & Dohme Llc | Affinity matured anti-lap antibodies and uses thereof |
CA3175523A1 (en) | 2020-04-13 | 2021-10-21 | Antti Virtanen | Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample |
WO2021209458A1 (en) | 2020-04-14 | 2021-10-21 | Ares Trading S.A. | Combination treatment of cancer |
CA3176979A1 (en) | 2020-04-27 | 2021-11-04 | Anthony Boitano | Methods and compositions for transducing hematopoietic stem and progenitor cells in vivo |
AU2021262744A1 (en) | 2020-04-27 | 2022-10-06 | The Regents Of The University Of California | Isoform-independent antibodies to lipoprotein(a) |
JP2023523450A (ja) | 2020-04-28 | 2023-06-05 | ジェネンテック, インコーポレイテッド | 非小細胞肺がん免疫療法のための方法及び組成物 |
US20220017636A1 (en) | 2020-05-19 | 2022-01-20 | Amgen Inc. | Mageb2 binding constructs |
EP3915641A1 (en) | 2020-05-27 | 2021-12-01 | International-Drug-Development-Biotech | Anti-cd5 antibodies and methods of use thereof |
TW202210101A (zh) | 2020-05-29 | 2022-03-16 | 美商安進公司 | 與cd33和cd3結合的雙特異性構建體的減輕不良反應投與 |
EP4161653A1 (en) | 2020-06-03 | 2023-04-12 | Bionecure Therapeutics, Inc. | Trophoblast cell-surface antigen-2 (trop-2) antibodies |
CA3184351A1 (en) | 2020-06-04 | 2021-12-09 | Amgen Inc. | Bispecific binding constructs |
WO2021249969A1 (en) | 2020-06-10 | 2021-12-16 | Merck Patent Gmbh | Combination product for the treatment of cancer diseases |
JP2023531406A (ja) | 2020-06-16 | 2023-07-24 | ジェネンテック, インコーポレイテッド | トリプルネガティブ乳がんを処置するための方法および組成物 |
JP2023531200A (ja) | 2020-06-18 | 2023-07-21 | ジェネンテック, インコーポレイテッド | 抗tigit抗体及びpd-1軸結合アンタゴニストを用いた治療 |
EP4172184A2 (en) | 2020-06-26 | 2023-05-03 | Amgen Inc. | Il-10 muteins and fusion proteins thereof |
WO2022006562A1 (en) | 2020-07-03 | 2022-01-06 | Dana-Farber Cancer Institute, Inc. | Multispecific coronavirus antibodies |
EP4175668A1 (en) | 2020-07-06 | 2023-05-10 | iOmx Therapeutics AG | Antibodies binding igv of igsf11 (vsig3) and uses thereof |
WO2022010797A2 (en) | 2020-07-07 | 2022-01-13 | Bionecure Therapeutics, Inc. | Novel maytansinoids as adc payloads and their use for the treatment of cancer |
TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Tigit及cd112r阻斷 |
WO2022020636A2 (en) | 2020-07-24 | 2022-01-27 | Amgen Inc. | Immunogens derived from sars-cov2 spike protein |
AU2021316017A1 (en) | 2020-07-31 | 2023-02-16 | F. Hoffmann-La Roche Ag | Anti-integrin beta7 antibody formulations and devices |
CN116568824A (zh) | 2020-08-03 | 2023-08-08 | 基因泰克公司 | 淋巴瘤的诊断和治疗方法 |
CA3188349A1 (en) | 2020-08-04 | 2022-02-10 | A. Scott Muerhoff | Improved methods and kits for detecting sars-cov-2 protein in a sample |
CN114057877A (zh) | 2020-08-07 | 2022-02-18 | 百奥泰生物制药股份有限公司 | 抗pd-l1抗体及其应用 |
EP4196612A1 (en) | 2020-08-12 | 2023-06-21 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
MX2023002125A (es) | 2020-08-20 | 2023-04-26 | Amgen Inc | Proteínas de unión a antígenos con disulfuro no canónico en la región fab. |
CN114106173A (zh) | 2020-08-26 | 2022-03-01 | 上海泰槿生物技术有限公司 | 抗ox40抗体、其药物组合物及应用 |
WO2022047381A1 (en) | 2020-08-31 | 2022-03-03 | Genentech, Inc. | Methods for producing antibodies |
EP4208197A1 (en) | 2020-09-04 | 2023-07-12 | Rutgers, The State University of New Jersey | Sars-cov-2 vaccines and antibodies |
IL301137A (en) | 2020-09-11 | 2023-05-01 | Regeneron Pharma | Identification and production of antigen-specific antibodies |
EP4210832A1 (en) | 2020-09-14 | 2023-07-19 | Vor Biopharma, Inc. | Chimeric antigen receptors for treatment of cancer |
EP4225786A2 (en) | 2020-10-07 | 2023-08-16 | Amgen Inc. | Rational selection of building blocks for the assembly of multispecific antibodies |
CA3187272A1 (en) | 2020-10-08 | 2022-04-14 | Thorsten Ross | Trispecific binders |
EP4229081A1 (en) | 2020-10-15 | 2023-08-23 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods |
WO2022087274A1 (en) | 2020-10-21 | 2022-04-28 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Antibodies that neutralize type-i interferon (ifn) activity |
WO2022093981A1 (en) | 2020-10-28 | 2022-05-05 | Genentech, Inc. | Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists |
JP2023547505A (ja) | 2020-11-02 | 2023-11-10 | エフ. ホフマン-ラ ロシュ アーゲー | SARS-CoV-2ヌクレオカプシド抗体 |
CN116801906A (zh) | 2020-11-02 | 2023-09-22 | 阿雷斯贸易股份有限公司 | 癌症的联合治疗 |
US20230372319A1 (en) | 2020-11-02 | 2023-11-23 | Ares Trading S.A. | Combination Treatment of Cancer |
EP3992205A1 (en) | 2020-11-03 | 2022-05-04 | Rheinische Friedrich-Wilhelms-Universität Bonn | Sars coronavirus-2 spike protein binding compounds |
CA3173151A1 (en) | 2020-11-03 | 2022-05-12 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies |
EP4240768A2 (en) | 2020-11-06 | 2023-09-13 | Amgen Inc. | Multitargeting bispecific antigen-binding molecules of increased selectivity |
JP2023551113A (ja) | 2020-11-06 | 2023-12-07 | バイオ-テラ ソリュ-ションズ,エルティーディー. | 二重特異性抗体及びその応用 |
KR20230104229A (ko) | 2020-11-06 | 2023-07-07 | 암젠 인크 | Cd3에 결합하는 폴리펩티드 구축물 |
EP4240407A1 (en) | 2020-11-06 | 2023-09-13 | Amgen Inc. | Antigen binding domain with reduced clipping rate |
AU2021374036A1 (en) | 2020-11-06 | 2023-06-08 | Amgen Inc. | Polypeptide constructs selectively binding to cldn6 and cd3 |
JP2023548595A (ja) | 2020-11-10 | 2023-11-17 | アムジエン・インコーポレーテツド | 多重特異性抗原結合ドメインの新規のリンカー |
CN114478770A (zh) | 2020-11-12 | 2022-05-13 | 迈威(上海)生物科技股份有限公司 | 抗体及其制备方法 |
WO2022106205A1 (en) | 2020-11-18 | 2022-05-27 | Rheinische Friedrich-Wilhelms-Universität Bonn | Corona virus spike protein binding compounds |
WO2022119841A1 (en) | 2020-12-01 | 2022-06-09 | Abbott Laboratories | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
WO2023102384A1 (en) | 2021-11-30 | 2023-06-08 | Abbott Laboratories | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
MX2023006573A (es) | 2020-12-03 | 2023-06-19 | Amgen Inc | Constructos de inmunoglobulina con multiples dominios de union. |
JP2024500251A (ja) | 2020-12-09 | 2024-01-05 | トリアンニ,インコーポレーテッド | 重鎖のみ抗体 |
IL303626A (en) | 2020-12-16 | 2023-08-01 | Regeneron Pharma | Mice expressing human FC alpha receptors |
CA3165366A1 (en) | 2020-12-23 | 2022-06-30 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses thereof |
WO2022140797A1 (en) | 2020-12-23 | 2022-06-30 | Immunowake Inc. | Immunocytokines and uses thereof |
EP4271998A1 (en) | 2020-12-30 | 2023-11-08 | Abbott Laboratories | Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample |
EP4274587A1 (en) | 2021-01-06 | 2023-11-15 | Tonix Pharma Limited | Methods of inducing immune tolerance with modified anti-cd154 antibodies |
UY39610A (es) | 2021-01-20 | 2022-08-31 | Abbvie Inc | Conjugados anticuerpo-fármaco anti-egfr |
WO2022162203A1 (en) | 2021-01-28 | 2022-08-04 | Vaccinvent Gmbh | Method and means for modulating b-cell mediated immune responses |
WO2022162201A1 (en) | 2021-01-28 | 2022-08-04 | Vaccinvent Gmbh | Method and means for modulating b-cell mediated immune responses |
CN117120084A (zh) | 2021-01-28 | 2023-11-24 | 维肯芬特有限责任公司 | 用于调节b细胞介导的免疫应答的方法和手段 |
JP2024512324A (ja) | 2021-03-05 | 2024-03-19 | ジーオー セラピューティクス,インコーポレイテッド | 抗グリコcd44抗体およびその使用 |
EP4294927A2 (en) | 2021-03-10 | 2023-12-27 | Immunowake Inc. | Immunomodulatory molecules and uses thereof |
BR112023018400A2 (pt) | 2021-03-12 | 2023-12-12 | Janssen Biotech Inc | Método para tratamento de pacientes de artrite psoriática com resposta inadequada à terapia de tnf com anticorpo específico anti-il23 |
IL305802A (en) | 2021-03-12 | 2023-11-01 | Janssen Biotech Inc | A safe and effective method for the treatment of rheumatoid arthritis with a specific anti-IL23 antibody |
KR20230156373A (ko) | 2021-03-15 | 2023-11-14 | 제넨테크, 인크. | 루푸스 신염의 치료 조성물 및 치료 방법 |
WO2022197776A1 (en) | 2021-03-16 | 2022-09-22 | Magenta Therapeutics, Inc. | Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients |
JP2024514530A (ja) | 2021-04-02 | 2024-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 切断型cdcp1に対する抗体およびその使用 |
EP4314078A1 (en) | 2021-04-02 | 2024-02-07 | Amgen Inc. | Mageb2 binding constructs |
WO2022216898A1 (en) | 2021-04-09 | 2022-10-13 | Genentech, Inc. | Combination therapy with a raf inhibitor and a pd-1 axis inhibitor |
CA3216559A1 (en) | 2021-04-20 | 2022-10-27 | Amgen Inc. | Balanced charge distribution in electrostatic steering of chain pairing in multi-specific and monovalent igg molecule assembly |
EP4330281A1 (en) | 2021-04-29 | 2024-03-06 | Amgen Inc. | Methods for reducing low molecular weight species of recombinantly-produced proteins |
CA3218697A1 (en) | 2021-05-03 | 2022-11-10 | Merck Patent Gmbh | Her2 targeting fc antigen binding fragment-drug conjugates |
BR112023022878A2 (pt) | 2021-05-04 | 2024-01-23 | Regeneron Pharma | Agonistas do receptor fgf21 multiespecíficos e seus usos |
EP4333613A1 (en) | 2021-05-05 | 2024-03-13 | Trianni, Inc. | Transgenic rodents expressing chimeric equine-rodent antibodies and methods of use thereof |
WO2022235940A1 (en) | 2021-05-06 | 2022-11-10 | Dana-Farber Cancer Institute, Inc. | Antibodies against alk and methods of use thereof |
CN117279947A (zh) | 2021-05-06 | 2023-12-22 | 安进研发(慕尼黑)股份有限公司 | 用于在增殖性疾病中使用的靶向cd20和cd22的抗原结合分子 |
CA3216320A1 (en) | 2021-05-18 | 2022-11-24 | Abbott Laboratories | Methods of evaluating brain injury in a pediatric subject |
AU2022280341A1 (en) | 2021-05-25 | 2024-01-04 | Merck Patent Gmbh | Egfr targeting fc antigen binding fragment-drug conjugates |
CA3220380A1 (en) | 2021-06-07 | 2022-12-15 | Rinat ZAYNAGETDINOV | Combination treatment of cancer |
WO2022263357A1 (en) | 2021-06-14 | 2022-12-22 | Argenx Iip Bv | Anti-il-9 antibodies and methods of use thereof |
WO2022266034A1 (en) | 2021-06-14 | 2022-12-22 | Abbott Laboratories | Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind |
AU2022297535A1 (en) | 2021-06-25 | 2024-01-04 | Amgen Inc. | Treatment of cardiovascular disease with trem-1 antigen binding proteins |
KR20240034218A (ko) | 2021-07-09 | 2024-03-13 | 얀센 바이오테크 인코포레이티드 | 항-tnf 항체 조성물을 생산하기 위한 제조 방법 |
IL309987A (en) | 2021-07-09 | 2024-03-01 | Janssen Biotech Inc | Production methods for the production of anti-IL12/IL23 antibody compositions |
KR20240032991A (ko) | 2021-07-09 | 2024-03-12 | 얀센 바이오테크 인코포레이티드 | 항-tnf 항체 조성물의 생성을 위한 제조 방법 |
WO2023010118A1 (en) | 2021-07-29 | 2023-02-02 | Vor Biopharma Inc. | Nfat-responsive reporter systems for assessing chimeric antigen receptor activation and methods of making and using the same |
IL308154A (en) | 2021-07-30 | 2023-12-01 | Affimed Gmbh | Double structure antibodies |
CA3228178A1 (en) | 2021-08-05 | 2023-02-09 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
AU2022328390A1 (en) | 2021-08-10 | 2024-03-21 | Adimab, Llc | Anti-gdf15 antibodies, compositions and uses thereof |
CA3229526A1 (en) | 2021-08-16 | 2023-02-23 | Hemogenyx Pharmaceuticals Llc | Anti-flt3 antibodies, cars, car t cells and methods of use |
WO2023023489A2 (en) | 2021-08-17 | 2023-02-23 | Hemogenyx Pharmaceuticals Llc | Bispecific anti-flt3/cd3 antibodies and methods of use |
AU2022339759A1 (en) | 2021-08-31 | 2024-03-07 | Abbott Laboratories | Methods and systems of diagnosing brain injury |
TW202325733A (zh) | 2021-09-03 | 2023-07-01 | 美商Go治療公司 | 抗醣化-lamp1抗體及其用途 |
TW202328188A (zh) | 2021-09-03 | 2023-07-16 | 美商Go治療公司 | 抗醣化-cmet抗體及其用途 |
WO2023056268A1 (en) | 2021-09-30 | 2023-04-06 | Abbott Laboratories | Methods and systems of diagnosing brain injury |
WO2023056430A1 (en) | 2021-10-01 | 2023-04-06 | Abcellera Biologics Inc. | Transgenic rodents for cell line identification and enrichment |
CA3235627A1 (en) | 2021-10-18 | 2023-04-27 | Byomass Inc. | Anti-activin a antibodies, compositions and uses thereof |
WO2023072904A1 (en) | 2021-10-26 | 2023-05-04 | F. Hoffmann-La Roche Ag | Monoclonal antibodies specific for sars-cov-2 rbd |
WO2023073615A1 (en) | 2021-10-29 | 2023-05-04 | Janssen Biotech, Inc. | Methods of treating crohn's disease with anti-il23 specific antibody |
WO2023079493A1 (en) | 2021-11-03 | 2023-05-11 | Affimed Gmbh | Bispecific cd16a binders |
CA3233696A1 (en) | 2021-11-03 | 2023-05-11 | Joachim Koch | Bispecific cd16a binders |
WO2023081898A1 (en) | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
CA3235395A1 (en) | 2021-11-10 | 2023-05-19 | Peter Burrows | Transgenic mammals and methods of use thereof |
US20230151087A1 (en) | 2021-11-15 | 2023-05-18 | Janssen Biotech, Inc. | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody |
WO2023095000A1 (en) | 2021-11-23 | 2023-06-01 | Janssen Biotech, Inc. | Method of treating ulcerative colitis with anti-il23 specific antibody |
WO2023097024A1 (en) | 2021-11-24 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Antibodies against ctla-4 and methods of use thereof |
WO2023114543A2 (en) | 2021-12-17 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Platform for antibody discovery |
WO2023114978A1 (en) | 2021-12-17 | 2023-06-22 | Abbott Laboratories | Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples |
WO2023114544A1 (en) | 2021-12-17 | 2023-06-22 | Dana-Farber Cancer Institute, Inc. | Antibodies and uses thereof |
WO2023111168A1 (en) | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | A novel antibody for detection of amyloid beta 42 (aβ42) |
WO2023122213A1 (en) | 2021-12-22 | 2023-06-29 | Byomass Inc. | Targeting gdf15-gfral pathway cross-reference to related applications |
US20230213536A1 (en) | 2021-12-28 | 2023-07-06 | Abbott Laboratories | Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan |
WO2023137161A1 (en) | 2022-01-14 | 2023-07-20 | Amgen Inc. | Triple blockade of tigit, cd112r, and pd-l1 |
WO2023139292A1 (en) | 2022-01-24 | 2023-07-27 | Cambridge Enterprise Limited | Tau therapy |
WO2023147107A1 (en) | 2022-01-31 | 2023-08-03 | Byomass Inc. | Myeloproliferative conditions |
WO2023150652A1 (en) | 2022-02-04 | 2023-08-10 | Abbott Laboratories | Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample |
WO2023164516A1 (en) | 2022-02-23 | 2023-08-31 | Alector Llc | Methods of use of anti-trem2 antibodies |
WO2023169896A1 (en) | 2022-03-09 | 2023-09-14 | Astrazeneca Ab | BINDING MOLECULES AGAINST FRα |
WO2023170216A1 (en) | 2022-03-11 | 2023-09-14 | Astrazeneca Ab | A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY |
EP4245772A1 (en) | 2022-03-18 | 2023-09-20 | Netris Pharma | Anti-netrin-1 antibody to treat liver inflammation |
EP4249509A1 (en) | 2022-03-22 | 2023-09-27 | Netris Pharma | Anti-netrin-1 antibody against arthritis-associated pain |
WO2023186968A1 (en) | 2022-03-29 | 2023-10-05 | Netris Pharma | Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor |
WO2023187707A1 (en) | 2022-03-30 | 2023-10-05 | Janssen Biotech, Inc. | Method of treating mild to moderate psoriasis with il-23 specific antibody |
WO2023194539A1 (en) | 2022-04-07 | 2023-10-12 | Heidelberg Pharma Research Gmbh | Methods of improving the therapeutic index of amatoxin-antibody conjugates |
WO2023201201A1 (en) | 2022-04-10 | 2023-10-19 | Immunomic Therapeutics, Inc. | Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof |
WO2023215498A2 (en) | 2022-05-05 | 2023-11-09 | Modernatx, Inc. | Compositions and methods for cd28 antagonism |
WO2023218027A1 (en) | 2022-05-12 | 2023-11-16 | Amgen Research (Munich) Gmbh | Multichain multitargeting bispecific antigen-binding molecules of increased selectivity |
WO2023223265A1 (en) | 2022-05-18 | 2023-11-23 | Janssen Biotech, Inc. | Method for evaluating and treating psoriatic arthritis with il23 antibody |
WO2023235415A1 (en) | 2022-06-01 | 2023-12-07 | Genentech, Inc. | Method to identify a patient with an increased likelihood of chemotherapy-induced peripheral neuropathy |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
WO2023240109A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules for modulating t-cell activity, and uses thereof |
WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
WO2024006876A1 (en) | 2022-06-29 | 2024-01-04 | Abbott Laboratories | Magnetic point-of-care systems and assays for determining gfap in biological samples |
WO2024015953A1 (en) | 2022-07-15 | 2024-01-18 | Danisco Us Inc. | Methods for producing monoclonal antibodies |
WO2024039672A2 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against msln and methods of use thereof |
WO2024039670A1 (en) | 2022-08-15 | 2024-02-22 | Dana-Farber Cancer Institute, Inc. | Antibodies against cldn4 and methods of use thereof |
US20240092859A1 (en) | 2022-08-18 | 2024-03-21 | Immunocore Ltd | T cell receptors and fusion proteins thereof |
WO2024059675A2 (en) | 2022-09-14 | 2024-03-21 | Amgen Inc. | Bispecific molecule stabilizing composition |
WO2024059708A1 (en) | 2022-09-15 | 2024-03-21 | Abbott Laboratories | Biomarkers and methods for differentiating between mild and supermild traumatic brain injury |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3180111A (en) | 1962-11-05 | 1965-04-27 | United Aircraft Corp | Combined insulating and cooling blanket |
US3180193A (en) | 1963-02-25 | 1965-04-27 | Benedict David | Machines for cutting lengths of strip material |
CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
US5286647A (en) * | 1982-05-21 | 1994-02-15 | University Of California | Human-human hybridomas for neoplasms |
US5672347A (en) | 1984-07-05 | 1997-09-30 | Genentech, Inc. | Tumor necrosis factor antagonists and their use |
DE3631229A1 (de) | 1986-09-13 | 1988-03-24 | Basf Ag | Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung |
US4950599A (en) * | 1987-01-29 | 1990-08-21 | Wolf Bertling | Method for exchanging homologous DNA sequences in a cell using polyoma encapsulated DNA fragments |
FR2637613B1 (fr) | 1987-06-19 | 1991-09-27 | Transgene Sa | Procede de preparation de lignees cellulaires stables pour la production de proteines determinees, a partir d'animaux transgeniques; lignees cellulaires tumorales et proteines obtenues |
US4959313A (en) * | 1987-06-22 | 1990-09-25 | The Jackson Laboratory | Cellular enhancer for expressing genes in undifferentiated stem cells |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
DE3853201T2 (de) | 1987-12-23 | 1995-09-14 | Univ Leland Stanford Junior | Schimäre immunkompromittierende Säugetiere und ihre Verwendung. |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
WO1991000906A1 (en) * | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
US5605690A (en) | 1989-09-05 | 1997-02-25 | Immunex Corporation | Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
JP3008208B2 (ja) | 1990-06-01 | 2000-02-14 | 武田薬品工業株式会社 | 新規ハイブリドーマ,その製造法および生理活性物質の製造法 |
FR2664073A1 (fr) | 1990-06-29 | 1992-01-03 | Thomson Csf | Moyens de marquage d'objets, procede de realisation et dispositif de lecture. |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5877397A (en) * | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) * | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
HU219537B (hu) * | 1991-03-06 | 2001-05-28 | Merck Patent Gmbh. | Humanizált és kiméra monoklonális antitestek, azokat tartalmazó gyógyászati készítmények, az antitesteket kódoló szekvenciát tartalmazó expressziós vektorok, valamint eljárás az antitestek előállítására |
US5919452A (en) | 1991-03-18 | 1999-07-06 | New York University | Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies |
US5656272A (en) | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
GB9119338D0 (en) | 1991-09-10 | 1991-10-23 | Inst Of Animal Physiology And | Control of gene expression |
AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0648265A4 (en) | 1992-06-18 | 1996-12-04 | Genpharm Int | PROCESS FOR THE PRODUCTION OF NON-HUMAN TRANSGENIC ANIMALS HAVING AN ARTIFICIAL YEAST CHROMOSOME. |
NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
EP0614984B2 (en) | 1993-03-05 | 2010-11-03 | Bayer HealthCare LLC | Anti-TNF alpha human monoclonal antibodies |
JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
WO1995023865A1 (en) | 1994-03-03 | 1995-09-08 | Genentech, Inc. | Anti-il-8 monoclonal antibodies for treatment of inflammatory disorders |
ES2191702T3 (es) * | 1994-03-17 | 2003-09-16 | Merck Patent Gmbh | Fv monocatenarios anti-egfr y anticuerpos anti-egfr. |
CA2219361C (en) * | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
AU2466895A (en) * | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
EP2305027B1 (en) * | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
TWI255853B (en) | 1998-08-21 | 2006-06-01 | Kirin Brewery | Method for modifying chromosomes |
GB9823930D0 (en) | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
ATE398172T1 (de) | 2001-05-11 | 2008-07-15 | Kirin Pharma Kk | Künstliches menschliches chromosom mit dem gen für die lambda-leichte kette menschlicher antikörper |
US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
IL226488A (en) | 2013-05-21 | 2016-07-31 | Aspect Imaging Ltd | Baby crib |
JP6071725B2 (ja) | 2013-04-23 | 2017-02-01 | カルソニックカンセイ株式会社 | 電気自動車の駆動力制御装置 |
US9605925B1 (en) | 2015-03-12 | 2017-03-28 | Josh M. McRoberts | Bump fire grip |
US11284893B2 (en) | 2019-04-02 | 2022-03-29 | Covidien Lp | Stapling device with articulating tool assembly |
-
1997
- 1997-12-03 EP EP10182932.3A patent/EP2305027B1/en not_active Expired - Lifetime
- 1997-12-03 KR KR1019997004855A patent/KR100643058B1/ko not_active IP Right Cessation
- 1997-12-03 CA CA2616914A patent/CA2616914C/en not_active Expired - Fee Related
- 1997-12-03 DE DE69738539T patent/DE69738539T2/de not_active Expired - Lifetime
- 1997-12-03 CA CA2722378A patent/CA2722378C/en not_active Expired - Lifetime
- 1997-12-03 ES ES04013481T patent/ES2384942T3/es not_active Expired - Lifetime
- 1997-12-03 JP JP52590998A patent/JP4215172B2/ja not_active Expired - Lifetime
- 1997-12-03 CA CA2273194A patent/CA2273194C/en not_active Expired - Lifetime
- 1997-12-03 KR KR1020087012502A patent/KR20080059467A/ko not_active Application Discontinuation
- 1997-12-03 EP EP10182935.6A patent/EP2314625B1/en not_active Expired - Lifetime
- 1997-12-03 AT AT97953227T patent/ATE387495T1/de active
- 1997-12-03 DK DK04013481.9T patent/DK1500329T3/da active
- 1997-12-03 DK DK97953227T patent/DK0942968T3/da active
- 1997-12-03 ES ES97953227T patent/ES2301183T3/es not_active Expired - Lifetime
- 1997-12-03 EP EP08003509A patent/EP1972194A1/en not_active Withdrawn
- 1997-12-03 PT PT04013481T patent/PT1500329E/pt unknown
- 1997-12-03 PT PT97953227T patent/PT942968E/pt unknown
- 1997-12-03 KR KR1020057002900A patent/KR100942002B1/ko not_active IP Right Cessation
- 1997-12-03 AT AT04013481T patent/ATE549918T1/de active
- 1997-12-03 WO PCT/US1997/023091 patent/WO1998024893A2/en active IP Right Grant
- 1997-12-03 AU AU57022/98A patent/AU5702298A/en not_active Abandoned
- 1997-12-03 EP EP97953227A patent/EP0942968B1/en not_active Expired - Lifetime
- 1997-12-03 EP EP04013481A patent/EP1500329B1/en not_active Expired - Lifetime
-
2000
- 2000-03-17 HK HK05106153.5A patent/HK1074348A1/xx not_active IP Right Cessation
- 2000-03-17 HK HK00101647A patent/HK1022720A1/xx not_active IP Right Cessation
-
2002
- 2002-02-19 US US10/078,958 patent/US7064244B2/en not_active Expired - Fee Related
-
2005
- 2005-01-28 JP JP2005021414A patent/JP4808412B2/ja not_active Expired - Lifetime
- 2005-10-14 US US11/250,805 patent/US7820877B2/en not_active Expired - Fee Related
-
2007
- 2007-08-20 US US11/894,779 patent/US8809051B2/en not_active Expired - Fee Related
-
2008
- 2008-05-12 JP JP2008124406A patent/JP2008194058A/ja not_active Withdrawn
- 2008-05-21 JP JP2008132621A patent/JP4195077B1/ja not_active Expired - Lifetime
-
2011
- 2011-06-30 JP JP2011146571A patent/JP2011212019A/ja not_active Withdrawn
-
2014
- 2014-08-18 US US14/462,499 patent/US20150250152A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4195077B1 (ja) | 複数のVHおよびVκ領域を含むヒトIg遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体 | |
Mendez et al. | Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice | |
KR100855998B1 (ko) | 비동족형 스위치 영역에 의해 인간 항체의 특정 이소타입을 생산하는 트랜스제닉 동물 | |
EP2319301B1 (en) | Transgenic animals bearing human Ig lambda light chain genes | |
AU2005202768B2 (en) | Transgenic Mammals Having Human IG LOCI Including Plural Vh and Vk Regions and Antibodies Produced Therefrom | |
AU2008200005B2 (en) | Transgenic Mammals Having Human Ig Loci Including Plural Vh and Vk Regions and Antibodies Produced Therefrom | |
AU2012211512A1 (en) | Transgenic Mammals Having Human Ig Loci Including Plural Vh and Vk Regions and Antibodies Produced Therefrom |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080910 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080924 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111003 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121003 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131003 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131003 Year of fee payment: 5 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131003 Year of fee payment: 5 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |